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Introduction 
Cancers, including those from the hematopoietic system such as leukemia,;; and lymphomas, arc 
characterized by the fact that affected cells differ from their nOll-cancerous neighbors in their 
genetic constitution. Environmental factors and/or genetic predisposition cause an accumulation 
of mutations, that will eventually result in neoplastic transformation. These mutations can be 
manifested by small changes in the DNA, such as pointmutations or microdeletions, or by more 
dramatic alterations that change the karyotype of the affected cells, such as chromosomal 
trans locations, deletions, inversions and amplifications (Cleary, 1991; Drexler ef al., 1995; 
Rabbitts, 1994). 
These deviations affect genes whose products interfere with cellular mechanisms that 
dictate the delicate balance between proliferation, differentiation or cell death (apoptosis). 
Proliferation can be defined as a continuous multiplication of cells, whereas differentiation is 
the process in which cells generally stop to proliferate and mature into nondividing cells with 
a specialized function. In chronic leukemia, for instance, hematopoietic cells have an enhanced 
proliferative potential, but are nonetheless capable of full maturation. In most acute leukemias, 
proliferating progenitor cells are arrested at an early stage of differentiation and are unable to 
convert to non-proliferating specialized cells (reviewed by Sawyers et al.(Sawyers et al., 1991). 
Apoptosis, in the classical Greek Hippocratic corpus from the roots apo-, apart, and ptosis, 
falling, referred to the loss of leaves in the autumn. The allusion is to acceptable loss, with the 
anticipation of renewal (Squier et al., 1995). To give an example of this, many hematopoietic 
cells eventually die due to activation of an intrinsic cellular destruction mechanism. However, 
due to continuous renewal an optimal hematopoietic cell population is maintained. In some 
types of leukemias and lymphomas apoptosis is prevented, thus interfering with disposal of 
unwanted cells (White, 1996; Yang & Korsmeyer, 1996). 
Chromosomal transiocations contribute to transformation by generation of oncogenes 
by two mechanisms: 1) activation of genes due to promoter or enhancer addition, 2) generation 
affusion proteins (Drexler et al., 1995). Although chromosomal translocations affect genes that 
encode proteins with a variety of functions, a major group of targeted genes belong to the class 
of transcription factors, TEL, also named ETV6, the subject of this thesis, belongs to a subgroup 
in this class of genes. It is part of the family ofETS transcription factors, encoding proteins that 
contain a specific homologous DNA binding domain, called the ETS domain. 
This thesis describes experimental work dealing with the molecular and biochemical 
characterization of TEL, as well as with its involvement in two translocatiolls, 
t(l2;22)(pI3;qll) in myeloid leukemia and t(12;21)(pl3;q22) in childhood pre-B ALL. The 
experimental work is preceded by an introduction regarding the role of ETS transcription 
factors in development, hematopoiesis and oncogenesis. to place the role of TEL in 
leukemogenesis in a broader context. 
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Aims of thesis 
Chromosomal aberrations of the short arm of chromosome 12, involving both deletions and 
translocations, can be detected in 2% of AML and 10% of childhood ALL. Translocation 
(l2;22)(pI3;qI1), associated with human myeloid leukemia, is a recurrent chromosomal 
translocation with a low incidence. The aims of this project were to characterize this 
translocation and to address the following questions: I. Is t(l2;22)(p13;qII) a variant 
Philadelphia translocation, involving the BCR gene on chromosome 22q II? 2. What is the role 
of t( 12;22)(p 13;q II) in leukemia? 3. Is the gene on chromosome 12p 13 a common target for 
transiocatiolls involving this region? 4. Is the gene on chromosome 12pl3 a candidate tumor 
suppressor gene, since this region is often deleted in childhood ALL? In this thesis I will 
present experimental work, that wilJ address these questions. 
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Chapter 1. Role of ETS factors 
1.1. General characteristics of ETS transcription factors 
The founding member of the ETS family of transcription factors, v-ETS (mammalian homolog 
ETS-J J, was discovered as part of a chimeric GAG/v-MYB/v-ETS protein that is expressed by 
the E26 avian erythroblastosis vil11s rn26 !ransfommtion-.1wecific)(Leprince et al., 1983; Nunn 
ef al., 1983). Subsequent isolation of homologous genes defined a family, of which all members 
encode proteins that contain a highly homologous sequence of 85 aminoacids, the ETS domain 
(reviewed by Seth et al. and Wasylyk et al. (Seth ef al., 1992; Wasylyk ef al., 1993). This DNA 
binding domain interacts with the major groove of a specific DNA sequence that is 
characterized by the common core motif GGAAIT (Nye ef al., 1992). Nuclear magnetic 
resonance (NMR) studies revealed that the ETS domain of ETS-I adopts a winged helix-turn-
helix (lITH) DNA binding stmcture (Donaldson ef al., 1996). Subsequent detennination of the 
crystal stmcture of the ETS domain of PU.I in complex with DNA showed that the helix 3, the 
second helix of the HTH motif, contacts the major groove of the DNA, but, in addition, two 
loops on either side of this helix interact with the minor groove (see figure I). Binding of PU. I 
to its cognate site induces an 8 degree bend in the DNA (Kodandapani ef al., 1996). This 
protein-induced DNA distortion is thought to create a stmcturai environment on which a temmy 
nucleoprotein complex can assemble which transactivates genes that regulate ceBular processes 
determining cell fate. Recent stndies with PU.I confirmed the loop-helix-loop scaffold as a 
general model for DNA recognition by ETS proteins, defining ETS factors as a new class of 
HTH DNA-binding proteins (Pio ef al., 1996). 
Figure 1. Depictioll of iJlteractioll of the ETS 
doma;n of ETS+} with the DNA. Interaction helix 
0:3 contacts the major groove. (derived from 
Werner,1996 Cell October 1996, erratum). Hl+ 
H3: a+heiices, BI+B4 ~~plated sheets 
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ETS family members can be divided in different subgroups on the basis of their degree 
of homology within the ETS domain (see figure 2a,b), the position of the ETS domain within 
the protein, and by the presence of a helix-loop-helix (HLH) domain (see figure 2c,d)(Wasylyk 
ef al., 1993). The HLH domain of TEL has been demonstrated to function as an oligomerization 
domain (Iousset ef al., 1997)(chapters 2.2 and 3.2). DNA binding activity of ETS-I can be 
repressed by an intramolecular mechanism (Jonsen et al., 1996; Lim et al., 1992; Petersen ef 
al., 1995), that can be relieved either by interaction with partner proteins. by posttranslational 
modifications, such as phosphorylation or by allosteric DNA interactions (Jonsen e( al., 1996; 
Petersen ef al., 1995; Rabault & Ghysdael, 1994). 
As will be discussed below, the activity of ETS transcription factors is regulated by 
posttranslationai modification, subcellular localization and interaction with partner proteins. 
For instance, trans activation activities of ETS-I and ETS-2 are enhanced by RAS-mediated 
phosphorylation (Yang e/ al., 1996), whereas PEA3 driven transcription activity was found to 
be influenced by two distinct MAPK cascades, the ERK and SAPK or INK pathways (O'Hagan 
et al., 1996). Transcription activity and localization of the Drosophila melallogaster ETS 
proteins Y AN and POINTED is also regulated by RAS mediated phosphorylation (see chapter 
1.2). 
Transcription induction of c-FOS, an immediate early response gene of epidermal 
growth factor (EOF) stimulation, is mediated in part by a ternary nucleoprotein complex, 
consisting of serum response factor (SRF) (Norman e/ al., 1988), ETS factor ELK-I (p62 TCF) 
(Hipskind e/ (/1., 1991) and the semm response element (SRE) within the promoter (reviewed 
by Treisman (Treisman, 1994). SAP I and SAP2INETIERP are ELK-I subfamily members and 
also form a ternary complex with SRF and SRE (Dalton & Treisman, 1992; lanknecht & 
Nordheim, 1992; Lopez e/ al., 1994) (see figure 3). ELK-I and SRF interact directly via a 30 
aminoacids domain in ELK-I (Janknecht & Nordheim, 1992; Shore & Sharrocks, 1994). 
Phosphorylation of ELK-I by MAPK family members positively regulates ternary complex 
formation, DNA binding and transcription induction of c-FOS (Gille e/ (/1., 1995; Ianknecht e/ 
al., 1993; Marais e/ al., 1993; Whitmarsh ef al., 1995). Whereas SRFIELK-I is the target of a 
RASfMAPK signaling pathway, SRFfSAPI is the target of Ca'+/calmodulin dependent kinase 
(CaMK) (Hipskind e/ (/1.,1994; Miranti ef al., 1995). Each of the ELK-I family members 
displays a certain degree of tissue specific expression. This suggests that distinct cytoplasmic 
signaling pathways can mediate c-FOS expression in diverse cell types via different ETS 
factors. 
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Figure 2. Homology between US transcription/actors. A.Dendogram representing the level of homology within 
the ETS domain ofETS family members. n.Sequence alignment oflhe ETS domains. C.Dcndogram representing 
the level of homology within the HLH domain ofETS family members D. Sequence alignment of Helix-Loop-
Helix oligomerization domain of ETS family members. Dark boxes indicate identity_ Gray boxes indicate 
similarity. Dendrograms and alignments were generated using Pileup (GCG) and Boxshade (Kay Hofmann) 
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Figure 3. SRE+lllediated transcription oj c-
FOS by ELK) and SRF, Mitogen activated 
protein kinase (ERK) mediates complex 
formation of monomeric ETS factor ELKI 
and homodimcric serum response factor 
(SRF) to the serum response element (SRE) in 
the c-FOS promotor, that contains ETS and 
SRF binding sites. 
Alternatively, cell specific or lineage specific activity of ETS factors can also be 
accomplished by interaction with partner proteins. For instance, Maffi, an AP-l like protein, 
interacts with ETS-l and inhibits erythroid differentiation, suggesting that it may estabJish and 
maintain a myelomonocytic phenotype of early myeloid cells by repression of ETS-I-indllced 
erythroid-specific gene expression (Sicweke ef al., 1996). On the other hand, PAX -5, a key 
regulator of early B cell lymphopoiesis, recruits specific ETS factors, forming a ternary 
complex on B cell specific promoters (Fitzsimmons e/ al., 1996). ETS factors can also 
influence the activity of other transcription factors. PIP, a lymphoid restricted interferon-
regulatory-factor (lRF), acts as an activator or repressor of O'lp-interferon-inducible 
transcription, dependent on the presence or absence of PU.1 (Brass ef al., 1996), 
In addition to cytoplasmic kinase-dependent signaling pathways, steroid hormone 
receptors were found to mediate ETS factor activity. The androgen receptor (AR) is a member 
of the steroid hormone receptor family. Upon hormone binding the receptor migrates to the 
nucleus and directly regulates transcription of target genes. AR intcracts with the ETS factor 
ERM (Schneikert ef al., 1996) and this interaction is thought to mediate the repression of 
matrix metalloproteinasc-l expression. Metalloproteinases are enzymes that degrade 
extraccllular matrix and play an important role in tissue morphogenesis, cell differentiation and 
wound healing. 
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1.2. ETS factors in development 
One of the best understood roles of members of the ETS family of transcription factors is in the 
development of the Drosophila eye (Wassarman e/ 01., 1995). In the developing eye the ETS 
factors Y AN and POINTED have been identified as nuclear targets of RAS mediated 
phosphorylation in the signaling pathway initiated by receptor tyrosine kinases (RTK) (see 
figure 4). Furthermore, these two ETS factors arc clear examples of how phosphorylation of 
ETS factors by mitogen activated protein kinases (MAPK) regulates their activity and 
influences cell fate. 
The Drosophila eye is composed of approximately sao identical units called 
ommatidia, each of which contains eight photoreceptor cells (R I-RS), four non-neuronal cone 
ceils, and eight accessory cells. Neuronal differentiation of the R7 precursor cell is initiated by 
interaction of the R7 transmembrane RTK Sevenless (SEV), with the RS specific Bride-of 
sevenless (Boss) ligand. Genetic evidence that an ETS factor was involved in differentiation 
of R7 photoreceptor cells came from the identification of Drosophila mutants. Y ANIPOK 
mutant flies have supernumerary photoreceptors, resembling the phenotype of flies, carrying 
an activated RAS I gene. Independent cloning of the mutated Y ANIPOK gene by two groups 
revealed that it encodes an ETS family transcription factor, that is expressed in nuclei of 
undifferentiated photoreceptor cells. Upon differentiation, Y ANIPOK activity is downregulated 
(Lai & Rubin, 1992; Tei e/ al., 1992). These data indicate that Y ANIPOK acts antagonistically 
to the signaling pathway mediated by SEV and RAS I. 
Another target of the RASIMAPK pathway is the ETS factor POINTED. that is 
necessmy for normal development of the Drosophila embryonic nervous system, including eye 
developmeut (Kliimbt, 1993). POINTED encodes two ETS-DNA binding proteins P2 and PI 
that are encoded by mRNAs transcribed from two different promoters (Kliimbt, 1993). P2 
contains a consensus recognition site (p-X-Srr-p) for phosphorylation of serine/threonine 
residues by MAPK. O'Neill et al. and Bnmner et al. (Brunner e/ 01., 1994; O'Neill e/ al., 1994) 
presented genetic and biochemical data that indicated that ETS transcription factors Y ANIPOK 
and POINTED are targets of the RAS I mediated phosphorylation pathway. Whereas Y AN 
seems to be a negative regulator of R7 photoreceptor cell development, POINTED appears to 
be a positive regulator. In agreement with this observation it was shown that stability and 
nuclear localization of Y AN are negatively regulated upon activation of the SEVIRAS 
phosphorylation pathway (Rebay & Rubin, 1995). Further evidence for the regulation of Y AN 
activity by phosphorylation comes from the observation that ectopic expression of a Y AN 
mutant without consensus MAPK sites blocks neuronal deVelopment of photoreceptor cells. 
Mutant Y AN may be responsible for a dramatic increase in cell death in the developing eye. 
Furthermore, it inhibited development of the embryonic eNS (Rebay & Rubin, 1995). Nonnal 
Y AN IVa, found to be expressed iu non-differentiated mesodenn derivatives, but could not be 
detected in differentiated tissues such as gut and muscle. These observations suggest that Y AN 
may playa more general role during development. 
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Figure 4. Receptor tyrosine killflse/RASI signal cascade ill the de\'elopillg Drosophila eye. Ligand dependent 
dimcrizalioll of the Sevenless tyrosine kinase receptor leads to subsequent phosphorylation of Raf (MAPKKK), 
Osorl (MAPKK) and RoI1ed (MAPK). Upon phosphorylation Rolled enters the nucleus and regulates activity of 
targets by phosphorylation (adapted from (Wassarman et al., 1995». 
In addition to YAN and POINTED, a third transcription factor, c-JUN, was found to be 
involved in Drosophila eye development (Bohmann e/ al., 1994). Treier et al.(Treier ef al., 
1995) presented genetic and biochemical evidence that JUN and POINTED cooperate in R7 
cell detemlination. The proteins are targeted to the same promoter and their activity is enhanced 
upon phosphorylation. Interestingly, JUN and POINTED cooperate in transcription activation 
of a repOlier constmct containing a single polyoma AP-IIETS element, whereas YAN represses 
the cooperative activity of POINTED and JUN. A candidate target gene of Y AN/POINTED 
mediated signal transduction pathway is PROSPERO. High levels of the homeodomain protein 
PROSPERa in R7 cells, required for proper connectivity of R7 photoreceptor axons to their 
synaptic targets, depend on SEV activation of the RAS IIMAPK pathway (Kauffmann ef al., 
1996). Taken together, at least three transcription factors, YAN, POINTED and JUN are 
involved in Drosophila R7 receptor cell differentiation, and their antagonistic activities are 
tuned by phosphorylatiou induced by activation of the SEVIRTK pathway. 
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Similarly, another ETS factor, D-ELG, is required for egg chamber patterning and 
development during Drosophila oogenesis (Schulz ef al., 1993). In D-ELG mutant females, the 
spatial localization of OSKAR and GURKEN mRNA, involved in posterior and dorsoventral 
patterning of the egg, is dismpted. Furthermore, specialized follicle cells fail to migrate over 
the developing oocyte. 
ETS-2 is expressed in a variety of cell types. During murine development it is highly 
expressed in newly forming cartilage, skull precursor cells and vertebral primordia (Kola e/ al., 
1993; Maroulakou e/ al., 1994). ETS-2 is located on chromosome 21 and is overexpressed in 
Down's syndrome (trisomy 21) (Chumakov ef al., 1992). Sumarsono et al. (Sumarsono ef al., 
1996) reported that ETS-2 transgenic mice develop neurocranial, visceral and skeletal 
abnormalities. These abnormalities have similarities with skeletal anomalies found in trisomy-
16 mice and humans with Down's syndrome, in which the gene dosage of ETS-2 is increased 
by trisomy 21. These results indicate that ETS-2 has a role in skeletal development and 
implicate the overexpression of ETS-2 in the genesis of some skeletal abnormalities that occur 
in Down's syndrome. 
1.3, ETS factors in hematopoiesis 
Regulation of cell-specific transcription factors plays a cmcial role in steering differentiation 
of pluripotent stem cells into certain hematopoietic lineages. The chacterization of 
chromosomal aberrations associated with malignancies of the hematopoietic system has 
revealed that transcription factors are often affected, indicating that altered transcription 
regulation plays a major role in leukemogenesis (reviewed by Cleary, Rabbitts and Barr (Barr, 
1996; Cleary, 1991; Rabbitts, 1994) 
A new method to study the role of transcription factors in hematopoietic development 
consists of mutation analysis of transcription factors by gene knock-out technology (reviewed 
by Shivdasani and Orkin (Shivdasani & Orkin, 1996)). The generation of nullizygous mice 
helped to elucidate the function of some ETS factors in hematopoiesis (figure 5). 
ETS-I is preferentially expressed in adult lymphoid tissue, with high levels in the 
thymus, but also in erythroid and myeloid cells. ETS-J is expressed as two isofolTIls, p54 and 
p68, that are translated from alternatively spliced mRNAs. Both proteins bind DNA via the 
ETS domain, but have different transcription transactivation activities. Whereas both p54 and 
p68 are expressed in immature erythroid cells, p54 is expressed exclusively in Band T 
lymphocytes (Queva ef al., 1993). As mentioned above, ETS-2 is expressed in almost every 
tissue. However ETS-l and ETS-2 are highly expressed in CD4+ CDS' thymocytes. 
Interestingly, in resting human T cells ETS-l is highly expressed, whereas ETS-2 expression 
is low. Upon antigenic or mitogenic stimulation, ETS-2 expression is dramatically upregulated, 
but ETS-l expression goes down, suggesting an antagonistic role of both proteins in the thymus 
(Bhat ef al., 1990)(reviewed by Wasylyk et al. and Seth et al. (Seth ef al., 1992; Wasylyk ef al., 
1993). As mentioned in chapter 1.1, ETS-l is also implicated in erythropoiesis. MafB, a 
t3 
myelomonocytic factor, prevents ETS-l mediated activation of the transferrin receptor, which 
is essential for erythroid differentiation (Sieweke ef al., 1996). This inhibition is thought to 
prevent reactivation of the erythroid differentiation program by ETS-l in myeloid cells. 
Nullizygous c-ETS-J mice displayed severe defects in both T- and B-cell lineages. T-cells 
numbers were dramatically reduced and failed to proliferated in response to mitogenic signals. 
T-cells were highly susceptible to apoptosis ill vitro. B-cells were hampered in their terminal 
differentiation (Bories ef al., 1995; Muthusamy ef al., 1995). 
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Figure 5, Schematic represelllarion o/tlie positiOI! a/essential/unction 0/ ITS/actors ill hematopoiesis. Position 
is based on earliest block in diffentiation (adapted from Shivdasani (Shivdasani & Orkin, 1996». 
PU.!, another ETS factor that is studied for its role in hematopoiesis, is expressed in 
a wide variety of hematopoietic cells, except for peripheral T cells. PU.l activates a series of 
promoters of myeloid and lymphoid specific genes, including its own (summarized by Moreau-
Gachelin et al.(Moreau-Gachelin et at., 1996». One of them is the receptor for macrophage 
colony stimulating factor (M-CSF-I), the c-FMS oncogene product (Reddy ef al., 1994). 
Interestingly, c-MYB represses this activation, suggesting that c-MYB mediates correct 
temporal expression of c-FMS during myeloid differentiation. Recently, PU.1 was found to be 
involved in CSF-I dependent macrophage proliferation, probably by upregulation of the 
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expression of its receptor (Celada ef al., 1996). Nullizygous PU.I mice died at late gestational 
age. Mutant embryos produced normal numbers of megakaryocytes and erythroid progenitors, 
but showed an impairment of erythroblast maturation. Furthermore, the mice displayed a 
l11ultilineage defect in the generation of lymphoid progenitors. monocytes and granulocytes, 
suggesting that PU.I acts in a multi potent progenitor in developmental programs of lymphoid 
and myeloid lineages during fetal liver hematopoiesis (Scott ef al., 1994). PU.I was also found 
to be required in yolk sac myelopoiesis (Olson ef al., 1995). Interestingly, expression of genes 
associated with terminal myeloid differentiation (eDI1h, CD64 and M-CSFR) was absent in 
PU.I nullizygous embryos and differentiated ES cells. In an independent study, nullizygous 
PU.l mice were born alive, but died of severe septicemia (McKercher ef al., 1996). In 
conclusion, it seems that PU.1 appears not to be essential for myeloid or lymphoid lineage 
commitment, but is required for terminal differentiation of most myeloid and lymphoid 
lineages. 
Mice, supposedly deficient in FLII, lVere viable, but exhibited thymic hypocellularity 
(Melet ef al., 1996). This phenotype was not due to a deficiency in a specific sUbpopulation of 
thymocytes or to increased apoptosis, but rather suggested a defect in a prethymic T-cell 
progenitor. However, detailed analysis revealed that a truncated FLII protein was synthesized 
that arose from an internal translation initiation site and alternative splicing. It is therefore 
questionable whether the phenotype was caused by the absence of nonnal FLIl or by expression 
of a novel truncated FLU. 
In conclusion, some members of the ETS transcription factors family appear to be key 
regulators in determining the lineage commitment as well as progression to full maturation of 
hematopoietic cells. The generation of nullizygous mice has proven to be a powerful tool to 
elucidate the function of some ETS factors in hematopoiesis. However, one drawback of 
generating a standard knockout is that a phenotype only shows the earliest stage at which a gene 
product is required, thereby loosing information about a possible function later in development. 
An approach that can be used to circumvent this problem, and to study the inactivation of a 
gene at a specific stage in development or in a specific cell type, is to make a conditional 
knockout based on the CRE-IoxP system (Oll ef al., 1994; Kilby ef al., 1993). Another 
drawback may be that redundancy of the protein can mask its function. 
1.4, ETS factors in oncogenesis 
As mentioned in chapter 1.1, v-ETS, was discovered as part of a chimeric gene with GAG and 
MYB, that is expressed by the E26 avian erythroblastosis vims (Leprince ef al., 1983; Nunn ef 
al., 1983). ETS-I, the mammalian homolog of v-ETS, is amplified in MDS (Ohyashiki ef al., 
1990) and transforms murine fibroblasts when overexpressed (Seth ef al., 1989). ETS-2 mRNA 
expression increases in AML(Santoro et af., 1992). These observations set the stage for the 
involvement of ETS factors in malignant transformation. Uncontrolled expression of ETS 
factors may lead to aberrant proliferation, since ETS factors were found to influence CSF-l 
receptor mediated mitogenic signaling by controling MYC expression (Langer et al., 1992; 
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Roussel ef 01., 1991; 1994). The GAG-MYB-ETS fusion oncogene, when expressed in a murine 
retroviral constmct, was found to induce serum free proliferation of murine fibroblasts ill vitro 
and erythroleukemia ill vivo (Ruscelli ef al., 1992; Yuan ef 01., 1989). Very recently, 
Athallasiou et al. (Athanasiou el al., 1996) reported that expression of p 1 35GAO-MYB-ETS in the 
IL3-dependent FDC-P2 myeloid cell line resulted in erythropoietin (Epo)-dependent inhibition 
of apoptosis upon withdrawal of IL3. This is the first report on an ETS factor associated with 
apoptosis. 
Besides retroviral mobilization in birds, two different mechanisms directly activate 
cellular ETS factors oncogenically: proviral insertion in rodents and chromosomal 
translocations in humans. New born mice, infected with S FFV -P and -A and F MuLV develop 
erythroid leukemia with high frequency. This is caused by proviral integration in the vicinity 
of two ETS factors, FLIl and SPJ-lfPU.1 in 75% and 95% of the tumors, respectively (Ben-
David ef al., 1991; Moreau-Gachelin ef al., 1988). The proviral LTR acts as an enhancer and 
induces overexpression of FLII and/or Pu.!. The involvement of SPI-lIPU. I in 
leukemogenesis was confirmed by generation of mice transgenic for SPI-J/PU.) , of which 50% 
of the animals solely developed erythroleukemia (Moreau-Gachelin ef 01., 1996). 
The human homolog of FLIl, located on chromosome 1) q24, fuses to EWS, a gene 
coding for a RNA binding protein as a result of t(lI;22)(qI2;q24) that can be detected by 
cytogenetic analysis in 85 % of Ewing's sarcoma (Delallfe ef 01., 1992). In EWS-FLII the RNA 
binding domain ofEWS is replaced by the DNA binding ETS domain of FLII. In contrast to 
normal FLIl, EWS-FLIl tranSf0I111S murine fibroblast. N-tenninal sequences in EWS as well 
as the ETS domain of FLIlare essential for transformation (May ef al., 1993a; 1993b). FLII 
and EWS-FLII bind DNA with the same sequence specificity. EWS-FLII is a more powerful 
transcription activator than FLII (Bailly ef al., 1994; May ef al., 1993b). Distinct domains in 
EWS contribute to the transfol1ning and trans activating activity of the fusion protein (Lessnick 
ef al., 1995). EWS-FLII may influence proliferation or differentiation by more efficient 
activation of FLII target genes or by inappropriate regulation of genes normally not responsive 
to FLII. FLII is expressed in hematopoietic tissues, including thymus and spleen (Klemsz e/ 
01., 1993). This mainly hematopoietic expression of FLII suggests that ectopic FLII expression 
in Ewing's sarcoma is one of the important components of malignant transformation of cells 
of neuroectodermal origin. Denny and coworkers characterized stromelysin and cytokeratin as 
potential target genes of EWS-FLIl using eDNA representational difference analysis of EWS-
FLI-I transformed fibroblasts (Braun ef 01., 1995). Stromelysin-I, a member of the 
metalloproteinase family, digests a variety of extracellular matrix proteins. While 
metalloproteinases function normally in tissue remodelling during repair and embryogenesis, 
the ectopic expression of these proteins has also been linked to tumor invasion and metastasis. 
Therefore aberrant expression of stromelysin-I by EWS-FLI-I could very well contribute to 
the EWS-FLI-I induced oncogenesis. 
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Interestingly, transformation of NIH3T3 by EWS-FLII is not so much determined by 
FLII, but by an EWS-ETS transcription factor chimera, since a variant t(21:22)(q24;qI2) in 
Ewing's sarcoma fuses the EWS gene to ERG in less than J 0% of the cases (Sorensen et al., 
1994). ERG had been characterized previously and was demonstrated to contain two 
transcription activation domains, one N-terminal (i.e. an HLH protein-protein interaction 
domain) and a C-termina1 domain (Rao ef al., 1987; Siddique ef al., 1993). In addition to its 
involvement in Ewing's sarcoma, ERG is also rearranged in AML (Shimizu e/ al., 1993), where 
it was found to be fused with another RNA binding protein TLSIFUS as a consequence of 
t( 16;21)(p 11 ;q22) (Panagopoulos ef al., 1994; Prasad ef al., 1994). III vitro studies 
demonstrated that overexpression of ERG results in a mitogenic stimulation and transformation 
of NIH3T3 cells (Hart ef al., 1995). ERG gene expression is normally restricted to the thymus 
in adult humans, but it can be detected in KGat, a early myeloid cell line, and in MOLT-4, a 
pre-T leukemic cell line, suggesting an association between malignancy and aberrant ERG 
expression (Watson ef al., 1992). 
A third variant in Ewing's sarcoma fuses EWS to ETV t (murine homolog ERS1) as a 
result of t(7;22)(pI2;qI2). ETV1 is differentially expressed in different tissues (Jeon ef al., 
1995). ER81 was demonstrated to be transcriptionally activated by the RASIMAPK pathway. 
ERSt contains an N-terminal acidic transactivation domain which contains potential ERK 
phosphorylation sites. Sequences downstream of this transactivation domain are thought to 
have a negative regulatory effect on transactivation by ER8!, suggesting a tight regulation of 
the transactivation activity of the protein (Janknecht, 1996). In t(7;22) the N-terminal 
trans activation domain of ETV 1, including the potential ERK phosphorylation sites, and the 
inhibitory domain have been replaced by EWS, suggesting that one of the consequences of the 
translocation may he a RASIMAPK independent transactivation of ETV 1 target genes. 
Stromelysin-1 expression was also found to be upregulated by EWS-ERG and EWS-ETV1, 
suggesting that in addition to their stmctural similarities these fusion proteins have overlapping 
functional roles in transformation. 
Rece~tly, a fourth translocation was found to fuse EWS to ETV4 (murine homolog 
E I AF), as a result of t(l7;22)(q 12;q 12) in a case of undifferentiated sarcoma (Kaneko ef al., 
1996). ETV4 was found to confer an invasive phenotype upon transfection into the non-
invasive human breast cancer cell line MCF-7 and to activate the transcription of MMP-9, a 
matrix metalloproteinase in these cells. Both ETV4 and MMP-9 mRNA expression was 
demonstrated to be elevated in some human invasive cell lines (Kaya ef al., 1996). 
The fifth translocation that fuses EWS to an ETS factor in Ewing tumors has been 
described by Delattre and coworkers (Peter ef al., 1997). As a result of a 
t(2;21;22)(q33:q22;qI2) EWS is fused to FEV, a new member of the ETS family of 
transcription factors. FEY expression seems to be restricted to prostate and small intestine. In 
general, it can be concluded that ectopic or aberrant expression of various ETS factors critically 
contribute to malignant transformation and tumor progression. 
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1.5. Chromosome 12p13 aberrations involving the TEL gene 
Chromosomal translocations and deletions, involving chromosome region 12p 11-13 have been 
described in 0.5 to 2 % of AML (Adriaansen, 1992) and in 10 % of childhood ALL (Raimondi 
el af., 1986). The cytogenetic detection of chromosome 12p13 translocations with several 
different chromosome pru1ners suggests that this loclls may harbor one or more genes that could 
be targets of the distinct translocations. Because of the frequent deletions in childhood ALL this 
region may also contain one or more tumor suppressor genes. 
Characterization of the breakpoints of four different translocations t(5; 12)(q33;p13). 
t(l2;22)(p 13;q 11). t(9; 12)(q34;p 13) and t(l2;21)(p l3;q22) by four teams of researchers resulted 
in the independent cloning of the TEL ({rans/ocation gTS leukelllia) (also named ETV6: gTS 
lranslocation y"ariant 6) gene on chromosome region 12p13. This provided powerful tools to 
study TELs involvement in other translocations in leukemias and lymphomas using molecular 
cytogenetic techniques (FISH), and Southern, Northern and RT-PCR analysis. In addition. TEL. 
candidacy for a tumor suppressor function could be further substantiated by LOH studies, 
molecular cytogenetic analysis and biochemical investigations. Furthermore, the clinical 
relevance of TEL rearrangements could be studied by using them as prognostic indicators for 
the leukemia. In this chapter I will present clinical and molecular data of chromosomal 
aberrations involving the TEL gene and I will discuss putative mechanisms by which TEL and 
TEL chimeric proteins contribute to leukemogenesis. The first part of this chapter describes 
chromosomal translocations listed in numerical order of the partner chromosome. The second 
part deals with deletions of the TEL locus. The TEL gene spans about 240 kb and encodes 8 
exons. Exon I, 2 and 3 are separated by two large introns of approximately 100 kb each (Baens 
et at., 1996). Exon 3 and 4 encode a putative helix-loop-helix (HLH) protein-protein interaction 
domain, whereas exon 6-8 encode the ETS DNA binding domain (figure 6). 
Tl'lllls/ocatiolls 
1(1;12) 
A single case of t(l; 12) has been mentioned by Golub et al. (Golub ef a/ .• 1996a) in which the 
breakpoint in TEL occurs between exons 5 and 6 (see figure 6). This case is mentioned here for 
the sake of completeness. No clinical data of the malignancy associated with the translocation 
were presented and the fusion partner of TEL has not been identified. 
1(3;12)(q26;pI3) 
Raynaud and coworkers (Raynaud ef a/., 1996c) described a recurrent t(3; 12)(q26;p13) in four 
patients with acute transformation of MDS and one with blast crisis of cALL. FISH analysis 
indicated that in 3 cases the 12p13 breakpoint occurred within the first and second introns of 
TEL and the 3q26 breakpoints were scattered 5' and 3' of EVJ I gene. This heterogeneity of 3q26 
breakpoints was also observed in t(3;21)(q26;q22) in which AMLI, located at chromosome 
region 21q22, is rearranged in fusion transcripts with two unrelated genes at 3q26, EAP and 
MDSJ, as well as with EVIl (reviewed by Nucifora and Rowley, 1995)(Nucifora & Rowley, 
t8 
1995). RT-PCR analysis of RNA of two leukemic samples associated with t(3; 12), revealed that 
the traIlSlocations result in chimeric TEL-EVIl and TEL-MDS I-EVIl transcripts ( Drs P. 
Peeters and P. Marynen; personal communication), The fusion transcripts only contain TEL 
exon 1 or 1 and 2, arguing that the TEL promoter induces ectopic transcription of the EVIl 
gene which is normally not expressed in hematopoietic cells (Morishita et al., 1990), 
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t(S;12)(q33;p13) 
The first published translocation involving TEL was t(5;12)(q33;pI3) , associated with a 
subgroup of chronic myelomonocytic leukemia (CMML) (Golub e/ al., 1994). CMML is a form 
of MDS that is characterized by abnormal clonal myeloid proliferation and progression to 
AML. The translocation breakpoint on chromosome 12 occurs between exon 4 and 5 of TEL 
(Golub e/ al., 1994; Wlodarska e/ al., 1995b). The translocation results in an in-frame fusion 
of TEL and the gene eucoding the PDGFp receptor on chromosome 5q33. The fusion protein 
consists of the N-terminal part of TEL, including its HLH oligomerization domain, and the 
transmembrane and tyrosine kinase domains of the receptor (figure 7). Although the ligand 
binding domain of the receptor is absent, activation of the kinase domain occurs as a result of 
oligomerization of the fusion protein via the TEL HLH domain. This ligand independent self-
association and constitutive activation of the kinase domain is thought to activate signal 
transduction pathways leading to neoplastic transformation. Furthermore, TEL-PDGF~R 
confers JL3 independent growth to the JL-3 dependent hematopoietic cell line BalF3 (Carroll 
e/ al., 1996). 
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t(6;12)(q23;p13) 
TEL was reported as the target of t(6;12)(q23;p13) in a cell line that was derived from leukemic 
cells of a patient with ALL (Suto ef al., 1995). Two different types of fusion cDNAs were 
characterized. The first type contained eXOll 1 and 2 of TEL fused to what is thought to be the 
3' untranslated region of the STL (six-twelve-leukemia) gene. A second eDNA contained 
sequences of STL fused to 31 TEL starting with exol1 6. 
t(7;12)(plS;p13) 
TEL involvement was demonstrated by FISH analysis in two ca,es of t(7;12)(pI5;pI3) 
(Wlodarska ef al., 1995a). In a case of AML MO the 12pl3 breakpoint was localized between 
TEL exons 2 and 8, whereas in a case of ALL L2 the breakpoint is located ncar exon I. Since 
the gene on chromosome 7p15 is not known, the functional implication of these two 
translocations remains to be determined. 
t(9;12)(q34;p13) 
The initial experiment that resulted in the discovery of TEL involvement in t(9; 12)(q34;pI3) 
was not the molecular analysis of this cryptic translocation per se, but a series of immune 
complex-kinase reactions to study protein tyrosine kinase activity of BCR-ABL fusion proteins. 
In a case of cALL without the Philadelphia chromosome, an ABL protein with elevated protein 
kinase activity was detected (Chan ef al., 1987). RACE-PCR cloning identified a TEL-ABL 
fusion transcript as a result of a t(9; 12)(Papadopoulos ef al., 1995). The breakpoint in TEL 
occUlTed between exons 3 and 4, similar to these found in cases of t(5; 12). No reciprocal ABL-
TEL product could be amplified. The resulting TEL-ABL fusion protein contained N-terminal 
TEL sequences, induding the Ill.H domain, fused to the kina'ie domain of ABL, a non-receptor 
tyrosine kinase (figure 7). This configuration is very similar to t(9;22) BCR-ABL, in which 
BCR provides a coiled-coil homodimerization domain (McWhirter ef al., 1993). In a case of 
AUL t(9; 12;14), a TEL-ABL fusion has been characterized in which the TEL breakpoint was 
located between exons 5 and 6 (Golub ef al., 1996b). Screening of 186 adult ALL and 30 
childhood ALL patients for a TEL-ABL fusion suggested that it is not a common event in ALL 
(Janssen et al., 1995). This is probably due to the opposed transcription direction of the genes 
on the involved chromosomes, i.e. towards the centromere for TEL on 12p13 and towards the 
telomere for c-ABL on 9q34. In order to generate a TEL-ABL fusion a more complex 
translocation is necessary, that involves inversion of one of the genes. 
The increased protein tyrosine kinase activity of ABL in the case described by 
Papadopoulos et al. (Papadopoulos ef al., 1995) already suggested that the HLH domain 
mediated oligomerization of TEL-ABL was responsible for this effect. ill vitro experiments 
indeed demonstrated that TEL-ABL is constiMively phosphorylated, depending on the 
presence ofTELs HLH domain (Golub ef al., 1996b). Like BCR-ABL (McWhirter & Wang, 
1993), TEL-ABL exhibits all the properties of an activated kinase; it localizes to actin stress 
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fibers, it transforms fibroblasts and primary bone marrow cells and confers ll.3 independency 
to the hematopoietic cell line BaJF3 (Golub ef al., 1996b). These data are consistent with the 
interpretation that ABLs kinase domain activates downstream signal transduction cascades that 
are necessary for neoplastic transformation. Although TEL-ABL is thought to be a rare 
translocation, study ofTEL-ABL could be important to reveal thc mechanism by which ABL 
contributes to leukemogenesis. Indeed, it was recently demonstrated that TEL-ABL and BCR-
ABL activate similar transduction pathways in hematopoietic cell lines (Okuda et al., 1996). 
In one of the TEL-ABL translocations mentioned above, the second TEL allele was 
deleted, resulting in loss of wild type TEL function. Golub and coworkers suggested that loss 
of TEL function alone may be a leukemogenic event and that TEL may act as a tumor 
suppressor gene. Arguing against this hypothesis is the fact that TEL-ABL transforms in a 
dominant fashion. Golub et aI. favor the hypothesis that interaction ofTEL-ABL with TEL may 
inhibit the activity of TEL-ABL. Deletion of the second TEL allele would circumvent that 
phenomenon. An alternative theory I favor is that both mechanisms may act synergistically. 
Deletion of the second TEL allele would lead to maximal activation of ABLs phosphotyrosine 
kinase activity that is further complemented by loss of the alleged tumor suppressor activity of 
TEL. 
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Figure 7. Schematic representation of chimeric TEL proteins, associated wirh IlUmml leukemias. The TEL 
sequences are indicated in white boxes, those of the fusion partners in shaded boxes. HLH::: Helix~Loop·Helix 
domain, ETS ::: ETS DNA binding domain, RUNT ::: RUNT homology DNA binding domain, PTK ::: 
phosphotyrosine kinase domain, QP::: glutamine/proline rich region 
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t(lO;12)(q24;p13) 
TEL involvement has been documented in a case of progressive MDS, with eosinophilia and 
monocytosis, associated with a t(lO;12)(q24;pI3)(Wlodarska ef al., 1995b). FISH analysis 
using cosmids containing 5'TEL and 3'TEL exons revealed that the 12p13 breakpoint was 
located within the TEL gene. Target genes on chromosome IOq24 have not been identified. The 
authors propose that in addition to t(5; 12), variant translocations like t( I 0; 12), could contribute 
to this subtype of MDS. 
t(12;13)(p13;q14) 
Tosi et a!. (Tosi ef al., 1994) reported two cases of adult AML of FAB subtype MO, with a 
cytogenetically detectable t(12;13)(pI3;qI2). Previously, cases with this translocation were 
reported in leukemia of lymphoid origin. At the time of publication only the status of the RB-l 
tumor suppressor gene at 13q14 had been analyzed by FISH. However, no definitive conclusion 
about the involvement of this gene could be established. By Northern analysis of patient RNA 
using a 3' TEL eDNA probe an aberrant transcript could be detected in both cases. Furthennore, 
the Y AC 964c I a containing the entire TEL gene was found to be split in FISH analysis (Dr 
Biondi; personal conmmnication). These data suggest TEL involvement in the translocation, 
but to date efforts to clone a chromosome 13q 14 fusion partner have not been successful. 
t(12;14)(pl1;q32) 
In a case of B non-Hodgkin lymphoma (NHL), FISH revealed a translocation 
t(12; 14)(pll ;q32), with a microdeletion of TEL sequences. The second chromosome 12 was 
involved in three different translocations, one of them a t(5; 12;?)(p II;p IlpI3;?) with the TEL 
breakpoint in the 5' end of the gene, upstream of the HLH domain. This was the first case of 
TEL reanangement in NHL (Dr. Wlodarska; personal communication). 
t(12;21)(p13;q22) 
Translocation (I2;21)(pI3;q22) can be detected in 0.05% of childhood ALL by standard 
cytogenetic analysis (Raimondi, 1993) and was first described by Soekannan et a!. in 1992 
(Soekarrnan ef al., 1992). It was independently characterized by two groups (Golub ef al., 1995; 
Romana ef al., 1995a), who found a fusion of TEL to the AMLI gene on chromosome 21 q22. 
The breakpoints in TEL are mainly clustered in an intron between exons 5 and 6. The TEL-
AMLI chimeric transcript encodes a fusion protein containing the HLH oligomerization 
domain of TEL and the RUNT DNA binding domain and transactivation domain of AMLI 
(figure 7). Molecular analysis of ALL by FISH, Southern analysis and RT-PCR analysis 
revealed that the translocation can be detected in up to 25% of childhood ALL, in both 
Caucasian (see chapter 3)(McLean ef al., 1996; Romana e/ al., 1995b; Shurtleff ef al., 1995) 
and Chinese populations (Liang e( al., 1996). It defines a subgroup of pediatric ALL of an age 
between 1 and 10 years with a B lineage immunophenotype, a nonhyperdiploid DNA content 
and an excellent prognosis (chapter 3.1). TEL-AMLl seems to be restricted to childhood ALL 
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as it is rarely detected in adult ALL (Raynaud ef al., 1996b; Shih ef al., 1996). A detailed 
description of the incidence of the translocation, its possible clinical significance and the 
molecular mechanism by which the fusion protein is thought to contribute to leukemogenesis 
can be found in chapter 3.1 of this monograph. In short, TEL-AMLI was found to repress 
AMLI dependent transcription of TCRP enhancer reporter plasmids ill vitro (Hiebert ef al., 
1996). Furthennore, it oligomerizes with TEL and in transfected fibroblasts it colocalizes with 
endogenous TEL in the cytoplasm. These characteristics arc dependent on the presence of the 
HLH domain in the fusion protein (see chapter 3.2). 
The translocation is frequently accompanied by deletion of the second TEL allele 
(Golub ef al., 1995; Raynaud ef al., 1996a; Romana ef al., 1995a; Wlodarska ef al., 1996). This 
deletion is a secondary event in the leukemia (Kim ef al., 1996; Raynaud ef al., 1996a; 
Wlodarska ef al., 1996), suggesting that it may provide a proliferative advantage to a TEL-
AMLl positive leukemic subclone. 
t(12;22)(p13;qll) 
In hematopoietic malignancies of myeloid lineages, the rare translocation(12;22)(pI3;qll) 
results in the fusion of the MNI gene on chromosome 22q II to TEL (Buijs ef al., \995)(see 
chapter 2.1). MN I was characterized by the group of Zwarthoff (Lekanne Deprez ef al., 1995) 
by cloning of the breakpoint at chromosome 22qll of a reciprocal t(4;22)(pI6;qll) in a patient 
with multiple meningiomas. The gene contains two exons, separated by an intron of 60 kb. The 
first exon encodes the main body of a nuclear protein that shows no homology to protein 
sequences in databases, except for two homopolymeric glutamine stretches. These are encoded 
for by repeated CAG sequences of which the inadvertent amplification in several genes leads 
to gene inactivation and causes certain inherited diseases, such as Huntington's chorea(Nance, 
1996). However this mechanism does not apply to MNl, since no instability in the CAG repeats 
of MNl could be observed in tens of cases of meningioma (Drs Riegman and Zwarthoff, 
personal communication). Another characteristic of MNl is that its N-tenninal one third is rich 
in proline residues. Together, these characteristics suggest that MNI is involved in transcription 
regulation (Gerber ef al., 1994). Since t02;22)(pI3;qll) is the subject of chapter 2 of this 
thesis, a detailed description of cloning of the translocation, characterization of the fusion 
transcripts and biochemical analyses of the fusion proteins can be found there. Here I will 
restrict myself to a summery of the data. 
Breakpoints in the TEL gene have been localized between exons 2 and 3 and exons 3 
and 4, i.e. 5' of or within the HLH domain encoding exons. Both reciprocal chimeric transcripts 
are expressed: TEL-MNI and MNI-TEL. The MNI-TEL fusion protein contain almost the 
entire MNI protein fused to the ETS domain of TEL (figure 7). We hypothesize that these 
fusion proteins interfere with expression of TEL target genes. Indeed, MN I-TEL type I was 
found to transform a murine fibroblast cell line, similar to the Ewing's sarcoma associated 
fusion protein EWS-FLII. The transforming capacity of the fusion protein is dependent on N-
terminal MN 1 sequences. Furthermore, the transforming potential of MN I-TEL was reduced 
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by mutating the ETS domain. Taken together these observations are in agreement with the 
above hypothesis. MN 1 and MN1-TEL were found to upregulate transcription of the Moloney 
sarcoma virus LTR. However, N-terrninal MNI sequences, essential for transformation do not 
coincide with sequences of MN 1 necessary for upregulation of transcription. Based on the 
structure of the fusion protein and its activities we favor the hypothesis that, in contrast to the 
fusion proteins mentioned above in which the HLH domain of TEL is instrumental, in :MN 1-
TEL the ETS DNA binding domain is instrumental in neoplastic transformation. 
Deletio1ls 
Deletions of chromosome 12p13 in pediatric ALL could be detected in approximately 5 % of 
the cases (1991; Raimondi ef al., 1986). Using FISH analysis with probes derived from this 
region, it was possible to map their smallest region of overlap to a genomic region that is 
bordered distal to the centromere by TEL and proximal by KIPl (Hoglnnd ef al., 1996; 
Kobayashi ef al., 1994; 1995; Sato ef al., 1995). Secondly, LOH of this region was found to 
be very common in childhood ALL (Cave ef al., 1995; Stegmaier ef al., 1995; Takeuchi ef al., 
1996). However, mutation analysis of both TEL and KIP I revealed a germline configuration 
of both genes (Seriu ef al., 1996; Stegmaier ef al., 1996), suggesting that neither of these genes 
would be the critical tumor suppressor gene in pediatric ALL. 
It has already been mentioned above that t(9;12) TEL-ABL and t(12;21) TEL-AMLI 
are frequently accompanied by a deletion of the non-rearranged TEL locus or in some cases by 
an intragenic TEL deletion. To date, deletions of TEL have only been observed in combination 
with a translocation of the other allele. It remains an interesting question whether hemizygosity 
of TEL is associated with genomic instability that could subsequently lead to deletion of the 
non-rearranged TEL locus andlor other genetic defects that promote progression of the 
leukemia. 
Concludillg remarks 
In this chapter an overview has been presented of chromosomal aberrations in human 
hematopoietic neoplasms in which the TEL gene on chromosome 12p13 has been implemented. 
In addition to the translocations mentioned above, TEL is a likely target of other translocations, 
such as t(2;12)(q37;p13), t(4;12)(qI2;pI3), dic(9;12)(p11-13;pll-12), t(l2;17)(pI3;qll), 
t(l2;18)(pI3;pll), dic(l2;19)(pI3;qll), t(12;20)(pI3;qI2) (Mitelman, 1991). TELs 
involvement in these translocations and their possible contribution to leukemogenesis is the 
foclls of ongoing research. 
The biochemically distinct HLH domain and the ETS domain of the protein contribute 
to different fusion proteins (see figure 6). TEL may also contribute to leukemogenesis by 
promoter addition, as seems to be the case in t(3; 12) TEL-EVIl. Furthermore, cytogenetic and 
biochemical data support a model in which the dosage of nuclear TEL may influence the 
progression of the disease. The diversity by which TEL is thought to contribute to the various 
hematopoietic malignancies is an intriguing aspect. In this respect TEL is unique. 
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Translocation (12;22) (p13;qll) in myeloproliferative disorders results in 
fusion of the ETS-like TEL gene on 12p13 to the MNI gene on 22qll 
Arjan Buijsl, Sarah Sherr', Sjozefvan Baal', Saskia van Bezouw1, Dorien van def Plas3, Ad Geurts 
van Kessel4, Peter Riegman2, Ronald Lekanne Deprez\ Ellen Zwarthoff2, Anne Hagemeijer3 and 
Gerard Grosveld' 
I Deparlmelll o/Genetics, Sf Jude Children's Research Hospital, PO Box 318, Memphis, Tellnessee 38101-0318, USA; Departments 
of1patllOlogy and JCell Biology alld Genetics, Erasmus Unil'crsity, PO Box 1738, 3000 DR Rollerdam, The Netherlands; 
4Departmellt of Humoll Genetics, Unil'ersity Hospital, PO Box 9101, 6500 HB Nijl/legel/, nle Netherlollds 
In myeloid and lymphoid leukemias recurrent chromoso-
mal aberrations can be detected in chromosome region 
12p13. We characterized the genes inmh'cd in t(12j22) 
(p13;qll) in two patients with m~'eloid leukemia and one 
with myelodyspfastic syndrome (l\IDS). !JINI, a gene OIl 
chromosome 22qll was shown to be fused to TEL, a 
member of the family of ETS transcription factors 011 
chromosome 12p13. TIle translocation results in tran-
scription of the reciprocal fusion mRNAs, I\'lNI-TEL 
and TEL-:MNl, of which l\,'lNI-TEL is likely to encode 
an aberrant transcription factor containing the ETS 
DNA-binding domain of TEL. In addition to fusion of 
TEL to the PDGF,B receptor in t(S;12) in chronic 
myelomonocytic leukemia (CMML), our data suggest 
that the imolyement of this protein in myeloid 
leukemogenesis could be dual; its isolated protein-
protein dlmerization and DNA-binding domains may be 
crucial for the oncogenic acth'ation of functionally 
different fusion proteins. 
Keywords: translocation; TEL; AfNl; myeloid leuke-
mia; chromosome 12p 
Introduction 
Thc translocation (12;22)(P13;qll) has been associated 
with myeloid malignancies· of different FAB SUbtypes, 
Originally it was found as an alternative translocation 
in chronic myeloid leukemia (CML) and it was 
proposed that the 22q - chromosome was an 
alternative Philadelphia chromosome (Engel et al., 
1977; van der Blij-Philipsen et al., 1977; Verma and 
Dosik, 1979). However, later the same specific 
translocation was also found in rare cases of acute 
myeloid leukemia (AML) MI, M7, M4 and MDS 
(Hagemeijer et al., 1981; Johansson et aI" 1990; Callen 
et al., 1991; Mitelman, 1991; Kashimura and 
Minamihisamatsu, 1993). The chromosomal region 
12plI-13 has been implicated in the genesis of 0.5-
2% of different myeloid (Adriaansen, 1992) and 10% 
of childhood acute lymphoblastic leukemias (ALL) 
(Raimondi et aI" 1986), In the case of myeloid 
leukemias, this often involves balanced translocations 
with a collection of different partner chromosomes 
(Mitelman, 1991), which is also true for the specific 
sub-band 12p13, involved in t(12;22), In ALL the 
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region is often deleted, but also balanced translocations 
have been described (Raimondi et al., 1986; Mitelman, 
1991; Krance et al., 1992; van der Plas et al., 1995). 
With respect to the cytogenetic data, different loci, 
present on 12pll, 12p12 and 12p13, may be involved 
in these malignancies (Mitelman, 1991). 
Our interest in this specific but rare translocation in 
myeloid malignancies was raised by the 22qll break-
point and its association with aspecific CML, which 
indicated a possible involvement of the BCR gene. 
However, initial mapping experiments with nCR 
cDNA probes excluded tlus possibility and the use of 
rodent/human hybrid cell lines, containing the segre-
gated chromosomes of a patient with t(12;22) AML, 
suggested that the translocation breakpoint mapped 
telomeric from the BCR gene on chromosome 22 
(DvdP, unpublished results), We set out to molecularly 
identify t(12;22) with the idea that it represented a 
crucial tumorigenic step in the genesis of myeloid 
malignancies and that the same locus on 12p13 may be 
involved in other chromosome translocations. 
Using hybrid cell lines from a patient with t(12;22) 
AML-M4, we could map and clone the genomic 
chromosomal breakpoint on 22qll. It was situated in 
the intron of MNl, a candidate gene for meningioma, 
encoding a protein with features characteristic of 
transcription factors (Lekanne Deprez et aI" 1995, 
this issue), This allowed us to clone chromosome 12 
sequences and to isolate fusion cDNAs, using a RT-
peR cloning procedure. The translocation results in 
the fusion of the UN 1 gene to the recently identified 
TEL gene on 12p13, a member of the ETS gene 
family of transcription factors (Golub et al., 1994). 
The amino-terminal part of the TEL protein, contain-
ing a putative protein-protein dimerization domain, 
was found to be fused to the tyrosine kinase domain 
of the PDGF,B receptor by the t(5;12)(q34;p13) in 
chronic myelomonocytic leukemia (CMML), In two 
out of three patients with different myeloid malig-
nancies, carrying t(12;22), both the TEL-MN 1 and 
MNI-TEL fusion mRNAs are expressed. In hybrid 
cell lines of the third patient, only expression of MNI-
TEL mRNA could be found, This transcript will 
encode a fusion protein, containing an ETS DNA-
binding domain, that may act as an altered 
transcription factor, similar to EWS-FLII in Ewing's 
sarcoma (Bailly et al., 1994). Our data suggest that 
the involvement of TEL in human myeloid malig-
nancies is dual. Distinct domains of the protein seem 
to be essential constihlents of functionally different 
fusion proteins, 
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Results 
Localization of chromosomal breakpoillt 01/ 22qJJ 
To localize the 22q II breakpoint of t(l2;22), probes of 
known localization in the 22qll-qI3 region were 
hybridized to DNA of somatic cell hybrids, containing 
the segregated translocation chromosomes of a t(12;22) 
AML patient. To this end, bone marrow cells of a 
patient (PI) with t(12;22) AML were fused to the 
hamster cell line A3 using standard procedures (Geurts 
van Kessel et at., 1981). After selection, individual 
clones were picked and characterized cytogenetically, 
using Reverse banding techniques. The chromosomal 
content of the relevant hybrid cell lines is shown in 
Table 1. DNA of human thymus, hamster cell line A3 
Table 1 Hybrid cdllines containing segregated t(12;22) chromosomes scored for chromosome 22q-s~ific markers 
centromere 
(I.S kb 
Markers telomere 
2,2 17.13' 
Chromosomes EcoRI16A4 MNI MNI 
Cell Line· 12 12p+ 22 22q- S'BCR D22S1 Cosmid eDNA cDNA 022S193 D22S56 LlF D22S15 e-sis 
A3JA 19A + + + + + + + + + + + 
A3JA 19C + 
A3JA 13B + + + + + + + 
A3JA 12A + + + + + + 
A3JA Ie + + 
A3JA 2B + + 
A3JA 12C + + 
A3JA 20A + + 
A3JA 14B + + + 
Chromosome; + chromosome seen in at least 5/10 metaphases. Marker: +positi\"e hybridization signal; - no hybridiza.tion signal. .: the hybrid 
cell lines have additional human chromosomes not listed in this table 
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Figure 1 (a) Schematic representation of human chromosome 22. Indicated are several lod with respect to t(l2;22)(P13;qll) (b) 
Restriction map of UNl on chromo~ome 21. Indicated below the map are probes BI.S, eDNA 2.2, EHJ.4, pUK4, eDNA 17.1 3' 
and D22S193 and cosmids clones 76A4 and 50Bll. Localization of ewns are indicated with black boxes. (c) Restriction map of 
TEL on chromosome 12. The t(12;22) breakpoints of patients 1, 2 and 3 are shown (pi, p2 and p3). Below the map, the phage 
eontig is shown of which clones MR41 to MR40 were isolated by chromosome walking starting \'ith chimeric phages containing the 
(12;22) breakpoint of p2. MR43 to MR47 were isolated by hybridization \\ith TEL eDNA clone hpc7A to a genomic phage library. 
The eDNA hpc7A is depicted underneath the phage contig. The positions of the type I and n in t(12;22} and the 1(5;12) fusions are 
indicated hy arrows. Dashed lines indicate genomic fragments (black boxes) that cross-hybridize to hpc7A subfragments. These 
genomic fragments were delimited by various restriction enzyme sites, not shown in this map. HLH=Helix-Loop-Helix domain; 
DBD=ETS DNA-binding domain; E=EcoRI, S=SacI, B=BamHI, X=XhoI 
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Figure 2 Localization of breakpoints on cbWffiosome 22 in pi and p2 (a) A Southern blot containing DNA of hamster cell line 
A3, hybrid cd1lines with the segregated translocation chromosomes derived from bone marrow of pi, bone marrow of p2 (2) and 
human th}1nuS DNA (N) was digested \\ith £CoRI, BamHI, Bglll or Hindill. Southern blots were hybridized \\ith a 1.4kb EcoRl-
HimiffI fragment, located al the 5' side of the 60kb intron in MN1. Sizes of nor IDa I fragments are indicated (in kb) and arrowheads 
indicate aberrant fragments (b) DNA of bone marrow from p2(2) and human thymus (1\'), digested \\ilh HeoRl, DomHI, BgaI, 
Hindlll or Pstl was hybridized v.ilh 4Akb £CoRI fragmcnt pUK4. Sizes of molecular weight markers are shown (in kb). 
Arrowheads indicate aberrant fragments. A map of the '\/N1 region Ilith I<Xalization of probes and the breakpoints of pi and p2 is 
shol\ll in the middle of the figure 
and hamster/human hybrid cell lines A3JA 19A (#22), 
A3JA 19C (# 12), A3JA I3B (# 12p') and A3JA 12A 
(# 12,22q-) was digested with EeoRI and BamHI. 
Southern blots were hybridized to 5/DeR, D22SI, 
D22S56, LIF, D22S15 and c-sis (for relative position of 
probes, see Figure la), respectively. The fonner two 
probes hybridized with DNA of hybrid cell lines A3JA 
19A and A3JA 12A, whereas the latter four hybridized 
with DNA of hybrid cell lines A3JA 19A and A3JA 
13B (Table I), indicating tbat the breakpoint was 
located between D22S1 and D22S56. Subsequent 
hybridization with probes from this area, D22S193 
and a single copy 1.8 kb EeoRI fragment, mapping 
between D22S1 and D22S56, revealed that D22S193 
was not translocated in pI, while tbe 1.8 kb EeoRI 
fragment was. These two probes are derived from a 
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cosrnid contig spanning the translocation breakpoint 
on chromosome 22q 11 of a meningioma associated 
balanced translocation t(4;22)(P16;qII), in a patient 
with sporadic meningiomas (Lekanne Deprez et al., 
1991) (Lekanne Deprez et al., 1995, this issue). The 
physical distance between the probes is 100 kb (Figure 
Ib), spanning a region containing a gene called MNI, 
consisting of two large exons separated by an intron of 
60 kb, oriented with its 3' end toward the centromere 
of chromosome 22 (Figure Ib). To analyse whether 
MNI was directly involved in t(12;22), we hybridized 
blots containing DNA of our hybrid cell lines with MNI 
eDNA probes 2.2 (1.5 kb) and 17.1 3' (1.4 kb), derived 
from the 5' and 3' eXOl1, respectively (see Figure Ib). As 
shown in Table I, cDNA 17.1 3' hybridizes with DNA 
derived from cell line A3JA 12A (# 12,22q-), but not with 
DNA derived from A3JA IC (# 12,12p+), while cDNA 
, 
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N Z 
10.5- .. 
RRO.3 
40-
BamHI 
1 
~ ~ ~ 
~ ~ 
('1 ~ ~ ~ 
<I; ~ ~ '**' (',j z 
2.2 hybridized with DNA derived fromcelllineA3JA 13B 
(# 12p+). Thus the probes are separated by the 
translocation, indicating that .I.UNI contains the 22qll 
breakpoint of the t(12;22) in pI. To map the position of 
this breakpoint, genomic subfragments of cosmid 50Bl1 
(see Figure lb) were hybridized to Southern blots 
containing DNA of the hybrid of this patient digested 
with EeoRl, Bam HI, BglIl and HindII!. One of these, 
probe EH 1.4 (Figures 1 band 2 a and b), detects a normal 
7.7 kb EeoRl fragment in DNA of hybrid cell line A3JA 
19A (#22), A3JA 2B (1I22,12p') from pi, in bone 
marrow DNA of p2 and normal human thymus DNA 
(Figure 3b), but an aberrant fragment of 5.7 kb in cell 
lines A3JA IC (# 12,12p+) and A3JA 2B. To exclude an 
EeaRl polymorphism, aberrant fragments were also 
detected in BamHI and BglII digested DNA of these cell 
lines (20 and 12 kb, respectively). 
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Hgurc 3 Fluorescent ill Ji/u hybridization and localization of the breakpoint on chromosome 12p13 in pI. (a) Chimeric TEL·MNI 
12·22 phage done MR2 from p2 was hybridized to metaphase chromosomes of nonnal human blood. Right panel shows position of 
chromosomes 12 and 22 with DAl'I staining. Hybridization of MR2 to the short ann of chromosome 12 (strong signal) and the 
long arm of chromosome 22 (weak signal) is indicated with an arrow. Localization of chimeric phage dones MR 20 and MR2 on 
the physical map of the 12pJ3 region is shown at the boltom of (b). Sequences deri,"ed of chromosome 12 are indicated with bold 
lines whereas sequences derived from chromosome 22 are indicated with thin lines (b) DNA derived from hamster un line A3, 
h)·brid cell lines containing the relevant translocation chromosomes of pi (I), bone marrow of p2 (2) and nonnal th)mus (N) was 
dige,ted \\ith EeoRl, BllmHl, Bglll or Hilldrn. The Southern blot was hybridized \\ith a single-copy O.3kh RsllI fragment (RRO.3). 
Sizes of nonnal fragments are indicated (in kb), aberrant fragments are indicated by an arrow. The physical map of the chromosome 
12p13 region is shown at the bottom of the figure and the position of phage dones MR36 and MR2 and MR20 is indicated. Probes 
used to localize the 12p + breakpoint of pi (I) are shown underneath 
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A similar approach was followed to find the 
breakpoint in the MNI gene in the bone marrow 
DNA of p2. The 4.4 kb EcoRI intronic fragment 
(pUK4; see Figure lb and 2b) detects aberrant 
fragments of 20 kb and 2.2 kb in addition to the 
nonnal EeoRl fragment of 4.4 kb (Figure 2b). Aberrant 
fragments were also detected in Bam HI, BglII, HindUI 
and Pstl digested DNA of p2. These results indicate 
that the breakpoints on chromosome 22 in pI and p2 
are located in close proximity to one another at the 5' 
side of the 60 kb intron of MNI. 
Localization of the breakpoints 011 chromosome 12p 
To identify the breakpoints of these patients on 
chromosome I2pI3, a genomic }.EMBL3 library (IO~ 
pfu) was constructed of bone marrow DNA from p2 
(MERO 12/22 library). From the recombinant phages 
hybridizing with probe pUK4, eight out of 13 showed 
restriction patterns that in part diverged from the wild-
type MNI restriction map and contained EeoRI 
fragments of aberrant size. Of these phages, MR20 
and MR2 appeared to contain the chromosome 12p 13 
and 22ql1 specific breakpoints, respectively (Figure 
3b). To verify whether MR2 indeed contained 
sequences derived from chromosome 12, the phage 
was used as probe in a fluorescent ill situ hybridization 
experiment (FISH) on metaphase chromosomes from 
human peripheral blood. As shown in Figure 3a, MR2 
clearly hybridized to chromosome 12 band pl3, 
confirming its alleged chromosomal position. Since 
this phage clone also contains 0,7 kb of chromosome 
22 sequences, a faint signal on chromosome 22 is 
visible. Similar data were obtained with phage MR20 
(not shown). Mapping of phage clones MR2, MR20 
and wild-type phages of a contig derivcd from this 
region (Figure Ie), revealed that the breakpoint of p2 is 
located in a 1.0 kb EeoRI - HiudfII fragment (see 
Figure Ic). The breakpoint on chromosome 12 in pI 
could be detected by Southern blot analysis of the 
hybrid cell lines using chromosome 12-specific probes 
(HH3.0, HH3.5, EEl.S and EEl.O, Figure 3b). Of 
these, HH3.5, EELS and EE1.0 remain on the I2p+ 
chromosome, while HH3,0 is translocated to the 22q-
chromosome (not shown), A single copy OJ kb Rsal 
fragment (RRO,3, Figure 3b) from this region, detectcd 
aberrant fragments containing the chromosome 12pI3 
breakpoint in EeoRI, BamHI, BgfII and HilldIII 
digested DNA of hybrid cell lines A3JA IC and 
A3JA 2B (Figure 3b), Exact mapping of the breakpoint 
showed that it is situated 13.5 kb telomeric from the 
12pI3 breakpoint in p2, 
RACE-PCR cloning 
Due to restricted amounts of patient material, we 
analysed the presence of aberrant mRNAs by RACE-
PCR (rapid amplification of cDNA ends) (Frohman et 
al., 1988; Belyavsky et aI" 1989). To analyse expression 
of 5' chromosome 12/3' MNI chimeric mRNA, I Jig of 
poly(A)+ RNA of p2 was primed with a 3' MNI-
specific antisense primer for first strand cDNA 
synthesis (Figure 4a, primer I). This product was then 
amplified using a 5' anchor primer and a nested 3' 
MNI primer (Figure 4a, primer 2). A PCR fragment of 
440 bp (not shown) was subcloned and sequenced, The 
fragment contains 282 bI' of new 5' sequences spliced 
to the 3' exon of MNI, In the reading frame of the 
MNI moiety of the clone, the new sequence contains 
an open reading frame with a possible AUG start 
codon 163 bp 5' of the MNI sequence. Comparison of 
the predicted protein sequence with the recently 
published sequence of TEL (Golub et aI" 1994), 
showed that they were identical. TEL is a member of 
the ETS family of transcription factors and contains, in 
addition to the carboxyl-terminal ETS DNA-binding 
domain, a putative helix-loop-helix (HLH) protein 
dimcrization domain, located at the amino-terminal 
side of the protein, In t(5;12) in CMML the HLH 
domain of TEL is fused to the kinasc domain of 
PDGFRp. However, in our case, the breakpoint in the 
TEL gene occurs at a position 5' of the HLH coding 
sequence, Therefore the TEL-MNI mRNA would 
encode a protein of 12 kDa containing the first 54 
amino acids of TEL fused to thc last 59 amino acids of 
MNI, not including the HLH domain of TEL. 
Expression of the complementary MNI-TEL fusion 
mRNA, was testcd by RT-PCR analysis using 
antisense TEL primers (Figure 4a, primcrs 4 and 5), 
Poly(A)+ RNA of p2 (1 fIg) was used to perform a RT-
PCR reaction with MNI sense primer 3 and TEL 
antisense primer 4 (see Figure 4a), Part of this reaction 
was used for a second rollild of peR with the same 
MNI primer 3 and a nested antisense TEL primer 5 
(see Figure 4a), Aftcr gel electrophoresis, a 550 bp 
product was visible (not shown), matching the size 
cxpcctcd for the MNI-TEL fusion eDNA which was 
subsequently confinned by sequence analysis, There-
fore, the respective mRNA is calculated to encode a 
fusion product of 177 kDa, containing the first 1259 
amino acids of MNI fused to the last 397 amino acids 
of TEL, including the helix~loop-helix (HLH) protein 
dimerization domain (Figure 4a; type I). 
Consistent expression of both fusion mRNAs was 
analysed in the other two t(12;22) patients, pI and p3. 
RT-PCR analysis was done on 5 Jig of total RNA of 
hybrid cell lines A3JA 2B (#22,12p+), A3JA IC 
(# 12,12p +), A3JA 20A (# 12,12p +) and A3JA 12C 
(#22q-, 12p+) for pI and on bone marro\v RNA for 
p3. Unfortunately, RNA from hybrid cell lines had to 
be used for pI, since leukemic cells were no longer 
available. In all hybrid cell lines containing the 12p+ 
chromosome, the same 550 bp MNI-TEL cDNA was 
amplified, while in cell lines A3JA 14B (# I2,22,22q-) 
and A3JA 12C (# 12p·,22qj no TEL·MNI eDNA 
could be amplified, RT-PCR amplification of p3 RNA 
from bone marrow cells produced both a TEL-MNI 
and a MNI-TEL-specific product, but the first 
appcared 165 bp longer and the second 165 bp shorter 
than the concomitant fusion cDNA products of pI and 
p2, Cloning and sequence analysis of these amplified 
fragments showed that the breakpoint in the TEL 
coding sequence occurs 165 bp farther 3', explaining 
the discrepancy in size of the amplified cDNA 
fragments. The breakpoint in the TEL coding 
sequence is located within the HLH region, indicating 
that neither of the predictcd fusion proteins will 
contain the intact HLH domain of TEL. We designate 
the fusion in pi and p2 as type I and p3 as type IT 
(Figure 4a). Figure 4b shows the sequence around the 
breakpoint areas of both types of rcciprocal fusion 
cDNAs, which in type I occurs at TEL codon 55 and 
37 
in type II at codon 110. As a result the type II TEL-
MNI and MNI-TEL mRNAs would encode for 
19 kDa and 170 kDa fusion proteins, respectively. 
eDNA clonillg and partial genomic organizatioll oj the 
TEL gene 
A human placenta cDNA library of a complexity of 
IO~ pfu was hybridized with the 5' TEL-specific 246 bp 
EeoRl- XIIOI fragment of the TEL-MNI fusion eDNA 
fragment of pI. Many hybridizing plaques were 
isolated of which we analysed one with an insert of 
1.7 kb (hpc7A) that contained the entire open reading 
frame of TEL as well as 5' and 3' UTRs of 106 bp and 
199 bp, respectively. This cDNA clone was hybridized 
to the genomic MERO 12/22 ).EMBL3 library of p2 
and out of 100 hybridizing plaques 20 were isolated 
and analysed. A partial physical map of TEL is shown 
in Figure Ic. Restriction analysis of phage MR44 
revealed that it has overlap with MR40, which belongs 
to a phage contig of 100 kb that was isolated with the 
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12p13 breakpoint of p2 as a starting point. Subfrag· 
ments of hpc7A were hybridized to the entire phage 
contig to identify fragment containing exons. The 
541 bp XIIOI-Sad TEL cDNA fragment hybridizes 
with the 2.2 kb XIIOI - EeoRl fragment of MR43, the 
12.5 kb SalI-EeoRI fragment of MR40, the 8 kb 
EeoRI fragment of MR44 and the 4.3 kb EeoRI 
fragment of MR46. Sequencing of the 2.2 kb XIIOI-
EeoRl fragment of MR43 showed that the exon/intron 
border coincides with the type I fusion point in the 
cDNA. The breakpoints in the TEL fusion cDNAs of 
our pI and p3 and the published CMML patients 
(Golub et al., 1994) (i.e. 5', within, and 3' of the TEL 
HLH sequence, respectively) mark the borders of 
different TEL exons. Since the type 11 and t(5; 12) 
CMML breakpoint map at least one exon apart and 
primer 4 (located between those breakpoints) hybri-
dizes with the 8 kb EeoRI fragment in phage MR44 
(Figure Ie). we deduce that the breakpoint of p3 is 
located within an iotron between these exons within 
this fragment. From the hybridization pattern of 5' and 
eDNAMNl 
eDNA TEL 
Type I }'~. __ 'm 
and TEL-MNl 
Typal! 
peR products 
5' CAG MC CCC MC AGC 
Q N P N S 
MNf TEL 
AM GM dbc ~TG CAG CCA A7~ TAC 
KEGsoLQPIY 
'fGG AGc3' Pr3 • PIS 550 bp 
\'1 S 
5' ATe CGC em CCT GCG 
R L P A 
TEL MN1 
CAC cm clCC CAC GAC CI'C CCT GeA MC MG 3' 
H L ~260 H D L PAN K 
Typal! 
MNf I TEL 
5' CAG MC CCC MC AGC AM GM GGT GAT G'I'G CTC TAT GAA CTC CTT 3' 
Q N PUS K E G
110 
0 V LYE L L 
5'CGe 
R 
TEL --],--- MNI 
TAT CGA 'Tel' CCT CAT TCA GeC CAC GAC 
Y R S PHS A H D 
"'" 
eTC CCT GCA MC MG 3' 
L P AUK 
Pr6· Pr2 310 bp 
Pr3 • Pr5 385 bp 
Pr6· Pr2 475 bp 
HgUle 4 Schematic representation of cDNAs and breakpoint regions in t(12;22) (a) cDNAs of nonna! MNI and TEL and the 
reciprocal type I and II fusion products. ORFs of MNI and TEL are shown in black and gray, respectively. Horizontally striped 
boxes indicate the HLH domain of TEL, whereas verticaUy striped boxes indicate the ETS·domain. Primers used in RT·PCR 
reactions are indkated above the MNI and TEL cDNAs. (b) Sequences of reciprocal fusion cDNAs around the type I and II 
breakpoints. Amino acid sequences deduced from the nucleotide sequence are shown in one-letter code below. Numbers indkate in 
which codon of TEL and MNI the fusion occurs for both types of translocations. The number on the right side indicates the length 
of the PCR fusion cDNAs \\ith the different primer combinations 
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3' genomic TEL fragments to the panel of hybrid cell 
lines of pI we conclude that the gene is located in a 5' 
telomeric 3' centromeric orientation on 12p13. This 
orientation is in agreement with the orientation of the 
PDGFRp (Morris et al., 1992) on chromosome 5q33 
and AfN / on chromosome 22q 11 (Lekanne Deprez et 
al., 1995. Ihis issue), predicting that fusion of these 
genes with TEL are the product of conventional 
balanced translocations. 
Discussion 
In this paper we show the existence of new leukemia 
specific fusion genes TEL-UNl and UN/-TEL as the 
result of the t(12;22) in different myeloid malignancies. 
The fact that in three out of three patients the same 
two genes are involved in the translocation provides 
compelling evidence for a direct role of the fusion 
products in the leukemic process. In contrast to most 
chromosome translocations both chimeric gene deriva-
tives are expressed in patient bone marrow cells. 
However, the observation is not unique as it was 
consistently found in acute prol11yelocytic leukemia 
(APL) (Alcalay et al., 1992), where both PML-RARox 
and RARC(-PML RNAs are expressed. In the hybrid 
cell lines of pi, containing chromosome 22q-, no TEL-
MN1 transcript could be amplified. Since the transcript 
was present in bone marrow cells of the two other 
patients, we suspect that its absence is due to silencing 
in the hybrid cell lines. Although we find both fusion 
RNAs using RT-PCR, we do not know their relative 
levels of expression in patient ceJls. Due to lack of 
patient material, we were not able to perform Northern 
blot hybridizations and we did not attempt t6 
quantitate the RT-PCR approach. 
The translocation involves the recently described 
ETS-related gene, TEL, and a gene with a possible role 
in meningioma, MN1. Golub et al. (1994) found TEL 
to be fused to the PDGFRp gene in CMML, a specific 
subtype of myeiodysplastic syndrome (MDS). TEL 
mRNA encodes a typical ETS-related transcription 
factor belonging to the subgroup that have the DNA-
binding domain at the carboxyl-terminal end and a 
HLH protein-protein interaction domain at the amino· 
terminal side (Wasylyk et al., 1993). In CMML, only 
the TEL-PDGFRfi' fusion transcript is expressed, while 
the complementary fusion gene, which would contain 
the DNA-binding domain, is silent. Because the 
breakpoint OCClirs just 3' of the HLH·domain, Golub 
et al. (1994) suggested that, in addition to ectopic 
expression of the PDGFfi' receptor by the TEL 
promoter, the putative dimerization motif may be 
important for ligand independent tyrosine kinase 
activation of the TEL-PDGFRp fusion protein. In 
our fusion products, the breakpoint occurs just 5' or 
within the HLH region (depending on the type of 
fusion), suggesting that this dimerization domain is 
nonessential for the function of the fusion proteins in 
t(l2;22) leukemic cells. 
The possible function of the MNI protein is much 
less clear. As shown by Lekanne Deprez et al. (1995, 
this iss lie) the gene was cloned from a t(4;22) in an 
isolated case of meningioma and the encoded protein 
does not show significant homology to ally known 
protein sequences. The only clue obtained so far is its 
alleged nuclear localization. TILis preliminary observa-
tion in combination with the glutamine/proline-rich 
amino-terminal sequence of the protein, a feature 
found in the activation domains of transcription 
factors (Gerber et al .• 1994), may indicate a role in 
transcription activation. However, whether MN1 
would function as a classic DNA-binding transcription 
factor or as transcription factor associating protein 
remains to be determined. 
As yet there are no clues whether TEL-MNI, MNl-
TEL or both are important for transformation of early 
myeloid precursors in t(12;22). Upon evaluation of 
their featmes we favor the latter product as a potential 
oncogene, since it has the structure of an altered 
transcription factor. It contains the carboxyl-terminal 
part of the TEL protein providing the ETS DNA· 
binding domain linked to almost the entire MNI 
protein. including the glutamine/proline-rich stretches. 
This structure is highly reminiscent of the EWS-FLI I 
and EWS-ERGI fusion proteins in Ewing's sarcoma, 
where the glutamine/proline-rich amino-terminal part 
of the EWS protein is linked to the ETS domains of 
FLIl or ERG (Delattre et al., 1992; Sorensen et al., 
1994). It was shown that substitution of normal amino-
terminal FLII by EWS sequences creates a transcrip' 
tion factor with much stronger transactivation 
potential (May et al., 1993; Bailly et al., 1994). 
Although it has not been analysed, it is reasonable to 
speculate that this is in part due to its glutamine/ 
proline-rich sequences of EWS, making it plausible that 
MN1-TEL could have similar characteristics. In 
addition, fusion of MNI could enhance the DNA 
binding affinity of the TEL moiety of the protein, by 
interference with a possible intra-molecular interaction 
in TEL that was shown to regulate DNA binding in 
several other ETS family members (Lim et al., 1992; 
Wasylyk et al., 1993). Both possibilities are currently 
under investigation. 
Regulation of transcription activity of several 
members of the ETS family. like Elkl and SAP in 
mouse (Janknecht et al., 1993; Marais et al., 1993; 
Hipskind et al., 1994) and pointed and yan in D. 
melallogaster (Brunner et al., 1994), is directed by 
phosphorylation by mitogen activated protein kinase 
(MAPK), that in turn is activated by several signal 
transduction pathways, one of which is the RAS 
pathway. It is interesting to note that TEL contains 
three candidate MAPK sites (Clark-Lewis ef al., 1991; 
Gonzalez et al., 1991) at anLino acid positions 20-23, 
200-204 and 255-258 indicating that activity of the 
protein may be regulated by MAPK, via the RAS 
pathway. In this respect it is interesting that a number 
of t(l2;22) patients, including p2, presents with a 
CML-Iike disease (Miteiman, 1991) while in CML 
tumorigenicity of the BCR-ABL protein in part 
depends upon continuollS activation of the RAS 
signaling pathway (Pendergast et al., 1993). In much 
the same way, the supposedly activated tyrosine kinase 
of the TEL-PDGFRfi' protein in CMML would result 
in activation of the RAS pathway. This indicates that 
RAS activation (Sawyers and Denny, 1994) and 
thereby probably activation of members of the ETS 
family of transcription factors plays a central role in 
the genesis of myeloid leukemia. Also the description 
of an altered ERG gene in AML carrying a t(16;21) 
(Shimizu et al., 1993) could conform to this general 
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picture. Although TEL mRNA is ubiquitously 
expressed, it remains to be analysed whether the 
protein is a natural target of the RAS pathway. 
Alternatively, if TEL is not a downstream target of 
RAS, the activated MNI-TEL protein may feed into 
the same downstream processes by competition for 
DNA binding sites that would normally be occupied by 
RAS-responsive ETS proteins, activating genes essen-
tial for myeloid transformation. 
To date, we have isolated 155 kb of genomic TEL 
sequences. Since the map of the large intron is 
incomplete and genomic DNA encoding the 5' and 3' 
UTRs still needs to be isolated, the gene may extend 
much farther. The involvement of TEL in t(5;12) 
(Golub et al., 1994) and t(12;22), in combination with 
detection of 12pI2-13 aberrations in 0.5-2% of 
myeloid (Adriaansen, 1992) and 10% of pediatric 
lymphoid (Raimondi et al., 1986) malignancies make 
this gene a prime candidate for other chromosomal 
translocations or deletions involving this region. This 
possibility is currently under investigation. In contrast 
to most cases \yith chromosome 12p12-13 abberations 
(Mitelman, 1991), t(12;22) is often the sole karyotypic 
abnormality, despite the variable phenotype of the 
leukemia. We favor the idea that additional, unde-
tected mutations lead to diversification, while actiYa-
tion of TEL is only one of the necessary steps in 
malignant transformation. In this respect it is 
worthwhile to mention that p2 and p3 showed the 
translocation at relapse after treatment with cytostatic 
agents. 
The most remarkable feature of TEL in these 
translocations seems that separate domains of the 
protein contribute to distinct fusion proteins that, 
although different in function, could lead to deregula-
tion of the same downstream targets needed for 
transformation of myeloid progenitors. 
Materials and methods 
Patiellfs alld eel/lilies 
Patient I (pI), a 19-year-old woman was diagnosed with 
A1·1L-M4. Cytogenetic analysis on bone marrow showed a 
karyotype 47,XX, +8, t(12;22)(p13;qII). Patient 2 (p2), a 
58-year-old man, was diagnosed with (ph chromosome 
negative) CML. Cytogenetic analysis of bone marrow 
showed a normal karyotype. Treatment with hydroxyurea 
was started and clinical status improved. However, 2 years 
later the patient relapsed with accelerated disease. 
Cytogenetic analysis of blood and bone marrow revealed 
a karyotype 46,XY, t(12;22)(p13;qI2). Clinical and 
cytogenetic status has recently been described in detail 
(Geurts van Kessel et al., 1994). Patient 3 (p3), a 15-year-
old boy, was diagnosed ,vith myelodysplastic Syndrome 
(RAEB). At diagnosis the karyogram was normal. 
Antileukemic treatment was started. One year later 
cytogenetic analysis revealed a karyogram 46,XY, 
t(12;22)(pI3;qll). 
A hamster/human hybrid eeliline panel was generated by 
fusion of hamster fibroblast cell line A3 with bone marrow 
cells of pi using inactivated Sendaivirus (Geurts van Kessel et 
al., 1981). Hybrid cell lines were cultured in Ham's FlO 
medium+ 10% FCS supplemented with I x HAT. Cytoge-
netic analysis of patient material and hybrid cell lines was 
done according to standard methods (Hagemeijer et al., 
1979). 
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SOli/hem blotting 
DNA of relevant hybrid cell lines was digested with various 
enzymes and electrophoresed on a 0.7% agarose gel. DNA 
was blotted onto nylon membranes (Hybond N+. Amer-
sham, UK). Filters were hybridized according to standard 
procedures (Sambrook e/ al., 1989) with probes labeled by 
random priming (Feinberg and Vogelstein, 1983). Filters 
were washed at a stringency of 0.3 x SSC at 65°C. . 
COllstrllctiolJ of genomic ).EAIBL3 library 
A genomic ).EMBL3 library was constructed of 300 Ilg 
DNA of bone marrow from p2 according to Frischauf el 
al. (1983). Recombinant phages (106) were plated and 
screened with a 4.4 kb BeoRl genomic fragment (PUK4) of 
,uNI. Phages that showed a restriction pattern diverging 
from wild-type UN I phages were considered as putative 
breakpoint containing recombinants and were analysed for 
chromosomal localization by FISH (Hagemeijer et al., 
1993). A genomic map of chromosome the 12p13 region 
was generated by chromosome walking. Before hybridiza-
tion, probes were competed with 100 Jig of human 
competitor DNA (Sigma, St. Louis, MO) for 1.5 h in 
100 fli 5 x SSC at 65°C. 
Fluorescent in situ hybridizatioll 
FISH ,vas done according to Hagemeijer et al. (1993). 
Chromosomes were identified by 4', 6'-diamino-2-phenyl 
indole (DAPI) banding, using a fluorescence microscope 
equipped with FITC and DAPI filters. 
RNA isolatioll 
Total RNA was isolated from bone marrow of patients or 
from A3JA hybrid cell lines using the acidic guanidinium 
thiocyanate method (Chomczynski and Sacchi, 1987). 
Poly(AV RNA was isolated using the PolyA Tract mRNA 
Isolation System III (Promega, Madison, WI). 
RACE clolling 
Poly(A)+ RNA (1 JIg) of p2 was used to clone 5' TEL-3' 
MNI fusion cDNA using the 5'-AmpIiFINDERTM RACE 
Kit (Clonteeh Laboratories, Palo Alto, CAl. First strand 
eDNA was synthesized with MNI antisense primer I (5'-
AGTTAGGGCAGCCACGAATG-3'). A nested antisense 
MNI primer 2 (5'-CTTGAATTCCCAAATCTGTTG-
GAG-3') was used in the PCR reaction. PCR was 
performed using three cycles of denaturation (45 s, 94°C), 
annealing (45 s, 45°C) and extension (2 min, noc, 
followed by 32 cycles of denaturation (45 s, 94°C), 
annealing (45 s, 62°C) and extension (2 min, n°C). PCR 
products were visualized by electrophoresis on a 2% 
agarose gel. PCR products were phenol/chloroform 
extracted. precipitated and digested with EcoRJ. After 
digestion the products were subcloned in pBluescript KS-
(Stratagene, La Jolla, CAl and sequenced using USB 
Sequenase™ Version 2.0 DNA sequencing Kit (USB, 
Cleveland, OH). 
eDNA clolling 
A human placenta eDNA library in ).gt11 (l06 pfu) 
(CIon tech Laboratories, Palo Alto, CAl was screened 
using a 5' TEL-specific 246 bp EcoRI-X//OI cDNA 
fragment of p2, resulting in the isolation of a 1.7 kb TEL 
eDNA clone hpe7A. 
RT·PCR 
MNI·TEL and TEL·MNI junctions were amplified using 
two sets of primers. 5,lg total RNA or I JIg poly(A)+ 
RNA was used to synthesize first strand cDNA with MNI 
antisense primer I with AMV Reverse Transcriptase 
(Promega, Madison, WI) at 4rC. PCR was performed 
using one cycle of denaturation (5 min, 94°C), annealing 
(5 min, 59°C) and extension (5 min, n°C), followed by 24 
cycles of denaturation (2 min, 94°C), annealing (2 min, 
59°C) and extension (3 min, n°C) with TEL sense primer 6 
(5'·AGTGTAGCATTAAGCAGGAACG-3'). 2.5 pi of 
PCR reaction was used in a second round of PCR with 
TEL primer 6 and MN1 primer 2 (Figure 4b), using three 
cycles of denaturation (2 min, 94°C), annealing (2 min, 
47°C) and extension (3 min, n°C) followed by 30 cycles of 
denaturation (2 min, 94°C), annealing (2 min, 60°C) and 
extension (3 min, 7rC). In case of MNI-TEL junction 
eDNA fragments TEL antisense primer 4 (5'·GTAT· 
GACCTCCGGCTG-3') was used to synthesize first strand 
eDNA. PCR was performed using MNI sense primer 3 (5'· 
TCCAGCTACAGAGGCA-3') for one cycle of denatura-
tion (5 min, 94°C), annealing (5 min, 47°C), and extension 
(5 min, n°C) followed by 24 cycles of denaturation (2 min, 
94°C), annealing (2 min, 47°C) and extension (3 min, 
n°C). 2.5 pi of this PCR reaction was used in a second 
amplification with nested antisense TEL primer 5, (5'-
CCAGGGTGGAAGAATG-3'), for 30 cycles of denatura· 
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Abstract 
Recently we have characterized the TEL gene (or ETV6) as the target of the t(12;22)(p \3;q II) 
in myeloid leukemia. TEL is a member of the ETS family of transcription factors and contains 
a Helix-Loop-Helix (HLH) protein interaction domain and an ETS DNA binding domain. By 
contrast to other chimeric proteins containing TEL, such as TEL-PDGFpR in t(5; 12)(q33:p 13), 
TEL-ABL in t(9;12)(q34:p\3) and TEL-AMLI in t(12;21)(p\3;q21) that all contain TELs i-ILH 
domain, MN I-TEL contains theETS DNA binding domain of TEL. Its N-tenninal MNI moiety 
is rich in proline residues and contains two polyglutarnine stretches. These characteristics 
suggest that MNl-TEL may function as an activated transcription factor (e.g., E\VS-FLII in 
Ewing sarcoma), We analyzed the subcellular localization, transforming potential, and 
transcriptional transactivation propel1ies of :rv1N I-TEL to understand its role in leukemogenesis. 
Using immunofluorescence analysis, we showed that MNI-TEL localizes predominantly in 
nuclear speckles. In contrast, MN I and TEL were expressed in a morc diffuse nuclear pattern. 
Unlike TEL and MN I, MNI-TEL transformed NfH3T3 cells as assayed by growth in soft-agar 
assays. This activity required N-tenninal MN 1 sequences as well as a functional ETS domain 
in TEL. Both MNI and MNI-TEL greatly increased transcription from the Moloney sarcoma 
virus LTR. The transactivating capacity of MN I-TEL depended on both the ETS domain and 
sequences in MNl; these MNI -associated sequences differed from those essential for 
transformation of Nlli3T3 cells. Because the fusion protein was functionally dependent on the 
ETS domain for both activities we characterized the consensus DNA recognition sequence of 
TEL. We demonstrate that TEL shows homotypic interaction dependent on its helix-loop-helix 
(HLH) domain. Since in MNl-TEL this domain seems not to be functional, our results suggest 
that MNI-TEL contributes to leukemogenesis by a mechanism distinct from that of other 
chimeras containing TEL. 
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Introduction 
Nonrandom chromosomal abnormalities are hallmarks of underlying gene alterations that have 
a direct causative role in tumorigenesis (Rabbitts, 1994). Translocations affecting the 12pl3 
region are associated with myeloid and lymphoid malignancies (Mitelman, 1991). TEL (or 
ETV6), a member of the ETS family of transcription factors, is the target of several 
translocations involving chromosome 12 band p13, including t(5;12)(q33;pI3) and 
t(9;12)(q34;pI3), in which the C-tenninus of TEL (including its ETS DNA binding domain) 
is replaced by the kinase domains of PDGFpR or ABL, respectively (Golub ef al., 1994; 
Papadopoulos ef al., 1995). The t(l2;21)(pI3;q22) combines the RUNT DNA binding domain 
of AMLl with the N-terminal region of TEL (Golub ef al., 1995; Romana ef al., 1995). The 
oncogenic activation of these three fusion proteins may rest (at least in part) upon the helix-
loop-helix (HLH) protein interaction domain in the N-terminal portion of TEL. For example. 
the TEL-ABL fusion proteins interact via the HLH domain ill vitro, and activation of the 
tyrosine kinase activity of ABL requires this interaction (Golub ef al., 1996). 
We recently characterized the t(l2;22)(pI3;qll), which is associated with myeloid 
leukemias and myelodysplastic syndromes (Buijs ef al., 1995). In t(12;22), N-terminal 
sequences of TEL are replaced by almost the entire MNt protein. Depending on the breakpoint 
in TEL two distinct fusion proteins may be encoded, in which fusion of MN 1 occurs either N-
temunal of (type I) or within (type II) its HLH oligomerization domain. Although its function 
is unknown, MNI seems to be a nuclear protein (Lekanne Deprez et a/., 1995), and its N-
tenninal region is rich in prolines and contains two polyglutamine stretches. These features are 
common to many transcription factors (Gerber et a/., 1994). 
In contrast to the translocations mentioned above, the product of t(12;22) retains the 
ETS domain of TEL. In this way, MNl-TEL is similar to EWS-FLIl, an activated transcription 
factor that is associated with Ewing sarcoma. Like TEL, FLIl is a member of the ETS family 
of transcription factors, and the ETS domain is retained in EWS-FLII. Further, expression of 
EWS-FLII causes transformation ofNIH3T3 cells ill vifro (May ef al., 1993a; 1993b), and this 
activity requires the ETS domain ofFLIl as well as transactivation- and transfonnation-specific 
sequences in EWS (Bailly ef al., 1994; Lessnick ef al., 1995). 
In light of structural similarities to EWS-FLIl, MN I-TEL may function as an activated 
transcription factor. Therefore, we analyzed the subcellular localization, transforming potential, 
and transactivation properties of MNI-TEL to understand its role in leukemogenesis. Our 
results suggest that MNI-TEL is implicated in leukemogenesis by disregulation of the TEL 
transcription cascade. 
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Materials and Methods 
Cel/lilles 
The NIH3T3 (mouse fibroblast), COS-I (simian kidney carcinoma), HeLa (human cervical 
carcinoma), and 293T (human embryonic kidney) cell lines were grown in DMEM 
supplemented with 10% fetal bovine semm. 
Plasmic/s 
See Figure 1 for schematic diagrams of the various eDNA constructs used in our experiments. 
These inserts were cloned into the CMV promoter containing expression vector pSCTOP 
(Fornerod ef ai., 1995) or into the retroviral vector pSRaMSVtkCD8 (Hirai ef ai., 1995). This 
second vector enables selection of transduced cells based on the expression of murine CDS. The 
integrity of all mutant cDNAs was verified by sequence analysis. N-tenninal tagged TEL was 
generated by cloning of a triple influenza hemagglutinin tag (Fornerod e/ al., 1995) into the 
Afllll site within the first codon of the TEL cDNA clone hpc7a (Buijs ef ai., 1995). The deletion 
mutant TELLi53-116 was generated by the in-frame deletion of the 192 bp FspI-XIIlIII fragment 
of TEL. We created a full-length MNI-TEL typelcDNA (MNI-TELI) by a three way ligation 
of the 3736 bp Saefl-NspI MNI cDNA fragment (Lekanne Deprez ef ai., 1995), the 1244 bp 
CiaI-EeaRl TEL fragment and the NspI-Cia I MN I-TEL fusion cDNA fragment obtained from 
patient 2 (Buijs ef ai., 1995). To generate MNI-TEL type fl (MNI-TEL 11), we ligated the same 
3736 bp Sacfl-NspI MNI cDNA fragment to a 1209 bp XIIIIlI-EcoRl TELcDNA fragment and 
to the NspI-XIlIIII fnsion cDNA product from patient 3 (Buijs ef ai., 1995). The various MNI-
TEL deletion mutants were obtained by deleting internal restriction fragments (shown in 
parentheses) from the MN I moiety of MN I-TEL l. These mutants included MN 1-TELLi692-
1123 (1296 bp PlIIll-SljI), MNI-TEUI8-1123 (3335 bp HiIlCfl-S,ft), MNI-TELLiI2-228 (651 
bp HiIlCIl), MNI-TELLiI8-454 (1311 bp MseI), MN I-TELLiI 2-95 I (2803 bp Mscl-PIII/I), and 
MNI-TELLi229-1223 (2985 bp Hillcfl-Eca47f1l). To generate a TEL mutant that was incapable 
of binding DNA (TEL-DBDM), we perfOlmed site directed mutagenesis on full-length TEL 
eDNA in bacteriophage M 13. We changed cedons 396 and 399 from arginine to leucine 
by using the oligonucleotide 5'-GAGAAAATGTCCTT AGCCCTGCTCCACTACT ACAA-3' 
and obtained mutant phage according to manufacturers recommendations (Biorad, Hercules, 
CA), These arginine residues are conserved among all ETS factors and interact with the DNA 
a-helix (Kodandapani ef ai., 1996). The VPI6-TEL fusion construct was created by PCR 
amplification of herpes simplex vims I (HSV I) VP 16 codons 413-489 (Dahymple ef ai., 1985) 
with the primers VPI6COOH (S'-CCCAAGCTTGCCGCCACCATGGCCCCCCCGACCGAT-
3') and VPI6BbsI (5'-CAGGCGGATCGAGTCTTCGTACTCGTCAATTCCA-3'), using 
pRG50 as template (kindly provided by Dr O'Hare). Primer VPI6COOH introduces a HilldIII 
cloning site, a Kozak consensus sequence for initiation of translation (Kozak, 1989), and 
substitutes an ATG for codon 412 of VP16 to provide a translation initiation site in the VP16-
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TEL cDNA construct. Primer VP 16BbsI contains codons 485-489 of VP 16, followed by a BbsI 
restriction site. The cycling conditions were 94°C x 2 min, 55°C x 2 min, and 72°C x 3 min 
for 2 cycles followed by 24 cycles of 94"C x 2 min, 65"C x 2 min, and 72 "C. The resulting 263 
bp HilldID-BbsI HSVI VPI6 cDNA fragment was cloned into the BbsI site at codon 45 of TEL. 
We created the pMSVluc reporter plasmid by cloning the 1.2 kb XhoI-HilldIII fragment, 
containing the 5' MSV LTR of pSRaMSVtkneo (Muller ef al., 1991), into pGL2-Basic 
(Promega, Madison,WI). 
Retroviral transductioll 
Retroviruses were generated by using calcium phosphate transfection (Graham & Eb, 1973) of 
3x 10' 293T cells (in a 10 cm dish) with 10 IIg of the appropriate pSRaMSVtkCD8-based 
construct (Hirai ef al., 1995) and 10 IIg of the ecotropic, replication-defective helper virus pSV-
'¥1l-MLV DNA (Muller ef al., 1991). After 20 hours, the precipitates were removed, and vims-
containing supernatants were harvested for 42 hours at 4-8 hour intervals. The supernatants 
wefC filtered over 0.45 11m gauze filters. We then overlaid 2x1O' Nlli3T3 fibroblasts for 3 
hours (in a 10 em dish) with 1.5 ml of higlHiter supernatant that contained 611g1ml polybrene. 
CD8-expressing cells were collected by using fluorescence-activated cell sorting (FACS) 60 
hours after infection. 
Antibodies 
A synthetic peptide containing the 10 C·terminal amino acids of TEL (Golub ef al., 1994) was 
conjugated to keyhole limpet hemocyanin and injected into New Zealand White rabbits 
(Rockland, Gilbertsville, PAl according to standard techniques (Harlow and Lane, 1988). 
Immunopurified a-TEL antibodies were obtained using affinity purification of the a-TEL 
serum 32 over a synthetic C-terminal TEL peptide·coupled Affi-Gel 10 column (Biorad, 
Hercules, CAl. Monoclonal antibody (MoAb) 2F2 was raised against a bacterially expressed 
N·terminal MNI fusion protein, and will be described in detail elsewhere (A.M.and E.Z.; 
manuscript in preparation). MoAb 12CA5, recognizing an influenza hemagglutinin tag has been 
described before (Wilson ef al., 1984). 
Immunofluorescence analysis 
Pools of lxlOs vil11s-infected, CD8+-positive cells were seeded on microscope slides. After 24 
hours, the cells were fixed in 3% paraformaldehyde for 15 min and permeabilized with 0.2% 
Triton in PBS for 10 min. The fixed cells were then incubated for 2 hours at room temperature 
with immunopurified a.-TEL (1:1250 in PBSIl% BSA), 211g1ml 12CA5 or MNI MoAb 2F2 
(\: 1000 in PBS/I %BSA). Bound antibodies were visualized by using fluorescein 
isothiocyanate-conjugated goat anti-rabbit or Texas Red-conjugated goat anti-mouse secondary 
antibodies as described (Fornerod e/ af., J 995). Images were obtained by using confocal 
microscopy (BioRad MRCIOOO Laser Scanning confocal microscope). 
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Transformation analysis 
For each transduced construct, we plated triplicate samples of 2x 104 CD8-positive fibroblasts 
into soft agar (3 em dish); the culture medium was Iscove's medium supplemented with 15% 
fetal bovine semm (Lugo & Witts, 1989). Colonies were counted 21 days after plating. 
bmmmoprecipitation and Westem blottillg 
By usiug calcium phosphate precipitation, 2xlO' HeLa or COS-I cells (6 em dish) were 
transfected with 10 fig of the appropriate pScrOP-based expression vector. After 20 hours, the 
precipitate was removed and 36 hours later, the cells were metabolically labeled for 12 hours 
with 100 flCi 35S-methionine/cysteine ill I'il'o labelling mix (Dupont NEN, Wilmington, DE) 
or 3H-Ieucine (Amersham Corp., Arlington Heights, IL) in 1.4 Illi of methionine/cysteine or 
leucine-free DMEM, supplemented with 8% dialyzed fetal calf serum. The labeled cells were 
washed twice with ice-cold PBS, then lysed and immunoprecipitated with MoAb 12CA5 
(BAbCo, Richmond, CAl as described, except that the Iysisbuffer contained 1% IGEP AL 
CA630 (Sigma Chemical Corp. St. Louis, MO) in stead of 1% NP40 (Fornerod ef 01., 1996). 
Immulloprecipitates were separated by SDS-PAGE and visuallzed by using autoradiography 
or electro blotted unto PVDF membrane (Millipore, Bedford, MA). Blots were blocked 
overnight in PBS containing 1% BSA, and then incubated for two hours with (t-TEL senUll 32 
diluted I in 1000 in PBSII %BSA. Bound antibody was visualized by using alkaliue 
phosphatase-conjugated antirabbit JgG secondary antibodies using colorimetry. 
Determination of the consensus DNA-binding sequence of TEL 
A full-length eDNA representing the TEL open reading frame was PCR-amplified from TEL 
eDNA clone hpc7a by using the primers 5'-AGATCTGAGACTCCTGCTCAG- 3' and 5'-
AGATCTGCATTCATCTTCTTGGTA-3'. A eDNA corresponding to the TEL ETS domain 
(codons 315-452) was generated through PCR amplification of the same template by using 
primer 5'-AGATCTATGAACCACATCATGGTC-3' and the antisense primer used for the full-
length eDNA. All three primers contained 8glII restriction sites for the in-frame cloning of the 
Bgill-digested fragments into the Balli HI site of pGEX-2T (Pharmacia Biotech, Uppsala, 
Sweden). The GST-TEL and GST-ETS domain fusion proteins were expressed in E.coli and 
purified as previously described (Smith & Johnson, 1988). The binding site lVas selected as 
previously described (lnaba ef 01., 1994). 
DNA binding assays 
Electrophoretic mobility shift assays (EMSA) of the purified GST-TEL and GST-ETS fusion 
proteins were done by using 3 fmol 32P-endlabeled double-stranded probes (the consensus TEL 
DNA-binding site or the mutant oligonucleotide probes 5'-GCATGTCCGGAAGTAGTGCC-3' 
and 5'-GCATGTCCCCAAGTAGTGCC-3'). GST-fusion protein was incubated with I /ll of 
anti-TEL sentm 32 for 2 hours on ice. The appropriate probe and protein were incubated on icc 
for 20 minutes in 20 mM HEPES-KOH (pH 7.9), I mM EDTA, ImM EGTA, 4% Ficoll (total 
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volume, 20 !II). CompJexed and free probe were separated on a 4% polyacrylarrtide gels in 0.25 
x TEE and visualized by using autoradiography (Meijer ef al., 1992). 
Transactiv(ltiOIl analysis 
For each expression constmct, we transfected triplicate dishes of 1.5x I 05 NllI3T3 cells (6 em 
dish) with 3 !lg of the appropriate pSCTOP-based vector, I ~lg pMSVluc, 150 ng of rat p-actil1 
promoter driven secreted alkaline phosphate expression construct and 5.9 Jlg pBluescript (as 
carrier). The medium was changed after 20 hours, and luciferase assays (Promega, Madison 
WI) were perfonned on transfected cells 24 hours later. Luciferase activity was measured with 
a Optocomp iIIuminometer. To control for transfection efficiency, the alkaline phosphatase 
activity in the medium was measured as described (Owen ef al., 1990). Induction of 
transactivation equaled the corrected activity associated with insert-containing pSCTOP 
plasmid divided by the activity associated with empty pSCTOP. 
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Results 
Subcel/u/ardistributioll oITEL, MN1, alld MNI-TEL 
Because the primary sequences of TEL and MN I have features that suggest their involvement 
in the regulation of transcription, we used indirect immunofluorescence analysis to study the 
subcellular localization of various TEL, .MN 1, and MN I-TEL products using immunopurified 
a-TEL antibodies or MNI MoAb 2F2 (Figure I). Endogenous TEL was found predominantly 
in the nucleus (excluding the nucleoli) of N1lI3T3 and HeLa cells, but some protein was also 
detected in the cytoplasm (figure 2a, b). The specificity of the TEL antibodies was verified by 
competing with bacterially expressed GST-TEL (figure 2c). No endogenous MNI could be 
detected in Nlli3T3 cells (figure 2d). Exogenously expressed TEL was detected in the nucleus 
(excluding the nucleoli) or cytoplasm or both subcellular compartments in TEL-retrovims 
transduced Nllf3T3 cells (figure 2e). The ETS DNA binding domain mutant, TEL-DBDM, 
which contained leucines instead of arginines at residues 396 and 399 (within the EfS domain), 
was expressed exclusively in the cytoplasm (figure 20. At present it is not known whether these 
mutations directly target the NLS of TEL or whether aberrant folding of the protein prevents 
nuclear transfer by masldng its NLS. The deletion mutant TELC.S3-ll6 (which lacks almost the 
entire HLH oligomerization domain) was concurrently expressed in both the cytoplasm and the 
nucleus (figure 2g). 
TEl IE ETS. VP16-TEl _'ID ETS. 
TElDBDM IE 'il VPHHEl DBDM I' &titJru Ell 
6,53--116 I-.- mil 
MNI II 
MNHElII II ml 
MNHEL II DBDMI II ~H. 
MNt-TELI II 'IIU ",I 
MNHEL I DBDM I II IIfU ~;;iI 
IHLl ETS. 6,18-1123 L 
- - - - -
-
- -- -
IHU ",g 11.12-228 L 1\ II ~-
11.692-1123 I II II fHU 31 
IIfU ETsI 11. 229-1223 I 
- - -- -
-
11.12-951 L 'HU ETS' 
-
- -- -
IHU 31 l!.18-454 L 
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II 
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Figure 1 Schematic representation or TEL, MNI, l'.1NI-TEL and VPI6-lELcDNA constructs. ETS is ETS DNA 
binding domain, HLH is Helix-Loop-Helix oligomerization domain, DBDM is DNA binding domain mutant; white 
lines represent nlUlated codons. Gray boxes in MNI sequences represent glutamine stretches. 
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Figure 2 Subcellular distribution of endogenous TEL and virally transduced TEL, MNJ, MN I-TEL and VP 16-
TEL proteins. A-C Indircct inununofluorescence analysis of endogenous TEL using immullopurificd a-TEL 
antibodies in NIH3T3 cells (A) and HcLa cells (D,C); analysis of competed a-TEL antibodies using bactcrially 
expressed GST-TEL fusion protein on HeLa cells (C). Endogenous and cxogcnous cxprcssion ofMNI in NIH3T3 
cclls (D, H). Distribution of viraUy transduced TEL, TEL DBDM, and TEL~53-116 (E·G), MNI-TEL I and 
MNI-TEL I DBDM (I,J), MNI-TEL II and MNI-TELII DBDM (K,L), MNI-TEL I deletion mutants ~18-1123, 
"'12-228, "'692-1123, "'229-1223, "'18-454 and "'12-951(M-R), VPI6-TEL and VPI6-TEL DBDM (S,T) in 
NIH3T3 celIs was analyzed using a-TEL antibodies (E.G,I,J,L,M·T) or MNI-specific MoAb 2F2 (D,H,K). 
Proteins were visualized using FITe-conjugated second antibody. Imagcs werc obtained by using confocal 
microscopy. Signals of A·D havc becn electronically amplified. 
Exogenolls :MNI was diffusely present throughout the nucleus (excluding the nucleoli, 
figure 2h). In contrast, a-TEL identified speckles of MN I-TEL I predominantly in the nucleus 
(figure 2i). The same pattern lVas found for MN I-TEL I DBDM (figure 2j). MN I-TEL II and 
MNI-TEL IT DBDM were expressed in a similar speckled nuclear pattern using MNl specific 
MoAb 2F2 or a-TEL antibodies, respectively (figure 2k,I). In double labeling experiments 
signals obtained with 2F2 and a-TEL were overlapping (data not shown). Preliminary analyses 
to identify whether these speckles colocalize with known nuclear domains demonstrated that 
they are different from PML Oncogenic Domains (PODs) (data not shown)(Dyck ef al., 1994; 
Koken ef al., 1994; Weis ef al., 1994). 
We then analyzed the localization of the MNI-TEL deletion constmcts to provide a 
control for the transformation and transactivation studies. The MNI-TELt.l8-1123 (figure 2m), 
MN 1-TELt.l2-228 (figure 2n), MN 1-TELl1692-1123 (figure 20), and MN I-TELl1229-1223 
(figure 2p) constructs were all solely or predominantly expressed in the nucleus. In contrast, 
MN 1-TELl118-454 and MN 1-TELl112-95 I were expressed in the cytoplasm. Whereas MN 1-
TELl112-951 displayed a diffuse cytoplasmic staining (figure 2q), MN I-TELl1 I 8-454 was 
expressed in large, perinuclear plaques as well (figure 21'). Although VPI6-TEL was expressed 
in the nucleus (fignre 2s), VP 16-TEL DBDM (like TEL DBDM) localized in the cytoplasm 
(2t). These results demonstrate that MN I-TEL is expressed in the nucleus in distinct speckles, 
which argue in favor of the hypothesis that MNI-TEL may act as an aberrant transcription 
regulator. Furthermore, analysis of subcellular localization of deletion mutants is a crucial 
control for the correct interpretation of our functional assays. Despite the presence of an alleged 
NLS in the ETS domain of the mutants, some of them do not transfer to the nucleus. 
Expression of MN 1-TEL leads to transformation of NIH3T3 fibroblasts 
The MN I-TEL fusion protein resembles t(11 :22) EWS-FLII, which is associated with Ewing 
sarcoma and transforms NIIBT3 cells (Lessnick ef al., 1995; May ef al., 1993a). We therefore 
virally transduced MNI-TEL type I, TEL and MNI into NIH3T3 fibroblasts to compare their 
transforming potential. Indirect immunofluorescence using TEL and MN I specific antibodies 
showed that more than 95% of the sorted CD8+ cells expressed the various cDNA constmcts 
(data not shown). The mOlphology of the MN I-TEL-infected cultures differed from that of the 
mock-, TEL- and MNI-transduced cells (figure 3a). Whereas the mock-, TEL- and MNI-
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infected cells grew in a contact-inhibited monolayer, the cells expressing MNl-TEL were not 
contact-inhibited and had a more rounded up, spiky morphology (figure 3a). 
To assess the transforming capacity of the various proteins, we plated retroviral1y 
transduced cells in soft agar. As shown in figure 3b and table 1, only cells transduced with 
MN I-TEL type I formed colonies above background. The same result was obtained in four 
independent experiments (table I). 
MOCK TEL 
8 MN1 MN1-TEL I 
MOCK TEL MN1-TEL I 
Figure 3 Morphologic analysis and soft agar assays demonstrating transformation of NnBT3 cells by retrovirally 
transduced MNI-TEL I. A Polyclonal populations of sorted CD8-positive NIH3T3 cells infected with mock, TEL, 
MNI or MNI-TEL I expressing retroviruses were seeded on plastic culture dishes, Only MNI-TEL I infected 
NIH3T3 cells were not contact-inhibited and displaycd an aberrant morphology. n MNI-TEL I infected CD8-
positive NlH3T3 cells form colonies in soft agar. Mock or TEL infccted cells did not form colonies when plated 
in agar. Cells were seeded into agar at a density of 20,000 cells per plate and at a serum concentration of 15%. 
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N-terminal sequences of MNI and the ETS domain of MN1-TEL are necessary for 
trails formation of NIH3T3 cells 
To determine sequences of MN I-TEL necessary for transformation of Nll-I3T3 cells, we 
generated a series of MN I-TEL I deletion constmcts (figure I). Cells infected with retrovimses 
expressing mutant MN I-TEL proteins were assayed for colony fOlmation in soft agar. Deletion 
of almost all MNI sequences (MNI-TELl'>18-1123) abolished the transforming activity of 
MNI-TEL (table I), demonstrating that they are necessary for transformation. More subtle 
deletions showed that removal of aminoacids 12-228, 18-454, or 12-951 from the N-terminus 
of MNI-TEL was also sufficient to eliminate colony formation (table I). Removal of 
aminoacids 692-1123 or 229-1223 greatly reduced the transforming capacity of MNI-TEL. 
However, a considerable increase in the number of colonies smaller than the macroscopically 
visible 150 /-un standard were generated (table I; right column), suggesting that these two 
mutants have some, but impaired, growth stimulating potential. 
TABLE 1 Number colonies scored in soft agar assays 
Number of colonies > 150t-tm total 
Construct mean stddev n mean stddev n 
MOCK 1 1 4 17 9 3 
TEL 1 3 3 1 1 2 
TEL.6.53-116 4 4 2 8 0 1 
MN1 0 0 2 5 2 2 
HN1-TEL I 49 5 4 146 63 3 
11N1-TEL I 1118-1123 10 3 2 22 0 1 
11N1-TEL I ..6.12-228 0 0 3 0 0 2 
HN1-TEL I .6.18-454 5 3 2 17 7 2 
HN1-TEL I .6.12-951 1 0 3 2 2 2 
MN1-TEL I .6.692-1123 7 0 1 39 0 1 
HN1-TEL I 6229-1223 7 0 1 44 0 1 
11N1-TEL I DBDM 2 0 1 65 0 1 
VP16-TEL 4 0 2 22 0 1 
stddev standard deviation, n number of independent experiments 
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In addition, the subcellular localization of each mutant was determined by indirect 
immunofluorescence analysis. As mentioned above, full-length MNI-TECI, MNI-TEL I 
DBDM, MNI-TEUIl8-1123, MNI-TELtiI2-228, MNI-TELti692-1123 and MNI-TELti229-
1223 were found in the nucleus (figure 2). Because MNI-TELtiI8-454 and MNI-TELti12-95I 
were exclusively expressed in the cytoplasm, these two deletion mutants were non informative 
for mapping domains of MNI-TEL, involved in transformation and transactivation. 
To test whether the ETS domain of MNI-TEL is necessary for transformation of 
NIH3T3 cells, we introduced the mutated ETS DNA binding domain into MNI-TEL. Although 
the subcellular expression of the mutant protein was identical to wildtype MN I-TEL I (figure 
2 ij), cells transduced with MN I-TEL I DBDM did not form colonies, bigger than the 150 f.lm 
standard (table I; middle column). However, like MN I-TEL deletion mutants 692-1123 and 
229-1223, gave rise to an increased number of smaller colonies (table 1: right column). This 
result indicates that the ETS domain is instrumental for MN 1-TEL-mediated transformation 
of NIH3T3 cells, since mutating the DNA binding domain greatly reduced its transforming 
potential. 
Additioll of the VP 16 transactivatioll domain to TEL or deletion of the HLH domain filils to 
induce trallsformatio1l of NIH3T3 cells 
To test whether MNI confers transforming activity to TEL by addition of a strong 
trans activating domain, we fused the acidic trans activating domain of the HSV 1 VP 16 protein 
to the N-tenninal side of the TEL sequences present in MN I-TEL type I. The resulting VP 16-
TEL fusion protein is similar to VP 16-FLII, which transforms NIH3T3 cells (Less nick ef al., 
1995). As shown in table I, VPI6-TEL failed to transform NIH3T3 cells, indicating that 
addition of a strong heterologous transactivating domain alone is insufficient to confer 
transforming ability to TEL. Further, cells transduced with a TEL mutant lacking the HLH 
putative oligomerization domain (TEL"-53-116) failed to form colonies (table I), suggesting 
that TELs inability to form colonies is not due to oligomerization via the HLH domain. 
TEL recognizes a canonical ETS recognition sequence CCGGAAGT 
Because TEL belongs to the ETS family of transcription factors, we wished to determine its 
DNA-binding site. Constructs that fused the GST protein to the ETS domain of TEL (i.e., the 
138 C-terminal amino acids), GST-ETS, or to the whole TEL ORF, GST-TEL, were expressed 
in bacteria. The GST-ETS fusion protein was used to identify a TEL consensus binding site by 
random oligomer amplification (Inaba ef al., 1994). All but I of the 26 amplified clones 
identified after six rounds of selection contained the canonical ETS recognition sequence 
GGAA (figure 4). After comparing the adjacent sequences, we determined that the consensus 
TEL recognition sequence is CCGGAAGT. 
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AGCATGTCC GGAA GTAGTGCCTTATCCTGTTTGTC 
GACTAGATCGGAAGTTGGGTACAAGGTGC GGAA GTACT 
-- GACTACGGCTATC GGAA GTGAATTGCCCCAGTACT 
GACCCA GGAA GAACCTCCAACAAGTATGAAGTACT 
GACGGATGAGTCGACT GGAA TCACTTCCGGTATCT 
GACTATAGACGAACCC GGAA ACACTGGTACATACT 
GACAGGATAGCA GGAA ATAAGACGTTCGTAGTTCT 
AGTGACC GGAA GCAAGTTAGTGCCGCTGGTTCGTC 
AGGA GGAA GTTCGGCTATGCCCCCTGCATGCAGTC 
GGAGGAATATACTGAAC GGAA GTTGACTG 
--ATAGTATCCC GGAA GTCTCCACAACTATCCG 
AGC GGAA ATTGCGTTATTCCAGGTAGTTCCCGG 
TATGAACC GGAA AATGCCTGCGCGTCGG 
CCGGATAGTAAGAACATTC GGAA ACTAGTA 
C GGAA CACATCCGCATTAGCCAGAACATCCT 
C GGAA GTTGGAAATAACTAAAGTATCAAGAC 
CA GGAA GACTTTCTAGGTAATAATACAGTGTC 
CACATTGACCGTGACAAA GGAA ATGATACT 
CAAAGCAAGC GGAA GTGTTAGCAAAGGATA 
CGAGATGGGTAATATCC GGAA GTGTACCGCC 
CTGGC GGAA ATGAATATGAGATGGGGTCCAC 
CAATCATCA GGAA GGAGAAACCAGTC 
ATTTCCAATTGGC GGAA GAGGAAAAGTGAATGCTT 
-- CTACC GGAA GAGCGGCCAGCTAAATGCCGGG 
TGGTGTAT GGAA GTAAATCGTATACTTTGTG 
GACTATAGTTCA GGAA GTGGATTCTGAAACTCTCT 
TGATCCG AGAA TGTTACGTTACGCCACATCCGGGTC 
Figure 4 TEL consensus DNA binding site. Nucleotide sequences resulting from six rounds of amplification and 
selection using bacterially expressed GST-ETS (Le. 138 C-terminal aminoacids of TEL) are shown from 5' to 3'. 
Sequences are aligned at canonical ETS recognition element GGAA. Consensus sequence is shown at bottom. The 
percent abundance of most prevalent flanking nucleotides at each position is shown. Underlined are additional ETS 
binding clements in sequences. 
DNA bindiug activity of TEL is modulated by intramolecular interactiolls 
To study the DNA binding activity of TEL, GST-ETS and GST-TEL fusion proteins were 
expressed in E. coli (figure Sa). Double-stranded oligomers containing the TEL consensus 
DNA-binding sequence (CCGGAAGT) or a mutant sequence (CCCCAAGT) were used in 
electrophoretic mobility shift assays (EMSA) to analyze the DNA-binding activities of GST-
ETS and GST-TEL. The GST-ETS protein shifted the consensus oligomer (lane 5), and 
addition of a-TEL antisemm led to a supershifted complex (lane 6)( figure 5b). Interestingly, 
the intensity of the signal increased dramatically. No shift was observed with the mutant 
oligomer (lane 4). These observations confirm the ability of the TEL ETS domain to bind the 
consensus TEL DNA-binding sequence. By contrast, the GST-TEL protein failed to bind to the 
consensus sequence probe (lane 8), but addition of a-TEL sel11m led to a weak specific signal 
(lane 9) and an a-specific signal (lanes 3, 6 and 9). Oligomers incubated with GST protein alone 
did not shift. These results suggest that binding of the antiserum to the C-terminus of the OST-
TEL fusion proteins increases their affinity for the consensus oligomer. The intensities of the 
signals in lanes 6 and 9 differed, suggesting that GST-ETS and GST-TEL have different 
affinities for the oligomer. Thus, OST-TEL may contain sequences that negatively interfere 
with the proteins affinity for or availability to the consensus oligonucleotide. 
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Figure 5 DNA binding analysis of bacterially expressed GST-TEL fusion proteins. A Eluates of bacterially 
expressed GST, GST-ETS (i.e, 138 C-tenninal aminoacids) and GST-TEL fusion proteins were analyzed on a 
10% SOS-polyacrylamide gel and visualized by COOinassic Brilliant Blue staining. B 0.1 III of GST and GST-ETS 
or I f.lI ofOST-TEL fusion protein eluates were used in a bandshift assay with radiolabclcd TEL consensus or 
mulant probe. Complexed and free probe were separated on a 4% polyacrylamide gel in 0.25 x TEE and vjsualized 
by using autoradiography. 
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MNI contributes trallsactivatillg sequences to MNI~TEL 
Both translocation partners MNI and TEL contribute features to MNI-TEL, that are necessary 
for transformation of NIH3T3 cells. We wondered whether addition of MNI (includiug its 
proline- and glutamine-rich regions) to the ETS domain of TEL would influence the 
transcriptional activity of TEL. Initial transient transfection studies in NIH3T3 cells, using a 
luciferase reporter construct containing 10 concatemerized TEL recognition sequences, cloned 
upstream of the SV40 minimal promoter in pGL2 (Promega) showed that both TEL and MNI-
TEL are transcriptionally silent in this promoter/cell type context (data not shown). Because 
the Moloney sarcoma vims LTR is regulated by ETS-I (Gunther ef al., 1990), we reasoned that 
it could also be a target of transcription regulation by TEL and we used this promoter in our 
luciferase reporter construct (pMSVluc). Co~transfection of pMSVluc with increasing amounts 
of CMV promoter driven TEL eDNA constmct resulted in a minimal (Le., 4-fold) activation 
of luciferase expression (fignre 6a). However, the MN I-TEL type I and type II fusion proteins 
induced luciferase activity in a dose-dependent manner (up to 18-fold). Cotransfection of the 
MNI-containing constmct with pMSVluc also led to dose-dependent induction of luciferase 
expression. These results showed that MN 1 contributes transactivating sequences to TEL and 
that MN 1 itself may regulate transcription. In addition, transactivation by MN I-TEL was 
dependent on a functional ETS domain of TEL; MN I-TEL I DBDM and MN I-TEL II DBDM 
failed to induce expression of luciferase. 
We used the VP 16-TEL expression construct as a positive control for TEL-mediated 
activation of pMSVluc. As shown in figure 6a, VP 16-TEL strongly induced the expression of 
luciferase. Because the DNA binding mutant VPI6-TEL-DBDM is expressed in the cytoplasm 
(figure 2t), we have no formal proof that transactivation induced by VP 16-TEL is dependent 
on the ETS domain. 
Distinct domains ill MN J mediate the trallsactivatillg capacity of MN J -TEL 
To determine whether the HLH domain of TEL is involved in transcription control of the MSV 
LTR and to map the sequences in MNl that transactivate the MSV LTR. we tested a HLH 
deletion mutant. TEL.6.53-116, and several MNI-TEL I deletion mutants in transient 
transcription assays. No difference in transactivation activity of the MSV LTR was observed 
between TEL and TELt.53-116, indicating that the HLH domain of TEL does not influence 
TELs inability to transactivate the MSV LTR (figure 6b). Deletion of almost the entire MNI 
moiety of MNI-TEL (MN 1-TELt.18-1123) abolished the transactivating capacity of the fusion 
protein. The MN I-TELt.l 2-228 and MNI-TELM92-1123 constructs induced expression of 
the luciferase gene. indicating that sequences spanning the glutamine-stretches are necessary 
for the transactivating potential of MN I-TEL. Because MN 1-TELt.12-228 transactivated the 
MSV LTR but failed to transform NIH3T3 cells, sequences within the first 228 amino acids of 
MNI-TEL seem to be essential for its transforming activity. A mutant containing this domain 
(MN 1-TELt.229-1223) moderately induced luciferase gene expression, indicating that these 
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sequences possess weak transactivation activity, which coincides with increased number of 
microscopic colonies induced by this molecule. Therefore, the transactivating sequences of 
MN 1 can be divided into two subdomains, the first of which is essential for transformation. 
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Figure 6 MN I contributes tnmscription activating sequences to TEL. A Transient transcription experiments were 
performed using increasing amounts of CMV promoter driven TEL, MN I, MNI-TEL and VP 16-TEL activator 
constructs (2,5 to 10 ~g), as well as their respective ETS DNA binding domain mutants, with 111g of pMSVluc. 
Luciferase assays were performed 24 hours after removal of calcium phosphate precipitate. Induction of luciferase 
(normalized to a secreted alkaline phosphatase control) arc relative to value of empty vector. B Transient 
transcription experiments using 3 ~lg of CMV promoter driven activator constructs were performed to analyze 
whether HLH domain in TEL and which domains in the MNI moiety ofIv1Nl-TEL I mediate Iransacliyulion of 
MSV LTR. Nonnalized ludferase values relative to empty vector are shown, Mean yalues of two experiments are 
shown. Each transfection was performed ill triplo. 
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The HLH domain is inactive in MN 1-TEL and does not engage ill homotypic interaction 
The HLH domain of TEL has sequence homology with known protein interaction domains in 
c-MYC and MyoD (Seth & Papas, 1990). This domain was recently shown to define a specific 
protein interaction interface, that mediates oligomerization of TEL (Jousset ef ai., 1997). This 
function also mediates oligomerization ofTEL-ABL and TEL-PDGFpR fusion proteins, which 
is essential for the activation of their tyrosine kinase activity (Carroll ef ai., 1996; Golub ef ai., 
1996). Although in MN I-TEL type I the junction occurs 5' of the HLH domain, the fusion in 
MN-TEL type II occurs within the HLH domain, suggesting that the HLH domain could be 
functionally unimportant or inactive in MNI-TEL type I, and it would therefore play no role 
in MNI-TELs transforming activity. 
We used the HAl-specific monoclonal antibody 12CA5 to immunoprecipitate 
complexes from HeLa cells cotransfected with expression plasmlds encoding TEL and 
HAlTEL or HAlTELi'l53-116. Inununoprecipitated complexes using MoAb 12CA5 were 
separated on a 10% SDS-polyacrylamide gel and electroblotted. By using Western analysis with 
a-TEL serum 32, a doublet of 67 kD (p67HAITEL; lane 3) and 58 kD (p58I!AITEU53'116; lane 2) 
was recognized (figure 7a). The identities ofp67HAlTEL and p5SHAlTEU53-116 were confirmed 
by subsequent Western analysis with monoclonal antibody 12CA5 (data not shown). 
Furthermore, only p67HAlTEL coprecipitated TEL (a doublet of 60 kD and a doublet of 50 kD; 
lane 3), detected with a-TEL antiserum. To analyze whether HAl TEL co-immunoprecipitated 
endogenolls TEL from HeLa cells, a similar experiment was performed in which only HA ITEL 
was transfected. Proteins of 60 and 50 kD were detected by a-TEL serum (lane 4). These 
observations show that we can visualize the HLH-mediated homotypic TEL interaction. Our 
results ftllther suggest that there may be multiple modified forms of two distinct TEL proteins. 
This was recently confirmed by Bernard and coworkers (Poirel ef ai., 1997). 
We then performed a similar cotransfection experiment to study whether the HLH 
domain in MNI-TEL type I is functional. Therefore COS-I cells were (co)transfected with 
either HAl TEL or HA I TEU53-116 in the presence of MN I-TEL I, MN I-TEL II or MN I-TEL 
I i'l229-1223. Cell were labeled with 3H-leucine, and HAl-tagged proteins were 
immunoprecipitated with 12CA5. Immunocomplexes were separated on a 8% SDS-
polyacrylamide gel. Proteins were visualized by autoradiography. COS-l cells only expressed 
endogenous p50TEL which was coprecipitated with transfected human HAl-tagged TEL (figure 
7b; lanes 3, 6, 10, 14, 15). In COS-I cells co-transfected with HAlTEL and MNI-TEL I no 
protein of the expected size of MN I-TEL I (200 kD) was immunoprecipitated with 12CA5 
(lane 6). However, in a subsequent immulloprecipitation with monoclonal 2F2 the presence of 
MN I-TEL I in these cells was verified, since a protein of the expected size of 200 kD was 
precipitated (lane 7). Similarly, HA ITEL did not coprecipitate MN I-TEL II (lane 10). These 
results indicate that although the HLH domain is present in MN I-TEL I, it does not physically 
interact with HAITEL or with endogenous simian TEL, possibly due to steric hindrance by the 
bulky MN I moiety of the fusion protein. To test this hypothesis, we analyzed if a substantial 
deletion ofMNl sequences would allow interaction with HAITEL and repeated the experiment 
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by co-transfection of HAl TEL and MN I-TEL 11>.229-1223. Endogenous pS01EL and a protein 
of the expected size of MN I-TEL 11>.229-1223 (approximately 7S kD) were coprecipitated with 
HA I TEL (lane 14). Similarly, MN I specific MoAb 2F2 precipitated MNI-TEL 11>.229-1223, 
pS01EL and HAlTEL (lane IS). As expected, HAITEL6S3-116 did not co-precipitate MNI-
TEL 11>.229-1223 (lane 16). In addition, endogenous pSOTEL did not co-precipitate with MN 1-
TEL 11>.229-1229 using MoAb 2F2 (lane 17), suggesting that the affinity of this deletion mutant 
for TEL is low. Overall, these results indicate that possible regulation of TEL function via the 
HLH domain has been eliminated in the MNI-TEL fusion protein. 
Figure 7 TELs Helix-Loop-Helix oligomerization domain is non functional in MN I-TEL. A HcLa cells were 
transiently transfcctcd with expression plasmids encoding HAITEL6.53-116, HAlTEL and TEL as indicated 
above the lanes. Proteins were immunoprecipitated with MoAb 12eA5. Complexes were separated on a 10% SDS-
polyacrylamide gel and electroblotted. Proteins were visualized by using Western analysis with a-TEL anliscmm. 
HAlTEL6.53-116 and HAITEL and co-precipitating proteins are indicated by arrows on the right. A molecular 
weight standard is indicated. B COS-I cells were (co)transfected with expression plasmids encoding HAlTEL or 
HAITEL6.53-116 and MNl-TEL I. MNl-TEL II and MNI-TBL 16.229-1223 as indicated above the lanes. 
Following metabolic labeling with 3H-leucine. proteins were immunoprecipitated using MoAb 12eAS. followed 
by immulloprccipitation \vilh MNl specific MoAb 2F2, and analyzed on a 8% SDS-polyacrylamidc gel. HAITEL, 
HAlTEUS3-116 and co·precipitating proteins arc indicated by arrows on the right. A molecular weight standard 
is indicated. 
62 
A CD ;;;; 
cr:: ::l 
-' -' § ~ w W I-- I--
g! ::c ::c ~ I I 
TEL 
MW (kDa) 
71 
16 
43 -. 
1 2 3 4 
B , 
<0 ~ 
I:: ~ 
t7 t7_ +-:; ,- Siif <>: iif rJ ~iif ~7 iif'" E I:: ~ /!!7 il ~7 & ~ if ii ;; 'f 'f 
+ + + + + + 12CA5 
+ + + + + + + 2F2 MW(kOa) 
200_ 
<- MN1-TEL I 
• • <- MN1-TEL" 
110 
MN1-TEL~229-1223 
., ,/ 71_ 
• 
, ...--HA1TEL 
• • 
:j,w • • •• <-HA1TEL~53-116 43_ '-p50TEL 
front --- . _-
- - - ,,-- - ~-- -.-.- ... 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
63 
Discussion 
Our results demonstrate that MN I-TEL, which is associated with cases of t02;22)(p 13;q Il) 
human myeloid leukemia (Buijs et al., 1995), ha.'i transforming and transactivating functions. 
Only NIH3T3 cells infected with a MNI-TEL-containing retrovirus displayed anchorage-
independent growth in soft agar. :MNl-TEL, however, has a weak transforming activity that can 
only be shown in a specific Nlli3T3 subline that is sensitive to transformation by ETS factors 
(May ef af., 1993b). Standard NIH3T3 cells could not be transformed by MNI-TEL, in contrast 
to activated RAS (data not shown). 
Deletion of N-terrninal sequences (aminoacids 12-228) from MNI was sufficient to 
abolish the transforming capacity of :MNl-TEL. This domain was not sufficient to render MN 1-
TEL transfonning, because deletion of aminoacids 229-1223 resulted in a decrease of colonies 
in size as well as in number. It is interesting to correlate the transactivation activity of MNl-
TEL mutants with their transfonning activity in Nll-I3T3 cells. Deletion of aminoacids 12-228 
from MNI-TEL had a minor impact on its transactivation of the MSV-LTR and fusion of these 
sequences alone to TEL confilmed their moderate transactivation activity. The strongest 
transactivating sequences of MN 1 are comprised within aminoacids 228 and 692. These 
sequences contain two glutamine stretches and proline-rich sequences, that can both function 
as transactivation sequences (Gerber et al., 1994). Glutamine stretches can form p-sheets that 
mediate protein-protein interaction by functioning as a polar zipper (Pemtz et al., 1994; Stott 
ef af., 1995). Glutamine stretches in SPI have been demonstrated to interact with the basal 
transcription machinery (Gill ef af., 1994). Interestingly, the presence of this strong 
transactivation domain in MN I-TEL is not sufficient for transformation, because the 
transformation potential of MN I-TEL was completely abolished or greatly reduced by deletion 
of aminoacids 12-228 or 692-1123, respectively. This observation is further supported by the 
VPI6-TEL protein that strongly trans activates the MSV-LTR but failed to transform NIH3T3 
cells. We conclude that MNI does not contribute to the transforming properties of MNI-TEL 
solely through addition of strong transactivating sequences. Our experiments identify the first 
228 amino acids of MN I as a functionally distinct domain. Because the domain appears to 
contain mild transactivating sequences, it remains entirely possible that it influences expression 
of genes cmcial for transformation. Alternatively, the domain may interact with cellular factors 
that directly or indirectly interfere with cell cycle control. not involving transcription regulation. 
Further studies are needed to distinguish between the different possibilities. Likewise, a domain 
between aminoacids 692-1123 also seems to be important for the transforming. potential of 
MN I-TEL. The finding that the transfOlming activity was greatly rednced, suggests that this 
domain, although it does not seem to contribute to trans activation of the MSV LTR, may be 
important for protein-protein interaction, and in that way may contribute to transformation. 
Also in EWS-FLIl, sequences were mapped that are important for transformation, but have no 
function in transactivation (Lessnick et al., 1995). 
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The finding that the transforming potential of MNI-TEL-DBDM mutant is impaired, 
strongly suggests that interference with expression of TEL target genes is a cmcial aspect of 
MNI-TELs transfOlming activity. The fact that mntation of the ETS domain impaired, but not 
completely eliminated, the transfonning potential of MN I-TEL may indicate that the molecule 
may still weakly interact with DNA via factors that normally cooperate in binding TEL to its 
cognate sequences as has been found for other ETS factors (Giese et al., 1995; Watson e/ al., 
1997). Therefore the study of this fusion protein will provide insight in subversion of the TEL 
pathway as an oncogenic event, which is fundamentally different from all other characterized 
translocations involving TEL. In those cases, the HLH domain of TEL is employed for the 
oncogenic activation of pathways controlled by the different fusion pMners, such as PDGFpR, 
ABL or AMLI. In addition, MN I-TEL-DBDM fails to transactivate the MSV-LTR, suggesting 
that activation of this promoter by MNI-TEL occurs via a TEL binding site. We determined 
the consensus binding site of TEL, CCGGAAGT, and found it to be similar to binding sites 
determined for other ETS family members (Wasylyk ef al., 1993) containing the ETS core 
motif GGAA. In in vitro binding studies most ETS family proteins are promiscuous, and it has 
been suggested that their ill vivo specificity derives from the context of the binding site and 
interaction with neighboring transcription factors (Wasylyk ef al., 1993). This is also suggested 
by the difference in transforming activity between the VPI6-TEL and VP16-FLII proteins. 
Although TEL and FLII bind to very similar sequences ill vifro, VPI6-FLII must activate 
transformation specific target genes in NIH3T3 cells (Lessnick ef al., 1995), that are not 
activated by VPI6-TEL. The MSV-LTR contains several ETS sites that, on the basis of their 
sequence, may also bind TEL including the one between the TATA box and CAAT box that 
was shown to bind ETS-I (Gunther ef al., 1990). Presently, we are using deletion analysis of 
the MSV-LTR to detennine which site(s) confer(s) MNI-TEL responsiveness. By contrast, a 
minimal promoter preceded by a ten-fold concatamerized TEL binding site could not be 
trans activated by TEL or MN I-TEL. This observation is again in accordance with the notion 
that ill vivo binding of TEL may need cooperation of other factors that bind in close vicinity and 
interact with TEL. 
The ill vitro DNA binding activity of full length TEL is inhibited. It can be activated by 
either deletion of N-terminal sequences (~1-314) or by incubation of the protein with C-
terminal TEL antibody. Because the two modifications synergize, a mechanism of 
intramolecular interaction could be responsible for inhibited DNA binding activity of TEL. One 
conld argue that fusion of TEL to GST could be the reason for its inability to bind DNA. 
However, bandshift analysis using extracts of TEL transfected cells never produced a TEL 
specific band shift, indicating that overexpressed TEL did not bind our consensus nucleotide 
either (A.B. and G.G.; unpublished observations). ETS-I also has low affinity for its 
recognition site and it was recently shown that the DNA binding activity of ETS-I is regulated 
by intramolecular interaction; short a-helical sequences, situated N-tcrminal and C-terminal 
of the ETS domain interact, preventing the ETS domain from binding DNA (Jonsen ef al., 
1996; Petersen ef al., 1995). Sequence comparison between TEL and ETS-I did not identify 
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homologous a-helical sequences in TEL, thus at present we cannot exclude alternative 
explanations for the DNA binding behavior of TEL. More detailed deletion analysis of TEL is 
needed to pinpoint the involved sequences which would confirm a possible intramolecular 
regulation of DNA binding activity. 
Endogenous TEL was predominantly localized in the nuclei of NIH3T3 and HeLa cells. 
although some protein was detected in the cytoplasm. Higher expressed, viraUy transduced TEL 
could be found in either the nucleus or the cytoplasm or concurrently in both compartments. 
This may indicate that the subcellular distribution of TEL is regulated and may be functionally 
relevant. Overexpression of TEL may ampJify a natural difference in the cellular distribution 
of TEL. In this respect it is interesting that. like its closely related ETS family member Y AN, 
TEL contains several consensus MAPK phosphorylation sites. The subcellular localization of 
Y AN was reported to be regulated by RAS dependent phosphorylation (Rebay & Rubin, 1995), 
which may be similar in TEL. Another possibility is that the two TEL proteins (p50TEL and 
p60TEL) translated from the TEL mRNA (Poirel ef al., 1997), have a different subcellular 
localization or their subcellular localization is regulated in a different manner. p50TEL is missing 
the first putative MAPK site, that is present in p60TEL. Similar to what was suggested above, 
phosphorylation of this MAPK site may have an important role in the subcellular localization 
of p60TEL. Alternatively, overexpression of TEL may account for the artificial cytoplasmic 
accumulation of TEL. A careful analysis of the cellular localization of TEL mutants with 
activating and inactivating MAPK-site mutations will be pursued to address these issues. 
Mutation of arginine residues 396 and 399 within the ETS domain of TEL restricted 
TEL DBDM and VPI6-TEL DBDM to the cytoplasm; these residues are required for DNA-
interaction (Kodandapani et al., 1996). At present, it is not clear whether mutation of the two 
arginine residues targets the NLS of TEL or leads to aberrant protein folding that prevents its 
NLS mediated transfer to the nucleus. In this respect, it will be interesting to analyze the 
subcellular localization of TEL-B, which lacks the ETS domain, including its alleged NLS, 
because of alternative splicing (Ringold ef al., 1996). [fTEL-B localizes to the cytoplasm, it 
may act as a dominant negative molecule through HLH-mediated interaction with TEL. MNl-
TEL-DBDM mutants were found in the nucleus, suggesting that the nuclear localization of 
MNl-TEL is mediated by an NLS within MNI. Indeed, sequence analysis identified a candidate 
NLS (RRPR) between residues 240 and 244 of MN I. Studies are in progress to analyze whether 
this candidate NLS is functional. Analysis of the subcellular localization of MN I-TEL deletion 
mutants proved to be an essential control for our transformation and transactivating studies. 
Mutants such as MNI-TELM8-454 and MNI-TELllI2-951 were non-informative to 
functionally map domains, since they appeared to be expressed exclusively in the cytoplasm. 
We confirmed that TEL interacts with itself via the HLH domain (Jousset ef al., 1997). 
In contrast, no heteromerization between MNl-TEL and TEL was observed, suggesting that the 
HLH oligomerization domain in t(12;22) MN1-TEL is non-functional. This inactivation may 
be of functional importance, since it is conceivable that MN 1 inhibits interaction of TEL with 
a protein, that normally regulates its transcription activity. By deletion of the bulk of MN 1 
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sequences (d229-1223) in MNI-TEL, the interaction with TEL via the HLH domain was 
restored. The simplest interpretation of these results is that the bulky MN I moiety of the protein 
sterically hinders oligomerization via the HLH domain. Alternatively. MN I sequences between 
229 and 1223 may specifically bind to the HLH domain of TEL, making it unavailable for 
interaction with TEL. We find this latter explanation less plausible because we never found 
interaction between TEL and MNI using co-precipitation analysis (data not shown), The 
observation that MNI-TEL ""229-1223 does not coprecipitate endogenous simian p50TEL , 
unless HAlTEL is present, suggests that the affinity of the mutant for p50TEL is low. 
Furthermore, it suggests that HA I TEL mediates the formation of at least a trimer of MN 1-
TELd229-1223, p50TEL and HAlTEL via its HLH domain. 
In conclusion, our data demonstrate that TEL is a proto-oncogene that can be activated 
by fusion to the transcription regulator MN I as a result of the t(l2;22)(p 13;q II) rearrangement. 
The resulting MNI-TEL chimeric protein has both transforming and transactivating properties. 
Unlike other TEL-containing fusion genes, MNI-TEL requires the ETS DNA-binding domain 
(rather than the HLH oligomerization domain) to cause oncogenic transformation. The diversity 
of the domains in MN I-TEL that contribute to its transforming and trans activating functions 
is similar to that seen with EWS-FLll. 
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Chapter 3.1. 
TEUAMLl fusion resulting from a clyptic t(12;21) is the most common genetic 
lesion in pediatric ALL and defmes a subgroup of patients with an excellent 
prognosis. (1995). Leukemia 9: 1985-1989. 
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lEAQJNG ARTIClE 
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic 
lesion in pediatric All and defines a subgroup of patients with an excellent 
prognosis 
SA Shurtleff!, A Buijs2, FG Behml,6, JE RubnitzV , SC Raimondjl·6, tv1l Han(ock~, GC-F Chan 3, C~H PUp,l,7, G Grosveld2 
and JR Downing1.s.6 
Departments oflPalh%gy and Laboratory Medicine, 2Genelics, lHemarofog)/Oncofog)', 'Biostatistics, and 'Tumor Cell Biology, 51 Jude 
Children's Research Hospital Jnd the Departmen15 o(6Pathology and 7Pcdialfics, Unil'ersity of Tennessee Health Science Center, 
Memphis, T"~ USA 
The 1(12j21)(p13;q22) Is Identified by routine cytogenetfcs In 
less than 0.05% of pediatriC acute lymphoblastic leukemia 
(All) patfenlS. This translocation encodes a TEUAML·1 chIm-
eric product comprisIng the helix-loop-helix domain of TEL, a 
member of the ETS·llke family of transcription factors, fused 
to AML-1, the DNA·blndlng subunit of the AML-1fCBFp trans-
cription factor complex. Both TEL and AML-1 are Involved In 
several myeloid leukemia-associated translocallons with 
AML-lfCBFP being altered In 20-30% of de novoacule myeloid 
leukemia (AMl) cases. We now demonstrate thai a TEUAML 1 
chimeric transcript encoded by a crypllc t(12;21) Is observed 
In 22% of pedlalrlc ALL, making It the mosl common genellc 
lesion In Ihese pallents. Moreover, TEUAML1 expression 
defined a distinct subgroup of patients characterized by an age 
between 1 and 10 years, B lineage Immunophenolype, non-
hyperdiploid DNA content and an excellent prognOSis. These 
data demonstrate that molecular dlagnosllc approaches are 
Invaluable in Identifying clinically distinct subgroups, and that 
the AML1/CBFP transcrlpllon complex Is the most frequent lar-
get of chromosomal rearrangements In human leukemia. 
Keywords: acute lymphoblastic leukemia; AML-l; TEl; trans-
locations 
Introduction 
The cytogenetic identification of leukemia-associated chro-
mosomaltranslocations has helped identify patient subgroups 
with defined clinical features arid therapeutic responses. l 
Moreover, cloning of the genes involved in these trans-
locations has provided insights into the mechanism of leuke-
mogenesis and has led to lhe development of molecular 
approaches for Ihe diagnosis and monitoring of a patient's 
response to therapy.2 
The most common translocalions in pediatric All, t(9;22), 
t(1 ;19), and 1(4;11}, have each been shown to identify a sub-
group of patients with distinct clinical features; however, over-
all these translocations are detected in less than 15% of pati-
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ology, and biological significance. 
ents.1 The majority of the remaining cases of ALL have either 
normal karyotypes, non-recurrent structural chromosomal 
abnormalities, or rafC recurrent translocations. 1 Recent data 
suggests that the low frequency of these laller cytogenetic 
lesions may be due, in part, to the inherent difficulty in 
cytogenetically identifying Iranslocalions involving some 
chromosomes. 
Deletions and translocations of the short arm of chromo-
some 12 are detected in greater than 10% of pediatric ALL 
cases; however, specific recurrent translocations involving Ihis 
locus are exceedingly rare.J,~ For example, the t(6;12), 1(7;12), 
1(8;12), t(12;17), t(12;18), or t(12;21), each occur in less than 
0.05% of patients. J Recently, one of these trans locations, the 
t(12;21), was cloned and shown to fuse the helix-loop-helix 
(HlH) domain of TEL to the DNA-binding and transacti\'ation 
domains of AMl-1.'i,f> AMl-J is the DNA-binding component 
of the AMl-l/CBFp transcription factor complex, which is the 
most frequent target of myeloid-associated translocations 
including, the t(8;21), 1(3;21), and inv(16).7.8 TEL is a member 
of the ETS-like family of transcription factors and was orig-
inally cloned as a TEUplatelet-derived growth factor receplor 
J3 (PDGFRJ3) fusion encoded b}' Ihe t(5;12) thai is observed in 
a subset of cases of chronic mye/omonoq,tic leukemia.'" TEL 
is also involved in several other rare trans locations including 
t(9;12), !(1O;12), and t(12;22). !() .. 12 
Although the 1(12;21) is only rarel~' identified by cytogen-
etics in pediatric All, fluorescence ill situ hybridization (FISH) 
analysis indicates that q'togenetics may underestimate its 
prevalence. B - 17 Moreover, recent work has demonstrated 
molecular evidence of a TEl./Ah-fL' fusion gene in a subset of 
8 progenitor Alls, indicating that this cl)'ptic translocation 
may be a more frequent evenl.o,17 To investigate the fre-
quency of TEL rearrangements, we have analyzed 160 cases 
of newly diagnosed ALL b~' Southern blot and reverse tran-
scriptase-polymerase chain reaction (RT-PCR) assays. VVe now 
show that TEL is rearranged in 24% of All cases, with greater 
than 90'Yo of these cases (22% of the tota/) expressing a 
TEl./AMU chimeric mRNA. lvtoreover, none of these cases 
had cytogenetic evidence of the 1(12;21), demonstrating that 
routine cytogenetics is unable to accuratel~' identify this gen-
etic lesion. Furthermore, our data suggests that cases express-
ing TEUAMU constitute a uniform subgroup of patients with 
an excellent prognosis. 
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Materials and methods 
Patient samples 
Ficoll-Hypaque-enriched leukemic blasts were obtained from 
bone marrow aspirates of 160 children with newly diagnosed 
ALL and 50 pediatric cases of AML These patients were tre-
ated at St Jude Children's Research Hospital (SjCRH) between 
1984 and 1994. A portion of each sample was analyzed for 
immunophenotypic markers and cytogenetics, and the 
remainder was cryopreserved. Immunophenotyping and cyto-
genetic analysis were performed as previously described. 18,1'1 
Although cases analyzed were selected based on the avail-
ability of cryopreserved material, no significant differences in 
clinical features or outcome were observed between analyzed 
and unanalyzed patients treated during the same period at 
SJCRH. Thus, this selected patient cohort does no! appear to 
represent a biased sample. \lVritten informed consent was 
obtained from patients or their legal guardians and all studies 
were approved by our Institutional Review Board. 
Southern blot analysis 
Genomic DNA was Southern blotted as previously 
described/o Briefly, high molecular weight DNA (5-10 I1g) 
was digested with either BamHI, Hindllf, or fcaRI restriction 
endonudeases, separated b}' electrophoresis in 0.8% agarose 
gels, and transferred to nylon membranes (Oncor, Gaithers~ 
burg, MD, USA). t .... \embranes were then sequentially 
hybridized with (lHp-dCTP-labeled partial TEL cDNAs includ-
ing a 5' 260-bp XIJOl fragment (pXX), a s38-bp central 
Xhol/Sacl fragment (pXS), and a more 3' 466-bp Sacl/BamHI 
fragment (pSB) (Figure 1 a). After high stringency washes, 
membranes were analyzed by autoradiography. 
a 
b 
Figure 1 Schematic of TEL cDNA and Southern blot analrsis of 
BilmHI-digested genomic DNA from pediatric patients with All. (a) 
The helix-loop-helix (HlH) and DNA-binding domain (080) of TEl, 
and the posilions of the restriction sites for the endonucleases Xhol 
(X), Sad (5), and Bam! II (S) arc indicated, as arc the positions of partial 
cDNA probes pXX, pXS, and pSB_ (h) BilmHl-digests were probed with 
the pSB eDNA probe and the washed membranes were exposed to 
XAR-S film for 24 h_ Palients (pt.) 1--8 are children with All whereas 
the controls arc the leukemic cell lines RS4;I 1 and Hl-60. 
76 
Reverse transcriptase-po/ymerase chain reaction (RT-
peR) assay 
RNA was extracted and RT-PCR performed as previously 
described.21 Samples were analyzed for the presence of 
both the der(21)t(12;21)-encoded TEl/M-ILI and the 
der(12)t(12;21)-encoded AMLI/TEL fusion products. The 
sequence of amplification primers for the Tfl/AML 1 product 
are the previously described set,6 5'TEl (5'CGT GGA TIT CM 
ACA GTC CA 3'), 3'AMLI (s'CAT TGC CAG CCA TCA CAG 
TGA C 3'). The primers for the reciprocal AML I/TH product 
are 5'AML1 (S'ATI TIC AGG AGG MG CGA TG 3'), and 
3'TEl (5'GATTIC ATC TGG GGT TIT CAT A 3'). After ampli~ 
fication, the PCR products were separated by electrophoresis, 
transferred to nylon membranes and hybridized with either an 
AML 1 probe (s'CCA TCT GGA ACA TCC CCT 3'), or a TEL 
probe (s'CGC CAC TAC TAC AM CTA AAC 3'), which are 
specific for the Tfl/AML 1 and AML l/TH products, respect-
ively. Samples negative for the der(21) Tfl/M-ILI product 
were reamplified using a more 5' TEL oligonucleotide, 5'ex3 
TEl (S'GAT GAC GTA GCC CAG TGG CTC 3') and the 
3'A/vfLl oligonucleotide and blotted with the AAILI probe. 
DNA sequence analysis 
PCR products were doned into the plasmid veclor pCRll 
(Invitrogen, San Diego, CA, USA), and sequenced by the 
dideoxynucleotide chain termination method modified for use 
with double-stranded DNA templates (US Biochemical, 
Cleveland, OH, USA). 
Northern blot analysis 
Total RNA was isolated, electrophoretically separated in a 
1.2% formaldehyde/MOPS (3-(N-morpholino)propanesulfonic 
acid)-containing gel,n transferred to nitrocellulose and pro-
bed with the pSB TEL cDNA probe labeled with 31P_dCTP. 
The washed membranes were analyzed by autoradiography. 
Statistical analysis 
The distributions of clinical and biologic features for patients 
with or without expression of the Tfl/AML 1 chimeric tran-
script were compared by the two-tailed Fisher exact test for 
categorical data and by the Wilcoxon test for continuous data. 
Life-table estimates of event-free survival (EFS) were derived 
b~' the method of Kaplan and Meier,2J and compared using 
the logrank test stratified by treatment regimens and WBC 
count at diagnosis.24 Failure to achieve remission was con-
sidered an event at time zero. 
Results 
To investigate the possibility of TEL rearrangements, Southern 
blots of BamHl, EcoRI, or Hindlll digested DNA from pediatric 
ALL cases were sequentially hybridized with partial TEL 
cDNA probes. As shown in Figure 1, TfL rearrangements were 
detected in a high frequency of cases lIsing a 466-bp 
SacVBamHI (pSB) TEL cDNA probe on BamHI digests. This 
probe encodes the central portion of TEL, including the N-
terminal third of the DNA-binding domain. By contrast, only 
rare cases were identified with rearrangements that extended 
outside of this area. Moreover, each of these lalter cases still 
had rearrangements that were detected with this 
probe/restriction endonuclease combination (data not shown). 
Accordingly, we used the TEL pSB probe to hybridize Sou· 
thern blots of BamHI~digested DNA from 160 ALL and so 
AML cases to determine the frequency of TEL rearrangements 
in pediatric aCllte leukemia. TEL rearrangements were 
detected in 24% (38/160) of ALL cases, but not in an}' of the 
50 AML cases analyzed. Similarly, TEL was not rearranged in 
samples from 19 non-leukemic control individuals, demon-
strating a lack of detectable polymorphisms with this restric-
tion endonucleaSe/probe combination. 
Most of the ALL cases with TEL rearrangements had two 
altered TEL BamHI fragments, consistent with detection of 
both reciprocal products from a TEL translocation. In addition, 
a 21-kb germ·line TEL fragment was detected in most cases, 
suggesting retention of a non·rearranged TEL allele (Figure 1 
and see beJow). 
The location of rearrangements within TEL were identical 
to those described for the t{12;21) translocation, which enco-
des a chimeric TEl/AMLI productY' To invesligate whether 
the observed rearrangements were the result of a cryptic 
1(12;21), RT-PCR analysis was performed for detection of the 
der(21 )to 2;21}-encoded TEl/AlvIU and the der{12)t{12;21)-
encoded AMUITEL chimeric mRNAs (Figure 2). RT-PCR 
analysis revealed the presence of the der(21)t(12;21) 
TEl/AMLI transcript in 35 of 38 cases. By contrast, the 
reciprocal der{12) AML IITEL fusion product was detected in 
only 29 cases, all of which also expressed TEl/AML 1. 
Sequence analysis of TEl/AML 1 PCR products demonstrated 
fusion points identical to those previousl}' published,5,t; with 
the exception of a single case in which the TEL breakpoint 
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Figure 2 Schematic of the der(21)t(12;21)-encoded TEUMIL/, 
dcr(12)t(12;21)·encoded AML1/TEL, oligonucleotide primers and pro-
bes used for RT·PCR anal~'sis, and the results of RT·PCR analysis of 
pali{lnts with leukemias containing TEl g{lne re<1rrangements. fa) The 
helix-loop-helix (HlH) and D'\'A-binding domain (DBD) of TEL, and 
the DNA-binding TUnt homology domain (RHD) of AMl-I are indi-
cated. The fusion points are shown with arrows. (b) RT·PCR products 
were size fractionated b~' electrophoresis, transfelred to nylon memo 
branes, and h~·bridized with the AMlI (TEUAAILi) or TEL 
(AML I/TELJ probes. 
occurred at a more 5' site that corresponded to the site 
of fusion described for the t(5;J2)·encoded TEl/POGFR/3 
product.9 
Although 35 cases had molecular evidence of the 
TEl/Ah'IL 1 fusion, none of the cases had a cytogenetically 
detectable t(12;21). However, 12/18 cases with other cyto· 
genetic abnormalities of chromosome 12p including 
deletions, dicentric chromosomes, or other 12p translo-
cations, expressed the fusion transcript, suggesting that the fre-
quency of this cryptic translocation may be even higher in the 
subgroup of patients with cytogenetic abnormalities of 
chromosome 12, band p12-13. 
Previous published data on a limited number of patients 
implied that cases expressing the TEl/AML 1 fusion transcripts 
frequently have deletions of the non-rearranged TEL aIJeJe.s,{. 
Our Southern blot anal}'sis, however, demonstrated definitive 
loss of the non-translocated TEL allele in only seven out of 35 
of the TEl/MIL I-expressing cases (data not shown). More-
over, Northern bIOi analysis performed on three TEl/AML 1 
containing cases that had greater than 95% blasts and reten-
tion of a non-rearranged TEL allele, revealed expression of a 
normal sized TEL mRNA. However, direct sequence analysis 
of TEL was not performed and thus the presence of inactivat-
ing point mutations or microdeletions in the non-rearranged 
allele cannot be excluded. 
The 160 patients analyzed were treated on one of 
three consecutive front-line ALL protocols at SJCRH, and 
had a median follow·up of 30 months (range, 5 to 123 
months).25-27 As described above, 35 of these 160 cases 
expressed the TEUM1L1 transcript. Analysis of the clinical 
features of these patients demonstrated that TEUAML I 
expression identified a uniform patient subgroup charac-
terized by an age between 1 and 10 years (100%), and 
leukemic blasts with a B precursor immunophenotype (100%), 
and nonhyperdiploid DNA content (DNA index less than 1.16 
or greater than 1.60) (100%.). Among the 126 B lineage cases 
that were analyzed, the 35 TEUAA'IL I-expressing cases 
appeared to have a better survival than the 91 cases that 
lacked evidence of this fusion product, with 5-year event-free 
survival (± s.e.) estimates of 92 ± 8% vs 70 ± 10% (P= 0.14 
b}' stratified logrank tesO. 
Discussion 
Although abnormalities of 12p13 occur often in All, the 
t(l2;21)(pJ3;q22), which encodes a TEl/AAILI chimeric pro-
duct, is rarely seen by cytogenetic analysis. Recently, how-
ever, the use of molecular approaches to detect this translo-
cation have suggested that its true frequency may be 
underestimated by routine cytogeneticsY-17 We now show 
that the fusion of the TEL and AML 1 genes, as a result of a 
cryptic t(12;21), is the most common genetic lesion in pedi-
atric ALL, occurring in 22% of patients. By comparison, the 
most common cytogenetically detected translocation, the 
t{1 ;19)(q23;p13), occurs in approximately 5% of ALL patients. 
Moreover, this translocation was unique to All cases and was 
not seen in any of 50 childhood cases of AML In addition, 
our data also suggests that expression of TEl/AMU defines a 
uniform subgroup of ALL patients age 1 to 10 years who have 
B precursor, nonhyperdiploid leukemic Iympnoblasts. Taken 
together, these data indicate that cytogenetic analysis is inad-
equate to accurately identify this large, but apparently distinct 
subgroup of patients. 
Analysis for the presence of 1{12;21 )·derived fusion products 
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in cases with TEL rearrangements demonstrated the nearly 
uniform expression of the der(21 )t(12;21)-encoded TEUAML 1 
transcript (35 of 38 cases), whereas the reciprocal AML 1/TEL 
mRNA was detected in only a subset of patients (29 of 38 
cases). These data suggest that the TEUAML~ 1 product is 
important in establishing the transformed phenotype in these 
cases. This product consists of the HlH-domain of TEl fused 
to almost the complete coding region of AMl-l. Although 
both genes are the frequent targets of other leukemia-associ-
ated translocations, the structure of this product suggests a 
primary role for altered AMl-l activity in leukemogenesis in 
these cases. 
AMl~1 is a member of a family of transcription factors with 
homology to the Drosophila gene runt, and encodes the DNA~ 
binding subunit of AWtll!CBFj3 transcription factor (Figure 
3).28--31 AWtl-l!CBFj3 has been shown to regulate expression 
of a variety of hematopoietic-specific genes, including the 
cytokines ll-3 and GM-CSF, the CSF-l receptor, and the 
myeloid specific gene myeloperoxidase.31 -33 Moreover, A/vll-
I/CBFj3 is the most common target of AMl-associated translo-
cations with the AWtl-1 subunit involved in the formation of 
fusion products with ETO and EVJ1 in the t{8;21) and 1(3;21)/ 
respectively, and the CBFj3 subunit involved in the formation 
of a fusion product with the smooth muscle myosin heavy 
chain, MYH11, in the inv(16)8 (Figure 3). Several of these 
chimeric produCls have been demonstrated to interfere with 
normal Nvll-I-dependent transcription, suggesting that trans-
formation results in part, from a dominant negative repression 
of normal AMl-1-target gene expression.34 The TEljAMl~1 
product may also function in leukemogenesis by abnormally 
regulating AMl-1 target genes in lymphoid cells. Several 
mechanistically different possibilities for this deregulation 
could be envisioned: (1) Fusion of the TEl-HLH domain 10 
AWtl-l may prevent AMl-J from binding to DNA and activat~ 
ing its normal target genes. (2) The TEUAMl-l fusion protein 
may still bind to the regulatory region of AMl-1 larget genes, 
but the chimeric protein may interfere with normal transcrip-
tional activity. (3) The TEl-HlH domain could also alter the 
DNA-binding specificity of AMl-l, leading to the expression 
or repression of genes not normally regulated by AMl-l. Irres-
pective of the ultimate transforming mechanism, these data 
now demonstrate that alteration of the AMl-l/CBFj3 complex 
occurs at a high frequency in not only myelOid leukemias, 
but also in lymphoid leukemias, and thus implicate the AMl-
-----_~TGtGG,.~._~--=:J:{i§~~io 
MPO, IL-3, GM-CSF 
CSF-1R 
Figure 3 Schematic of the MIL-l/CBFJ3 transcription factor com~ 
plex and the leukemia-associated chromosomal rearrangements that 
affect this complex. 
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l/CBFj3 transcription complex as the most frequent target of 
chromosomal rearrangements in human leukemia. 
Direct alterations of cellular processes regulated by the nor-
mat TEL encoded product are also likely to contribute to trans-
formation in these cases. Either reciprocall{12;21)-encoded 
chimeric product may directly interfere with the function of 
normal TEL In addition, the moderate frequency of deletion 
of the non-rearranged TEL alle[e suggests that loss of normal 
TEL may also contribute to leukemia progression in a subset 
of patients. 
Three cases were identified that contained TEL rearrange~ 
ments but lacked expression of TEUAML 1 mRNA. These find~ 
ings may have resulted from a 1(12;21) with alternative break-
points that result in a chimeric product that could not be 
amplified by our oligonucleotide primers. Alternatively, in 
these cases TEL may be fused to genes other than AMLl 
or may be partially deleted. Further studies are underway to 
clarify the molecular baSis of the lesions in these cases. 
To date, the only subset of B lineage ALL cases with a favor-
able prognosis has been the hyperdiploid group.25.3S Our 
analysis of outcome data from patients treated on three 
sequential total therapy All protocols suggests that patients 
with leukemic blasts expressing TEUAA1L 1 identifies a second 
subset of B lineage cases that have favorable clinical features. 
However, in this patient cohort, which spans over 10 years 
and represents patients treated on a variety of intensive multi-
agent rotational chemotherapy protocols, the differences in 
EFS between this group and other B lineage cases was not 
statistically significant. Nevertheless, the apparent improved 
prognosis of cases with TEUAMLI expression suggests that the 
clinical significance of this molecular lesion should be evalu-
ated further, by analyzing a large group of patients receiving 
uniform treatment. 
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Gerard Grosveld I 
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Abstract 
The t(l2;21)(pI3;q22) occurs in 25% of cases of childhood pre-B acute lymphoblastic 
leukemia and results in the fusion of TEL on l2p13 to AMLl on 21q22. This translocation is 
often accompanied by deletion of the second TEL aBele. In a few cases the deletion 
occurred intragenic, suggesting that TEL is a potential tumor suppressor gene. Recent data 
indicate that TEL-AMLI acts as a dominant repressor of AMLI dependent transcription 
regulation. By using immunofluorescence analysis, we show that exogenously expressed 
TEL-AMLI localizes to the cytoplasm of retrovirally transduced and transiently transfected 
cells. The cytoplasmic localization of the fusion protein is dependent on the helix-loop-helix 
(HLH) domain in the TEL moiety. Although endogenous TEL is a nuclear protein, 
expression of TEL-AMLI causes TEL to colocalize to the cytoplasm. This colocalizatioll 
seems to be the result of physical interaction between the HLH domains of TEL and TEL-
AMLl. However, in human B cell lines, expressing TEL-AMLl, the chimeric protein 
localized to the nucleus. Furthermore, overexpression of TEL in fibroblasts resulted in the 
induction of cell death. Our data support the hypothesis, that diminishing of the effective 
dosage of nuclear TEL protein provides a proliferative advantage to t( 12;21) leukemic cens 
in childhood pre-B ALL. 
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Introduction 
Cytogenetic studies demonstrate abnormalities of the short arm of chromosome 12 in 10 % 
of lymphoid and myeloid leukemias (Raimondi ef al., 1986). The cryptic t(12;21)(pI3;q22) 
is identified in fewer than 0.05% of cases of childhood acute lymphoblastic leukemia (ALL) 
(Raimondi, 1993). Molecular analysis of the breakpoint revealed that the translocation 
results in the fusion of TEL, a member of the ETS family of transcription factors, and 
AMLl, the human homolog of the Drosophila pair-rule RUNT gene (Golub ef al., 1995; 
Romana ef at., 1995a). TEL was first reported as a result of its involvement in t(5;12) in 
chronic myelomonocytic leukemia (Golub ef al., 1994), in which its N-terminus, including a 
helix-loop-helix (HLH) protein interaction domain, was fused to the PDGFpR. TEL has 
also been found to be fused to ABL in t(9;12) and MN1 in t(12;22) (Buijs ef al., 1995; 
Papadopoulos ef al., 1995). The AMLl gene was identified through its involvement in 
t(8;21), which is associated with 15% of cases of acute myelogenous leukemia (Miyoshi ef 
al., 1991). In addition, AMLI is important in hematopoiesis, as mice homozygous for a 
mutated AMLl allele, died at mldgestation because of defective fetal liver hematopoiesis 
(Okuda ef al., 1996). 
The TEL-AMLI transcript derives from chromosome 21q- and encodes a fusion 
protein that contains N-tenninal TEL sequences, including its HLH domain, linked to the 
RUNT DNA-binding domain and transactivating sequences of AMLI. Using Southern blot 
and reverse transcriptase-polymerase chain reaction analyses, we and others have shown 
that t(12;21) occurs in 16% to 25% of cases of childhood ALL (Mclean ef al., 1996; 
Romana ef al., 1995b; Shurtleff ef al., 1995), making it the most frequent translocation in 
pediatric ALL. This chromosomal abnormality defines a subtype of pediatric ALL with a B 
lineage immunophenotype and non hyperdiploid DNA content that is found in patients who 
are I to 10 years of age. A retrospective study of 188 cases of childhood pre-B ALL 
revealed that t( I 2;21) is a favorable prognostic indicator for this subgroup of patients 
(Rubnitz ef al., 1997). 
About 5% of cases of childhood ALL have cytogenetically detectable deletions in 
the 12pl3 region (Raimondi ef al., 1991). In addition, loss of heterozygosity of the TEL 
locus has been observed in 15% to 26% of cases of pediatric ALL and ill 27% to 40% of 
patients with pre-B ALL (Cave ef al., 1995; Stegmaier ef al., 1995; Takeuchi ef al., 1996). 
T(12;21) is frequently associated with deletion of the second TEL allele (Golub ef al., 1995; 
Raynaud ef al., 1996; Romana ef al., 1995a; Wlodarska ef al., 1996). This deletion is a 
secondary event ill pre-B ALL (Kim ef al., 1996; Raynaud ef al., 1996; Wlodarska ef al., 
1996). In one case, the deletion was intragenic in a subclone of leukemic blasts. Such a 
deletion may correlate with a proliferative advantage for these cells, in turn suggesting that 
TEL may be a tumor suppressor gene. However, mutations in the coding region of TEL are 
rare in childhood ALL (Stegmaier et al., 1996), thereby calling into question the validity of 
this hypothesis. 
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Little is known about the biochemical mechanism by which TEL-ALL contributes to 
leukemogenesis. Recent ill vitro studies of TEL-AMLI suggested that it may act as a 
dominant negative repressor of AMLl-dependent regulation of transcription (Hiebert et al., 
1996). In light of its alleged nuclear localization, it was hypothesized that TEL-fuVlLl, 
through the HLH domain of TEL, recruits repressors for AMLl-dependent activation of 
transcription. 
In contrast to these previous studies, we used immunofluorescence analyses to show 
that TEL-AMLI is located in the cytoplasm of cells that express the fusion protein after 
retroviral transduction or transient transfection. The cytoplasmic localization ofTEL-AMLI 
is dependent on the HLH domain, which mediates both the homotypic association with 
TEL-AMLI and heterotypic association with TEL. In transfected cells, TEL-AMLI 
relocates endogenous TEL from the nucleus to the cytoplasm, presumably due to a physical 
interaction of TEL and TEL-AMLI. However, in human pre-B cell lines, that express TEL-
AMLl, the chimeric protein was localized to the nucleus. In addition, retroviral transduction 
of TEL eDNA in murine fibroblasts resulted in cell death, of which the onset was 
accelerated by a serine to alanine mutation at a putative phosphoacceptor site at serine 
residue 22. Cell death was not induced by a mutant lacking the HLH domain. We feel that 
our data support the hypothesis that TEL has tumor suppressor activity. 
Materials and Methods 
eel/lines 
Mouse fibroblast NIH3T3 cell line, human cervical epithelial cell line HeLa, lung 
carcinoma cell line C33A, simian kidney cell line COS-l and kidney carcinoma cell line 
293T were maintained in DMEM +10% FBS. Human B cell lines REH, SUP-B2S, UoC-BI 
and Nalm-6 were maintained in RPMI + 10 % PBS. 
Constructs 
Various TEL and TEL-ANILI cDNA inserts were cloned into the CMV promoter driven 
expression vector pSCTOP (Fornerod et al., 1995) and into the retroviral expression vector 
pSRaMSVTKCDS. The latter allolVs the selection of transduced cells based on the 
expression of CDS (Hirai et al., 1995). Influenza virus hemagglutinin-tagged proteins (e.g., 
HAITEL) were generated by the in-frame cloning of three HAl epitopes 5' of the ATG 
codon of TEL. To generate mutants lacking the HLH domain (TELA53-116), we deleted the 
192 bp FspI-XIIlIlI fragment (corresponding to amino acids 53 through 116) from the TEL 
eDNA construct. The TEL22s->22A construct was generated through site-directed mutagenesis 
in bacteriophage M13 according to manufachlfer's recommendations (Biorad, Hercules, 
CAl by using the oligomer 5'-ACACCTCCAGAGGCCCCACTGCCGAG-3', in which 
codon 22 of TEL was mutated from AGC (Ser) to GCC (Ala), thereby eliminating a 
putative MAPK phosphorylation site. The TEL-OCT6 fusion construct was generated by 
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cloning the 1219bp EcoRI-SspI TEL cDNA fragment into the SmaI site of the OCT6 
deletion clone, N229 (Meijer ef (II., 1992). This cloning resulted in the in-frame fusion of 
the first 366 amino acids of TEL to the last 219 amino acids of OCT6 which include its 
POD homeD DNA binding domain. Figure 1 provides schematic diagrams of the constructs 
used in our experiments. 
TEL ~ 
TELl53·116 I~ 
TEL·AML1 ~IRj ITA I 
TEL·AML1653·116 ~H ITA I 
AML1 II~ H I 
TEL·OCT6 
TEL·OCT6~53·116 
Figure 1 Schematic representation of the various constructs used in these studies. See Materials and Methods 
for cloning details. HLH, helix-loop-helix domain, ETS, ETS DNA-binding domain, RT, RUNT DNA-binding 
domain, TA, lransactivuting sequences, PODs, POU specific domain, POUh, POU-homeo domain. Bright line 
in TEL indicates serine residue 22 
Retroviral transduction 
Retroviruses containing TEL, TELA53-116, TEL'2S~22A, TEL-AMLl, TEL-AMLlA53-116, 
HAITEL-AMLI, HAITEL-AMLIA53-116 and RAS were generated by using calcium 
phosphate precipitation of 3xl06 293T cells in a 10 em diameter dish cotransfected with 10 
~lg of the appropriate pSRaMSVTKCD8-based plasmid and 10 I1g of the replication-
defective helper plasmid pSV-IJI-E-MLV (Muller ef al., 1991). After 20 hours, the 
precipitate was removed and virus-containing supernatant was harvested for 42 hours at 4-8 
hour intervals. The supernatants were filtered over a 0.45 J!m gauze filters. We then overlaid 
2x 10' NIH3T3 fibroblasts, which were plated in a 10 cm diameter dish, with 1.5 ml of high-
titer supernatant that contained 6 llg/m1 polybrene. The vims-containing supernatant was 
replaced with fresh medium 3 hours later, and CD8-expressing cells were collected by using 
fluorescence-activated cell sorting (FACS) 60 hours after infection. These cells were then 
tested for anchorage-independent growth in soft agar and for protein expression of the 
transduced cDNAs using immunofluorcscence(see following). 
A1ltibodies 
A synthetic peptide containing the 10 C-terminal amino acids of TEL (Golub ef al., 1994) 
was conjugated to keyhole limpet hemocyanin and injected into New Zealand \Vhite rabbits 
(Rockland, Gilbertsville, Pal according to standard techniques (Harlow & Lane, 1988). 
Immunopurificd C-tenninal (/.-TEL antibodies were obtained by passing sel1lm 32 over a C-
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terminal TEL peptide-coupled Affi-Gel 10 column (Biorad, Hercules, CAl. N-terminal TEL 
antisemm was kindly provided by Dr. P. Marynell, Leuven, Belgium. The a-AMLI semm 
has been described previously (Meyers el al., 1993). MoAb 12CA5, recognizing an 
influenza hemagglutinin tag has been described before (Wilson el al., 1984). 
ImmWlOfluorescellce analysis 
We seeded 1.5xlO' cells from each CD8-expressing, retrovirally transduced N1lI3T3 
population on microscope slides. In addition, 1.5xlO' C33A, COS-I, N1lI3T3, or HeLa 
cells were seeded on microscope slides and transfected with 10 Jlg of the various pSCTOP-
based plasm ids by using calcium phosphate precipitation (Graham & Eb, 1973). After 24 
hours, the precipitate was removed. Cytospin preparations of human B cell lines were 
generated. Cells were fixed in 3% paraformaldehyde for 15 min and permeabilized with 
0.2% Triton in PBS for 10 min. The cells were incubated with immunopurified a-AMLI 
(diluted 1:100 in PBSIl%BSA), C-terminal a-TEL (diluted 1:1250 in PBS/I%BSA), N-
terminal a-TEL (diluted 1:1500 in PBSIl% BSA) or the monoclonal antibody 12CA5 (2 
flg/m1 PBS/l %BSA), as described (Fornerod el al., 1995). a-TEL antibodies were competed 
with bacterially expressed GST -TEL fusion protein for 1 hour at room temperature (Buijs et 
aI., manuscript in preparation). Images were obtained by using confocal microscopy 
(BioRad MRCIOOO Laser Scanning confocal microscope) or conventional microscopy. 
iml111llloprecipitatioJl and Western analysis 
By using calcium phosphate precipitation, 1.5x 105 HeLa cells were seeded in a 6 cm dish 
and transfected with 10 J.tg of the pSCTOP-based expression vector containing TEL, TEL-
AMLl, HAlTEL, HAITELA53-116, HAITEL-AMLI, or HAITEL-AMLIA53-116. After 
16 hours, the precipitates were removed, and 36 hours later, the cells were metabolically 
labeled by using 100 J.1Ci of a 35S-methionine-cysteine in vivo labeling mix (DuPont NEN, 
Wilmington, DE) in 1.4 ml of methionine-cysteine-free DMEM supplemented with 8% 
dialyzed FBS. Irnmunoprecipitations with the anti-HAl monoclonal antibody 12CA5 were 
performed as described (Fornerod el al., 1996). Immunecomplexes were separated on a 10% 
SDS-PAGE gel and electroblotted onto PVDF membrane (Millipore, Bedford, MA). To 
control for efficient transfer, gels were analyzed after blotting by autoradiography for 
residual protein. Blots were blocked overnight in PBS/l % BSA, then incubated for 3 hours 
with affinity purified a-TEL (diluted I: 1000 in PBS/I %BSA) or 12CA5 (I J.tg/ml). Bound 
antibody was visualized with an alkalinephosphatase-conjugated secondary antibody and 
colorimetry. 
RNA isolalion and RT-PCR analysis 
RNA isolation and RT-PCR analysis have been performed as been described (Shurtleff el 
al., 1995). 
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Results 
Exogenous TEL-AMLI is a cytoplasmic fusion protein 
To address whether the t(l2;21)-specific TEL-AMLI fusion gene could transform NIH3T3 
fibroblasts, we first generated replication-defective retroviruses that contained either TEL, 
TELA53-116, HAlTEL, HAITELA 53-116, AMLlB, TEL-AMLl, HAlTEL-AMLI, TEL-
AMLlA53-116, HAITEL-AMLIA53-116, or activated RAS (figure I). Only cells 
transduced with the retrovirus containing activated RAS showed significant colony 
formation in soft agar (data not shown). This observation suggested that, except for 
activated RAS, non of the transduced viruses displayed transforming activity in this assays. 
Concomitantly with the soft agar assays, aliquots of the transduced cells were tested 
for expression of exogenous protein by immunofluorescence analysis. In contrast to what 
was suggested by previous cell fractionation studies in which TEL-AMLI was found to be 
associated with the nuclear and nuclearmatrix fractions (Hiebert et al., 1996), we found 
TEL-AMLI and HAlTEL-AMLI proteins solely in the cytoplasm of cells transduced with 
the respective constructs, using a-AMLI antibodies and 12CA5 respectively (figure 2a, b). 
Cytoplasmic localization of these products was dependent on the presence of the HLH 
domain of TEL, because proteins lacking amino acids 53 through 116 (which span the HLH 
domain) localized to the nucleus (figure 2c, d). Exogenous ANILIB was predominantly 
found in nucleus (figure 2e). Retrovirally transduced TEL, expressed at a high level was 
present in the cytoplasm, nucleus, or both subcellular compartments, whereas TEL 
expressed at low level was predominantly nuclear (figure 21). TELA53-116 was equally 
present in the cytoplasm and the nucleus (figure 2g). 
To verify the cytoplasmic localization of the fusion proteins also in cen lines not 
transducible by ecotropic retroviruses, we studied the cellular distribution of TEL-AMLI 
and TEL-AMLIA53-116 in transiently transfected C33A, COS-I, and HeLa cell lines. 
Immunofluorescence analysis of all three cells lines localized HAITEL-AMLI in the 
cytoplasm of the vast majority of the transfected cells and HAlTEL-AMLlA53-116 in the 
nuclei of the cells (figure 3 a,c). In a small percentage of transfected cells HAITEL-AMLI 
was detected in the nucleus, when expressed at low levels (figure 3a). This localization was 
independent of the presence of the N-terminal HAl tag (data not shown). 
To verify that the behavior of TEL is a function of the HLH domain, we linked the 
HLH domain to a heterologous DNA binding domain. We expressed the HAITEL-OCT6 
and HAlTEL-OCT6A53-116 fusion cDNAs by transient transfection, in which the ETS 
domain of TEL was replaced by the POU-homeo domain of transcription factor OCT6 
(Meijer ef al., 1990). HAITEL-OCT6 also localized to the cytoplasm of transfected HeLa 
cells, despite the presence of the OCT6 nnclear localization signal (NLS)(figure 3b). By 
contrast, the HLH-deletion mutant HA I TEL-OCT6A53-116, like TEL-AMLI A53-116, was 
expressed in the nucleus (figure 3d). 
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Figure 2 Subcellular localization of proteins expressed by retrovirally transduced cDNAs. Images represent 
NIH3T3 cells retrovirally transduced with TEL-AMLl (A), HAlTEL-AMLl (8), TEL-M1Llti53-116 (C), 
HAITEL-AMLI653-116 (D), M1Ll-B (E), TEL (F) and TEL653-116 (G) cDNAs. Proteins were detected 
with immunopurified a-AMLl antibodies (A,C and E), innnunopurified a-TEL antibodies (F,G), and HAl-
specific MoAb 12CA5 (8 and D). The presence of the first antibody was visualized by a FITC-Iabelled second 
antibody. Images were obtained by using confocal microscopy. 
Figure 3 Subcellular distribution ofTEL-AMLl, TEL-AMLI653-116, TEL-OCT6 and TEL-OCT6653-116. 
Indircct immunofluorescence of HeLa cells transfected with HAlTEL-AMLl (A), HAlTEL-AMLI,153-J 16 
(8), HAITEL-OCT6 (C) and HAlTEL-OCT6653-116 (D). HAl tagged proteins were detected with MoAb 
12CA5. The presence of first antibody was visualized with a FITC-Iabelcd second antibody. Images were 
obtained by using confocal microscopy. 
89 
Colocalizatio1l of HAITEL-AMLI a1ld endogenolls TEL ill the cytoplasm requires the HLH 
domain 
Because the localization of TEL-AMLI to the cytoplasm depended on the presence of the 
HLH domain of TEL, we determined the localization of endogenous TEL in HeLa cells 
transiently transfected with HA I TEL-AMLI or HA I TEL-AMLlA53-116. Endogenous TEL 
localized predominantly to the nucleus in untransfected cells (figure 4a ,e, d). By contrast, 
endogenous TEL was detected in the cytoplasm of cells transfected with HAITEL-AMLI 
(figure 4a,e), but when transfected with HAITEL-AMLlA53-116, endogenous TEL and 
exogenous HAITEL-AMLIA53-116 colocalized in the nucleus (figure 4 d,h). In the few 
cells that expressed HA I TEL-AMLI in the nucleus, TEL localized in the nucleus as well 
(figure 4 e,g). To verify that the signal obtained with immunopurified a-TEL antibodies was 
derived from endogenous TEL, the immunofluorescence signal could be competed by 
addition of bacterially expressed GST-TEL protein in cells transfected with HAITEL-
AMLl(figure 4 b,t). These data suggest that TEL-AMLI relocates TEL from the nucleus to 
the cytoplasm, dependent on the HLH domain. 
HAHEL-AML1 HA HEL-AML1 HAHEGAML1 HA HEL-AML1 ~53-116 
a-TEL 
12CA5 
Figure 4 Cytoplasmic colocalization of endogenous TEL and exogenous TEL-AMLl. HeLa cells were 
transiently transfected with HAITEL-AMLI (A,ll,C,E,F,and G) or HAlTEL-AMLlto.53-116 (D and H), 
Proteins were detected by indirect immunofluorescence in a double immunostaining using a-TEL antibodies 
(upper panel) ond HA I specific MoAb l2eAS (lower panel). Anti-TEL signal was competed using bacterially 
expressed GST-TEL protein (ll). Proteins were visualized using FITC- or Texas-Red-conjugated second 
antibodies. Arrows indicate transfected cells. Images were obtained by using confocal microscopy. Signals of 
A, ll, C, D find G have been electronically amplified. 
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TEL-AMLI localizes to the 1/ue/eus inienkelllic t( 12;21) pre B eel/lines 
Because exogenous TEL-AMLI localized to the cytoplasm, we wished to address whether 
the localization was due to overexpression of the protein or whether it reflected its 
localization in leukemic cells. By using immunofluorescence analysis we studied the 
localization of TEL-AMLI in pre B-cell lines, which carry t(l2;21) and have been 
demonstrated to express a TEL-AMLI chimeric transcript (Kim et al., 1996). First, we 
performed RT-PCR analysis to confirm the presence of TEL-AMLl, AMLl-TEL and TEL 
transcripts in the leukemic cell lines. Figure 5 (right upper panel) demonstrates that the 
TEL-AMLI chimeric cDNA (1164 bp) was amplified from both REH and SUP-B28, but 
not from HL60, Nalm-6 and UoC-B I. However, no wildtype TEL cDNA product (1007 bp) 
could be amplified from REH and SUP-B28, whereas it was amplified from HL60, Nalm-6 
and UoC-BI (figure 5 upper left panel). We also amplified the reciprocal AMLl-TEL 
cDNA product SUP-B28 (380 bp) (figure 5; lower left panel) As a control a 364 bp c-ABL 
cDNA was amplified from all cell lines, demonstrating the integrity of the mRNAs (figure 
5; right lower panel). 
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FigUl'C 5, RT-PCR analysis ofTEL-AMLl, AMLl-TEL and TEL mRNA in human prc-B cell lines. mRNA 
transcripts, specific for TEL (upper left pane!), TEL-AMLI (upper right pane!), AMLl-TEL (lower left panel) 
and c-ABL (lower right pancl) were amplified and run on a 2 % agarose gel. Arrows indicate the spccific 
products. 
By using immunofluorescence analysis, TEL-AMLI was localized to the nucleus in 
pre B-cell Hnes REH using N-tenninal TEL antisel1lm (figure 6a). To verify that the signal 
was indeed derived from TEL-AMLI, we showed that addition of bacterially expressed GST-
TEL protein to the incubation of the TEL antibody abolished the signal (figure 6b). No signal 
could be obtained using C-tenninal TEL antibodies, confinning the absence of TEL in this cell 
line (figure 6c). Similar results were obtained for SUP-B28 (data not shown). It is interesting 
to note that, despite the presence of AMLl-TEL mRNA, the reciprocal AMLI-TEL protein 
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could not be detected in SUP-B28 using C-terminal TEL antibodies, suggesting that it is not 
translated or rapidly degraded (data not shown). As a control, we studied the localization of 
TEL in human B-cell line UoC-B 1 using either N-tenninal or C-tenninal TEL antibodies. 
With both antibodies TEL could be localized to the nucleus (figure 6d, e). Some signal is 
localized to the cytoplasm of REH and UoC-B I cells using N-terrninal TEL antibodies (figure 
6a, d). Because the same signal was obtained when the samples were not incubated with the 
primary antibody, it is likely that the signal is due to aspecific binding of the secondary goat 
anti-rabbit IgG antibodies. This conclusion is further supported by the observation that 
competition with GST-TEL did not eliminate this signal (figure 6b). These results indicate that 
in leukemic pre-B cellliues carrying t(l2;21), TEL-AMLI is predominantly nuclear. 
Figure 6. Subcellular distribution ofTEL-AMLI and TEL in human pre B-ceillines. Proteins were detected 
by using indirect immunofluorescence analysis of cytospin preparations of human pre-B cell lines REH and 
UoC-B I. (A) TEL-AMLI was detected in the nucleus of REH cells by indirect inmmnofluorescence analysis 
using N-terminal antibodies. (n) Anti-TEL signal was competed using bacterially expressed GST-TEL protein. 
(C) No TEL specific signal could be obtained by using C-terminal TEL antibodies. (D,E) TEL was detccted in 
the nucleus of UoC-B 1 cells using N-terminal (D) or C-terminal TEL antibodies (E). Proteins were visualized 
using FITC- (A, n, c, E) or Texas-Red-eonjugated second antibodies (D). Imagcs were obtained by using 
confocal microscopy (A, n, D) or conventional microscopy (C and E). 
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TEL-AMLI ([ml TEL co-iwlIlll1loprecipitate through illferactioll (~ftheir HLH domains 
To address whether TEL and TEL-AMLI interact via their HLH domains we used HeLa 
cells that expressed TEL or TEL-AMLI and the HA I-tagged version of the these molecules. 
By immunoprecipitating the HAl-tagged proteins from these cells with MoAb 12CA5, we 
analyzed whether the un tagged molecules would co-precipitate. To this end we transfected 
HeLa cells with TEL or TEL-AMLI in the presence of HAlTEL, HAITELt\53-116, 
HAlTEL-AMLI, or HA I TEL-AML I t\53-1 16. The cells were then labeled with 35S_ 
methionine!cysteine, and the HA I-tagged proteins were precipitated with 12CA5. After 
SDS-PAGE, separated proteins were electroblotted onto nylon membranes and identified by 
Western analysis. 
Figure 7a shows a Western blot of 12CA5 immunoprecipitates from cells co-
expressing endogenolls (lanes 1-7) and exogenous (lanes 1-5) TEL together with the 
different HAl-tagged molecules after probing with the C-terminal TEL antibody. The 
antibody recognized HA I -tagged TEL proteins HA I TELt\53- I 16 (lane 2) and HA I TEL 
(top band in lanes 3 and 6), and co-precipitated untagged TEL proteins of 60 and 50 kDa 
(lanes 3,5,6 and 7). The fact that two TEL proteins are co-precipitated coincides well with 
data from Bernard and coworkers, who showed that two TEL proteins are translated from a 
single mRNA by alternative initiation codon usages (Poirel ef aT., 1997). The untagged TEL 
products were not present in co-precipitations with HLH deletion mutants of HAITEL and 
HAITEL-AMLI (lanes 2 and 4). The data show that co-precipitation of TEL with HAITEL 
and HA ITEL-AMLI is dependent on the presence of the HLH interaction domain. 
Figures 7b and 7c show a similar analysis for TEL-AMLI and HA I-tagged TEL and 
TEL-AMLI proteins. After co-transfection, cells were metabolically labeled with 35S_ 
rnethionine!cysteine, HAl-tagged proteins were immllnoprecipitated with 12CA5, separated 
on SDS-PAGE and electroblottcd onto nylon filters. Figure 7b shows the Western blot 
probed with 12CA5, whereas labeled proteins that remained in the gel after blotting are 
shown in figure 7c. Figure 7b identified the different HAl-tagged proteins that are labeled 
with an asterix in the autoradiogram of the immulloprecipitates in figure 7c. This allowed us 
to deduce that p96TEL-AMLI co-precipitated with HAITEL (lanes 3) and HAITEL-AMLI 
(lanes 5), but not with the Ill.H deletion mutant of TEL (lanes 2). This conclusion can not 
be drawn for the HLH deletion mutant from TEL-AMLI, because HAITEL-AMLlt\53-1 16 
and p96TEL ... AML1 are of the same size. These data show that TEL-AMLI interacts with itself 
and we infer, but can not conclude from this experiment, that this interaction is mediated by 
the HLH domain. 
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Figure 7 TEL and TEL-AMLl interact via the HLH domain of TEL. (A) HeLa cells were (co)transfected 
with expression plasmids encoding TEL, HAlTEL.6.53-116, HAlTEL, HAlTEL-AMLl1153-116 or HAlTEL-
AMLl as indicated above the lanes. Proteins were immunoprecipitaled with MoAb 12CA5. separated on a 
10% SDS-polyacrylamide gel and c1ectroblotted. Proteins on the Western blots were visualized using C-
terminal a-TEL antiserum. HAlTEL1153-116, HAlTEL and co-precipitating proteins are indicated with 
arrows on the right. (H,C) HeLa cells were transfected with expression plasmids encoding TEL-AMLl, 
together with HAITEL.6.53-1l6. HAITEL, HAlTEL-AMLl.6.53-1l6 or HAlTEL-AMLL Following 
metabolic labeling with J!iS-methionine/cysteine, proteins were immunoprecipitaled with MoAb 12CA5, 
separated on a 10% SDS-polyacrylamide gel and electroblotted. Proteins on the Western blot were visualized 
using MoAb 12CA5 (H). Residual protein in the gel after blotting was visualized by autoradiography (C). 
HAlTEL1153-1 16, HAlTEL, HAITEL-AMLl1153-116, HAlTEL-AMLl are indicated with asterisk. Proteins 
are indicated with arrows on the right. Molecular masses of standard proteins are indicated (kDa). 
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Figure 8 Induction of cell death by rctrovirai transduction of TEL into NIH3T3 cells. (A) Morphologic 
appearance of2 x 105 NIH3T3 cells Elated on plastic 16 hours after selection for CD8 that are transduced with 
mock, TEL, TELi153-116 or TEL 52 A cDNAs expressing retroviruses. (n) Analysis of protein expression of 
infected cells at the time of CD8 selection. Proteins were separated on a 10% SDS-polyacrylamide gel and 
elcctroblotted. Proteins were visualized by using a-TEL antiserum in Western analysis. (C) Indirect 
immunofluorescence analysis of NIH3T3 cells that are transduced with mock, TEL, TELtl53-116 and TELSl2A 
cDNAs expressing retroviruses using C-terminal a-TEL antibodies, Images ,vere obtained by conventional 
microscopy, (D) Transient transcription experiments in NIH3T) cells were performed using 3 f-lg of CMV 
driven TEL, TELil53-I16 and TELS22A activator constructs with Ipg of pMSVluc reporter. Induction of 
ludferase (normalized to a secreted alkaline phosphatase control) are relative to empty vector (see Buijs ct aI., 
submitted for publication), 
Overexpressioll of TEL induces cell death 
At present, the biological role of TEL is still elusive, \Ve observed tbat retroviral 
transduction of TEL into NIH3T3 fibroblasts resulted in dramatic cell death 24 to 30 hours 
after selection of CDS-positive, transduced cells (figure 8a). Induction of cell death was 
dependent on the presence of the HLH domain, because cells transduced with TELil53-1 16 
did not die, Furthermore, cells transduced with a TEL mutant in which serine residue 22, a 
putative phosphoacceptor of a consensus MAPK phosphorylation sequence, had been 
eliminated, died even more rapidly (within 12 hours after sorting). This phenomenon was 
observed in at least three independent experiments. Figure Sb demonstrates the expression 
of exogenous TEL proteins in infected cells, analyzed by \Vestern analysis with C-terminal 
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a-TEL antibodies at the time of cell sorting. Approximately equal amounts of the proteins 
were expressed, indicating that the difference between the observed phenotypes is not due to 
different expression levels of the proteins. These data directly or indirectly link TEL 
overexpression to the induction of cel1 death. Elimination of a putative MAPK 
phosphorylation site in TEL by mutation of serine residue 22, seems to enhance this 
activity. This observation opens the possibility that TEL normally has a positive regulatory 
role in induction of cell death. 
To further analyze this phenomenon, the subcellular distribution of virally 
transduced TEL, TELA53-1l6 and TELs22A was analyzed by indirect immunofluorescence 
analysis. Figure 8c demonstrates that C-terminal TEL antibodies detected TEL S22A 
exclusively in the nucleus of infected NIH3T3 cells, whereas TEL was distributed in the 
cytoplasm, the nucleus or in both compartments and TELA53-116 was predominantly 
nuclear, suggesting that TEL function is in part regulated by localization. 
We recently observed that the MSV LTR is transcriptionally activated by MNI-TEL, 
dependent on the ETS domain of TEL, but luciferase expression is hardly induced by TEL 
(Buijs et aI., submitted for publication). To determine whether deletion of the Ill..H domain 
or mutating S22 to A22 altered TELs transactivation activity of the MSV LTR, we tested 
the TEL mutants in transient transcription assays. Co-transfection of the reporter pMSVluc 
with CMV promoter driven TEL, TELL\53-116 or TELs22A demonstrated that the 
transactivation activity of TEL was not changed by deleting the HLH domain. However, an 
increase in transcription activity was detected for the TELs22A mutant (figure 3d). These 
observations suggest that TEL transcriptional activity may be regulated by serine/threonine 
kinases. 
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Discussion 
We showed that t(12;21) TEL-AMLI, which is associated with 25% of the cases of 
childhood pre-B acute lymphoblastic leukemia (McLean ef al., 1996; Romana ef al., 1995b; 
Shurtleff ef al., 1995), is predominantly located in the cytoplasm of transiently transfected 
or stable, virally transduced cells. This cytoplasmic localization is dependent on an intact 
HLH protein-protein interaction domain. We observed the same phenomenon in cens 
transfected with a TEL-OCT6 construct, in which the ETS domain of TEL was replaced by 
the POU-homeo domain of OCT6. Perhaps TEL-AMLI and TEL-OCT6 remain in the 
cytoplasm because the HLH domain may mask the nuclear localization signals of the 
RUNT domain of AMLI or of the POU-homeo domain of OCT6. However, other 
explanations are equally plausible. Ghysdael and coworkers reported that TEL forms 
oligomers using the HLH domain as an intetface (Jousset et al., 1997). We demonstrated by 
using immunoprecipitation that TEL-AMLI interacts with itself and with TEL, confirming 
the observations of Golub and coworkers who used ill vitro transcribed/translated TEL-
AMLI (McLean ef al., 1996 1133). It is therefore possible that homotypic or heterotypic 
TEL-AMLI and TEL oligomers form insoluble cytoplasmic protein complexes that can not 
be processed by the nuclear import machinery. This possibility is supported by the 
observation that deletion of the oligomerization domain in TEL-AMLI and TEL-OCT6 
prevents complex formation and causes the proteins to localize to the nucleus. For the same 
reason one would expect TEL,6,53-116 to localize exclusively to the nucleus, which is not 
the case. The observation is not necessarily in contradiction with the above, since it can not 
be ruled out that the HLH mutant TEL protein may have different folding properties that 
partly shield its NLS from recognition. 
Our observations are in contradiction with a recently published study, in which TEL-
AMLl, expressed in transient transfection experiments, was found to reside solely in the 
nucleus, based on results of cell fractionation and subsequent Western analysis (Hiebert et 
al., 1996). This apparent discrepancy may be attributed to the different experimental 
approaches used for localization. It is entirely possible that, if oligomerized TEL-AMLI is 
insoluble, that aggregates residing in the cytoplasm would cofractionate with nuclear and 
nuclear matrix preparations in the procedure used by Hiebert and coworkers. Because TEL-
AMLl,6,53-116 localized to the nucleus in transient transfection experiments we are 
convinced that our immunolocalization of TEL-AMLI in the cytoplasm is not an artifact of 
the detection system. Furthermore, transfected TEL-AMLI and endogenous TEL colocalize 
in the cytoplasm. whereas in cells transfected with a TEL-AMLI cDNA construct that lacks 
the HLH domain, TEL resides in the nucleus. 
Most importantly, TEL-AMLl in transfected cells seems to sequester endogenous 
TEL in the cytoplasm, thereby diminishing the concentration of nuclear TEL. Recently, Kim 
et al. described pre-B cell lines that were derived from leukemic blasts of patients with 
t(12;21) ALL (Kim ef al., 1996). By using immunofluorescence analysis, we demonstrated 
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that in contrast to exogenous TEL-AMLl, endogenous TEL-AMLl localized to the nucleus 
of pre B-celllines REH and SUP-B2S. In these cell lines no endogenous TEL was present. 
Although TEL-AMLl localized predominantly to the nucleus in the B cel1s, we can not 
exclude that small amounts ofTEL-AMLl are expressed in the cytoplasm. 
Our data suggest that one of the cousequences of t( 12;21) is an association of TEL-
AMLl and TEL via the HLH domain. Therefore, TEL-AMLI will reduce the effective 
concentration of TEL in the nucleus. In this respect, it is noteworthy that t(12;21) is 
frequently associated with deletion of the second TEL allele (Raynaud ef al., 1996; 
Wlodarska et al., 1996). These deletions have been found to occur intragenically and as a 
secondary event in the pre-B ALL (Kim ef al., 1996; Raynaud ef al., 1996; Wlodarska ef al., 
1996). Elimination of TEL protein seems to confer a proliferative advantage to these cells, 
leading to clonal selection. Thus, reduced TEL concentrations may already provide a partial 
growth advantage, which could be one of the growth promoting aspects of TEL-AMLI 
expression. Similarly, TELffEL-AMLl oligomers may still be able to bind to the cognate 
TEL DNA binding sites, adding to the partial inactivation of nonnai TEL activity. In 
addition, TEL-A.MLl may interfere with AMLI dependent transcription regulation, 
representing the second growth promoting aspect of the fusion protein. 
Our observation may invalidate the interpretation that TEL-AMLI has a dominant 
negative effect on A1vfi..l-B and AML2 dependent transcription of the TCRP enhancer 
containing reporter piasmids in transient transfection assays by competition for the binding 
sites (Hiebert ef al., 1996; Meyers ef al., 1996). Although it cannot be excluded that small 
amounts of TEL-AMLI in transfected cells enter the nucleus, where it may inhibit AMLI 
dependent transcription, a'i suggested, the large amount of cytoplasmic TEL-Ai\1Ll in these 
cells may trap its dimerization partner, CBFp. This would make it unavailable to nuclear 
AMLIB or AML2. hence providing an interpretation for the observed dominant negative 
effect ofTEL-AMLl in these experiments. Therefore to prove the dominant negative role of 
TEL-AMLI on AMLI/CBFP transcription regulation, the transient expression experiments 
should be repeated in a cell line in which the expression of TEL-AMLI can be regulated to 
a level where the protein is still nuclear. Provided that TEL-AMLI functions as a repressor 
then TELffEL-AtYlLI oligomerization could impair TEL-AMLIs alleged repressing 
activity. Deletion of the second TEL allele would potentiate the repressing activity of TEL-
AMLI. 
In concordance with the finding of Bernard and coworkers (Poirel et al., 1997), both 
endogenous and exogenous TEL were present in two forms of 60 kDa and 50 kD. p60TEL is 
translated from the first ATG, whereas p50TEL is initiated from the ATG at codon 43 of the 
TEL ORF. It needs to be noted that the first ATG in the ORF of TEL, in contrast to the 
second, is in a suboptimal Kozak initiation sequence (Kozak, 1989). Addition of an HAI-
tag to TEL with a model Kozak initiation sequence apparently suppresses initiation of 
translation from. TEL ATG I and 43 codons since HAITEL is expressed as a single doublet 
of67 kDa. 
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Overexpression of TEL in Nlli3T3 cells induced rapid cell death. The inductiou of 
cell death was dependent on the HLH domain of TEL and was dramatically accelerated by 
mutation of the consensus MAPK phosphorylation site at serine residue 22, suggesting that 
TEL activity may be regulated by a MAPK pathway mediated phosphorylation. Similar 
observations have been made in Drosophila. Transgenic flies expressing Y AN eDNA, in 
which all eight MAPK phosphorylation consensus sequences had been mutated, exhibited a 
dramatic increase in cell death in the eye imaginal disc (Rebay & Rubin, 1995), suggesting 
that cells continuously prevented from responding to inductive signals may eventually opt to 
die. The 22S---722A mutation in TEL also influences its subcellular distribution, opening the 
possibility that TEL function is in part regulated by localization, as has been demonstrated 
for YAN (Rebay & Rubin, 1995). Furthermore, the trans activating activity of TEL was 
increased by mutating the putative phosphoacceptor site, suggesting that TELs transcription 
activity is regulated by phosphorylation. At present it is not known whether p60 TEL and 
pSOlEL have similar functions or whether their activities are similarly regulated. It could be 
of significance that the MAPK site at aminoacid 22 is absent from pSOTEL, suggesting that 
its putative regulatory function concerns p60TEL. The present observations for TEL are 
reminiscent of those of Drosophila ETS factor POINTED, which encodes two proteins, PI 
and P2. Transcription of the POINTED gene is initiated from two distinct promoters 
(Kliimbt, 1993). These proteins have a common C-terminus, which includes the ETS 
domain, but have different N-terminal sequences. In addition, P2 contains a single MAPK 
phosphorylation site, which P I lacks. When tested in transient transcription assays, P I was 
a significantly stronger activator of transcription than was P2 (O'Neill et al., 1994). Further, 
activation of the RASlERK2 pathway increased P2-associated effects on transcription but 
did not affect P I-related activity. Mutation of the phosphoacceptor residue in the MAPK 
consensus site of P2 abolished its ability to activate transcription. 
Although the nature of TEL induced cell death is unclear at present, TEL may be 
directly or indirectly involved in regulation of cell death in pre B-cells. Ablation of TEL 
function may therefore inhibit cell death and thus contribute to an excess of pre B-cells, 
providing a rationale for TELs alleged tumor suppressor activity. Experiments to investigate 
whether overexpression of TEL-AMLI in growth factor dependent B-cells prevent 
induction of apoptosis are in progress. Other ALL-associated translocations containing N-
terminal TEL may display similar effects as t(l2;21) TEL-AMLI. For example, t(9;12) 
TEL-ABL is found in the cytoplasm and contains the HLH domain of TEL. We predict that 
the effective concentration of nuclear TEL will be reduced by oligomerization with TEL-
ABL. Further, in one case of t(9: 12) TEL-ABL deletion of the second TEL allele has been 
reported (Golub et al., 1996). 
In conclusion, our studies suggest that TEL-AMLI may have a dual role in 
leukemogenesis: it may tether TEL activity and influence AML IICBFp-regulated 
expression of hematopoietic genes. 
99 
Acknowledgements 
The authors wish to thank Dr. Dick Ashmun and coworkers for FACS analysis, Drs. Judith 
Boer and Victor Garcia for assisting with confocal microscopy, Dr. Scott Hiebert for 
providing a-AMLI antibodies, Dr. Peter Marynen for providing N-terminal TEL antiserum, 
Dr. Santos for providing the activated RAS eDNA, Peggy Burdick and Charlette Hill for 
secretarial assistance and Amy Frazier for editing of the manuscript. These studies were 
supported by Cancer Center CORE Grant CA-2l765 and by the Associated Lebanese Syrian 
American Charities (ALSAC) of st. Jude Children's Research Hospital. 
100 
References 
Buijs, A., Sherr, S., van Baal, S., van Bezouw, S., van der Plas, D., Geurts van Kessel, A., Riegman, P., 
Lekanne Deprez, R., Zwarlhoff, E., Hagemeijer, A. & Grosveld, G, (1995). Oncogene, 10, 1511-
1519. 
Cave, H. t Gerard, B., Martin, E., Guidal, c., Devaux, I., Weisscnbach, J., Elion, J" Vilmer, E. & Grandchamp, 
B. (1995). Blood, 86, 3869-3875. 
Fornerod, M., Boer, J" van Baal, S., Jaeglc, M .• Von Lindern, M., MUfti, K.G., Davis, D., Bonlen, J" Buijs, A. 
& Grosveld, G, (1995), Oncogene, 10, 1739-1748. 
Fornerod, M., Boer. J" van Baal, S., Morreau, H. & Grosvcld, O. (1996), Oncogcne, 13, 1801-1808. 
Golub, T.R., Barker, O.F., Bohlander. S.K" Hiebert, S.W., Ward, D.C., Bray-Ward, p" Morgan, E., 
Raimondi, S.C., Rowley, J.D. & Gilliland, D.O. (1995). Proc Natl Acad Sci USA, 92,4917-4921. 
Golub, T.R., Barker, G.F., LoYett, M. & GiIlilnnd, D.G. (1994). Cell, 77, 307-316. 
Golub, T.R., Goga, A., Barker, G.F., Afar, D.E., McLaughlin, J., Bohlander, S.K., Rowley, J.D .• Witte. D.N. 
& Gilliland, D.O. (1996). Mol Cell Biol.16, 4107-4116. 
Oraham, F.L. & Eb, A.J. (1973). Virology, 52, 456·467. 
Harlow & Lane. (1988). Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory: New York. 
Hiebert. S.W., Sun, W., Dayis, J.N., Golub, T., Shurtleft~ S., Buijs, A., Downing, J.R., GrosveJd, G., ROllssell, 
M.P., Gilliland, D.G., Lenny, N. & Meyers, S. (1996). Mol. Cell. Bioi., 16, 1349-1355. 
Hirai, H., Roussel, M.F., Kato, J., Ashmun, RA. & Sherr, C.l. (1995). Mol Cell BioI, 15,2671-2681. 
Jousset, C., Carron, C .• Boureux, A, TranQuang, c., Dury, c., Dusanter-Fourt, I., Charon, M., Levin, J., 
Bernard, O. & Ghysdael. J. (1997). EMBO J,16, 69·82. 
Kim, D.-H .• Moldwin, RL., Vignon, C., Bohlander, S.K., Suto, Y .• Giordano, L., Gupta, R, Fears, S., 
Nucifora, G .• Rowley, J.D. & Smith, S.D. (1996). Blood, 88, 785·794. 
KHimbt, C. (1993). Development, 117,163-176. 
Kozak, M. (1989). J Cell BioI, 108, 229-41. 
McLean, T., Ringold, S .• Neuberg, D., Stegmaier, K., TantraYahi, R, Ritz, J., HP, H.K., Takeuchi, S., Janssen, 
J., Seriu, T., Bartram, c., Sallan, S., Gilliland, D. & Golub, T. (1996). Blood, 88, 4252·8. 
Meijer, D., Graus, A. & Grosvcld, O. (1992). Nuci Acids Res, 20, 2241-2247. 
Meijer, D., Graus, A., Kraay, R., Langeveld, A., Mulder, M.P. & Grosveld, G. (1990). Nucl Acids Res, 18, 
7357-7365. 
Meyers, S., Downing, J.R. & Hiebert, S.W. (1993). Mol Cell Bioi, 13,6336·6345. 
Meyers, S., Lenny, N. & Hicbcrt, S.W. (1995). Mol Cell BioI, 15, 1974-1982. 
Meyers, S., Lenny, N., Sun, W. & Hicbcrt, S.W. (1996). Ollcogene, 13, 303-312. 
Miyoshi, H., Shimizu, K., Kozu, T., Mascki, N., Kaneko, Y. & Ohki, M. (1991). Proc Nat! Acad Sci USA, 88, 
10431-10434. 
Muller, A.J., Young, J.c., Pcndergast. A, Pondel, M., Landau, N.R., Littman, D.R. & Witte, O.N. (1991). Mol 
Cell Bioi, 11,1785-1792. 
Okuda, T., van Deursen, J., Hiebert, S.W., Grosvcld, G. & Downing, J.R. (1996). Cell, 84, 321-330. 
O'Neill, E.M., Rebay, I., Tjian, R & Rubin, O.M. (1994). Cell, 78,137-147. 
Papadopoulos, P., Ridge, S.A, Bouchcr, C.A., Stocking, C. & Wiedemann, L.M. (1995). Cancer Res, 55, 34-
38. 
Poirel, H., Oury, C., Caron, C., Duprez, E., Laabi, Y., Romana, S., Tsapis, A., Machauffe. M., LeConiat, M., 
Bergcr, R. Ghysdael, J. & Bernard, O. (1997). Oncogelle, 349-357. 
Raimondi, S. (1993). Blood, 81, 2237-51. 
Raimondi, S.c., Privitera, E., Williams, D.L., Look, A.T., Bchm, F., Rivera, G.K., Crist, W.M. & Pui, C. 
(1991). Blood, 77, 2016-2022. 
Raimondi, S.C., Williams, D.L., Callihan, T., Peiper, S., Rivera, G.K. & Murphy, S.B. (1986). Blood, 68, 69-
75. 
Raynaud, S., Cave, H., Baens, M., Bastard, C., Cacheux, V., Orosgeorgc, J., Ouidal-Giroux, c., Guo, C., 
Vilmer, E., Marynen, P. & Grandchamp, B. (1996). Blood, 87, 2891-2899. 
Rebay, I. & Rubin, G.M. (1995). Cell, 81, 857-866. 
Romana, S.P., Machauffc, M., Le Conial, M., Chumakov, I., Le Paslier, D., Berger, R. & Bernard, O.A. 
(1995a). Blood, 85, 3662~3670. 
Romana, S.P., Poirel, H., Leconiat, M., Flexor, M.A., Mauchauftc, M., Jonvcaux, P., Macintyre, B.A., Berger, 
R. & Bemru-d, O.A. (l995b). Hlood, 86, 4263-4269. 
101 
Rubnitz, J.E., Downing, J.R., Pui, C.~H., Shurtleff, S.A, Raimondi, S.C., Evans, W.E., Head, D.R., Crist, 
W.M., Rivera, O.K., Hancock, M.L., Boyett, J.M., Suijs, A, Orosveld, G. & Behm, F.O. (1997). J 
Clill Ollcol, 15, 1l50~1157. 
Sacchi, N., Schiaffonati, L., Magnani, I., Pappalardo, C., Hughes, AJ., Jr., Darfler, M. & Hoogcveen, AT. 
(1996). Oncogene, 12, 437-444. 
Shurtleff, S.A., Buijs, A, Behm, F.G., Rubnilz, J.E., Raimondi, S.C., Hancock, M.L., Chan, G.C, Pui, C., 
Orosvcld, G. & Downing, J.R. (l995). Lellkemia, 9, 1985-1989, 
Stegmaier, K" Pendse, S., Barker, G,F" Bray-Ward, p" Ward, D.C" Montgomcry, K.T" Krauter, K.S" 
Reynolds, C, Sklar, J., Donnelly, M" Bohlandcr, S.K., Rowley, J,D" Sallan, S,E" Gilliland, D.G. & 
Golub, T.R. (1995). Blood, 86, 38-44. 
Stegmaier, K" Takeuchi, S" Golub, T,R., Bohlander, S,K., Bartram, CR., Koeffler, H.P. & Gilliland, D,G, 
(1996), Callcer Res, 56, 1413-1417. 
Takeuchi, S., Bartram, c.R., Miller, C.W" Reitcr, A, Seriu, T., Zimmermann, M" Schrappe, M., Mori, N" 
Slater, J" Miyoshi, I. & Koeffler, H.P. (1996), Blood, 87, 3368-3374. 
Wilson, LA., Niman, H,L., Hougten, R,A., Cherenson, AR., Connolly, M.L. & Lerner, R.A. (1984). Cell, 37, 
767-778. 
Wlodarska, I., Baens, M" Peeters, P., Aerssens, J., Mecucci, C" Brock, p" Marynenc, P. & van den Berghe, 
H. (1996). Cancer Res, 56, 2655-2661. 
102 
Chapter 4. Discussion 
Elltities ojt(12;22) associated lellkemia 
In the 1970s t(12;22)(p13;qll) has been described as a chromosomal aberration associated 
with CML (Engel ef al., 1977; van der Blij-Philipsen ef al., 1977; Verma & Dosik, 1979). 
These observations led to the hypothesis that it may represent an alternative Philadelphia 
translocation, involving the HeR gene on chromosome 22ql1. However, Hagemeijer et a!. 
reported t(12;22) as a sole chromosomal abeITation in a case of AML FAB subtype MI 
(Hagemcijer et al., 1981). The translocation seems not to be associated with a specific FAB 
subtype, because it has been detected in acute myeloid leukemias of FAB classifications M2, 
M4, M7 as well as in MDS (Mitelman, 1991). The basis of classifying t(l2;22) as a variant 
Philadelphia translocation in CML was fmiher undennined by the finding that MNI rather 
than BCR was disrupted by the aberration (chapter 2.1). 
Since t(l2;22) has been identified as the sole chromosomal abnormality in some 
leukemic samples, it has been argued that it could be the primary event in leukemogenesis (Hu 
et al., 1996). The incidence of t(l2;22) as a sole recurrent translocation is low. It is more 
frequent in leukemic cells with a karyotype that is dominated by complex rearrangements 
(Mitelman, 1991). However, cases have been described in which t(12;22) was only detected at 
relapse, suggesting that the translocation is involved in progression of the disease (chapter 2.1) 
(Buijs ef a/., 1995). The generation of the growth factor dependent cell line UCSDI AMLl, 
that was established from leukemic cells of a patient with ll1ultilineage AML in relapse, 
support this notion. \Vhile only a subset of leukemic cells in the bone tnatTOW of the patient at 
relapse carried the translocation, it was present in all cells of the cell line (Oval ef al., 1990). 
These cells responded to a broad range of growth factors. This suggests that selection for this 
cell population may have occurred ill vitro in the presence of growth factors, which may 
reflect clonal selection of cells carrying the translocation by a proliferative advantage ill vivo. 
In conclusion, t(12;22) represents a distinct chromosomal rearrangement, that does not identify 
a specific leukemogenic FAB phenotype. The fusion protein seems to be involved in 
progression of the disease. 
Ptltativejlltlcfioll ojMNI-TEL 
The characterization of t(12;22) enabled us to initiate a series of experiments to unravel the 
molecular mechanism by which the .MNI-TEL fusion protein may contribute to 
leukemogenesis. We demonstrated that MNI-TEL transformed a specific subline of NIH3T3 
fibroblasts, using a retroviral transfer system (chapter 2.2). However, it had a weak 
transfomling potential, since, unlike activated RAS, it did not transform standard Nlli3T3 
fibroblasts. Apparently, MN I-TEL needs additional mutations to transform. 
The transforming potential of MNI-TEL was fonnd to depend on a functional ETS 
domain, suggesting that the fusion protein aben·antly regulates transcription of TEL target 
genes, leading to malignant transformation. Indeed, unlike TEL, MN I-TEL was found to 
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transactivate transcription of a luciferase reporter gene driven by the Moloney sarcoma virus 
LTR in transient transcription assays. Likewise, MNI transactivated the MSV LTR. 
Transcription activation of a reporter construct by 1viN 1 has also demonstrated in yeast and 
HeLa cells when linked to a GAlA DNA binding domain. Furthermore, MNI could induce 
expression of a reporter constnlct under the control of the HSV TK promoter in NllI3T3 cells, 
but not in hepatoma cell line Hep3B (Molijn and Zwarthoff; manuscript in preparation). This 
may reflect a tissue specific function of MN 1 in transcription regulation. 
Transcription factors typically contain distinct domains for DNA binding and 
activation of target genes (Triezenberg, 1995). At present, it is unknown whether MNI can 
bind DNA. However, it contains proline-rich sequences and glutamine stretches, characteristic 
for transcription activators that act from a proximal promoter position in conjunction with an 
enhancer element (Gerber et al., 1994). Glutamine stretches form p-sheets that can function as 
oligomerization domains (pemtz ef al., 1994; Stott ef al., \995). The human transcription 
factor SP I, that has two glutamine rich domains, enhanced transcription of a reporter gene by 
interaction of SPI molecules bound to GC-rich recognition sites 1.8 kb apart. This interaction, 
that mediates DNA bending, was dependent on the glutamine-rich sequences (Su et al., 1991). 
Furthermore, SPl bound the Drosophila TAX, a component of TFllD of the transcription 
initiation complex, via its glutamine sequences (Gill et al., 1994). This interaction is thought 
to stabilize the transcription/initiation complex. Likewise, MNI sequences in .MNl-TEL may 
contribute to abelTant transcription activation of TEL target genes by influencing the 
stabilization of the basal transcription complex. Alternatively, MNl-TEL may result in the 
aberrant transactivation of genes nOlmally regulated by MN 1 and an ETS factor. 
VP16-TEL, a synthetic fusion protein that contains the acidic trans activating domain 
of HSV l, also transactivated the MSV LTR. However, it did not transfonll murine fibroblasts. 
Fmihennore, a domain within the first 228 aminoacids of MN I-TEL appeared to be essential 
for transfOlmation, while deletion of this domain did not influence its capacity to transactivate 
the MSV LTR. Based on these two observations, it seems that MNl does not render .MNl-
TEL transforming by simple addition of transactivating sequences to TEL. We postulate that a 
domain within the first 228 aminoacids of MN I-TEL mediates specific protein-protein 
interactions that are impOltant for the transcription activation of target genes that initiate 
transformation pathways. The observation that the first 228 aminoacids of MNI, when linked 
to TEL, have some transforming potential, supports this hypothesis. 
At present only two chromosomal translocations, t(l6;21) FUS/CHOP-ERG and 
t(12;22) MNI-TEL, have been documented in human leukemia, in which the DNA binding 
domain of an ETS factor is present in a chimeric protein, (Buijs et al., 1995; Prasad et al., 
1994; Shimizu et al., 1993). Our data indicate that subversion of nonnal transcription 
regulation by ETS domain containing fusion proteins may contribute to the pathogenesis of 
leukemia, in analogy to some tumors ofneuroectodennal origin (chapter 1.4). 
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Aberrant localization of MNI-TEL 
Oncogenic mutation of proteins has been found to result in altered subcellular localization that 
may be of functional importance for leukemogenesis. For example, c-ABL, a non-receptor 
tyrosine kinase, that is mainly expressed in the nucleus, is located in the cytoplasm as a result 
of its fusion with BCR by the Philadelphia translocation (Dhut ef al., 1990; Van Etten ef al., 
1989). BCR-ABL associates with F-actin fibers, which is essential for malignant 
transformation (McWhirter & Wang, 1993). 
Altered distribution within a subcellular compartment has also been observed for 
proteins involved in chromosomal translocations, that are associated with leukemia. Acute 
promyelocytic leukemia (APL) is characterized by t(l5;17) that results in a PML-RARo; 
fusion protein (1991; de The ef al., 1990; Goddard ef al., 1991; Kakizuka ef al., 1991). PML is 
localized in nuclear bodies or PML oncogenic domains (PODs), a macromolecular stmcture, 
of which the function is unknown (Dyck ef ai., 1994; Koken ef ai., 1994; Weis ef ai., 1994). In 
leukemic cell lines expressing PML-RARa these nuclear bodies are disrupted and the 
functional dimerization partner of RARa. RXR. is redirected to aberrant stmctures in the 
nucleus. Treatment of these cells with retinoic acid (RA) induces a relocation of RXR to 
PODs. 
A distinct speckled pattern has been described for E2A-PBXI, associated with t(l;19) 
in pre B-ALL (Kamps ef al., 1990; Nourse ef al., 1990). When transfected into Nlli3T3 cells, 
E2A-PBXl was concentrated in spherical domains denoted chimeric oncoprotein domains 
(CODs). Deletion of an N-terminal transcription activation domain in E2A. essential for 
transformation by E2A-PBXl. or transfection of HOXB7, a homeodomain protein capable of 
enhancing DNA binding by PBXI and E2A-PBXI, impaired COD fonnation (LeBrun ef ai., 
1996). At present, it is not known whether overexpression of HOXB7 reduces the 
transforming capacity of E2A-PBXl. These data indicate that aberrant localization of fusion 
proteins in nuclear bodies may also be of functional importance for leukemogenesis. 
Do TEL and ETS·1 have a common DNA binding mechanism? 
The transforming and trans activating potentials of 1VIN I-TEL were found to be dependent on a 
functional ETS domain. Data presented in chapter 2.2 indicated that the ETS domain of TEL 
binds a canonical GGAA sequence, CCGGAAGT. This sequence closely resembles the 
recognition sequences for ETS-I in the MSV LTR and for ELKI and ERG in the E74 
promoter (Wasylyk ef al., 1993). As mentioned in chapter l.l, DNA binding by ETS-I is 
regulated by an intramolecular mechanism involving two regions: an a-helix upstream of the 
ETS domain and the C-terminus. DNA allosterically induces unfolding of the helix and 
transiently relieve..') inhibition. Interaction with a partner protein may stabilize the proteinlDNA 
complex (petersen ef al., 1995). Graf and coworkers (Lim ef al., 1992) presented a model that 
the inhibitory domain and the C-terminus interact, thereby preventing DNA binding via the 
ETS domain (figure I; upper panel). Graves and coworkers modified this model and suggested 
that interaction with the DNA results in a uncoupling of the inhibitory domains, followed by a 
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conformational change of the ETS domain (Jon sen et ai., 1996). Seth et al. demonstrated that 
DNA binding of ETS-I to ETS binding sites was stabilized by addition of ETS-I specific 
monoclonal antibodies (Seth et al., 1993), Preliminary data suggest that a similar mechanism 
may regulate TEL DNA binding. Addition of antibody directed against the last ten aminoacids 
of TEL resulted in an intensified supershifted signal, suggesting that binding of the antibody 
may interfere with an intramolecular interaction, involving sequences in the C-tenrunus of 
TEL that mediate a DNA binding regulatory mechanism (figure I; middle panel). 
Furthermore, deletion of sequences N-tenninal of the ETS domain abolishes the 
intramolecular interaction and thereby interferes with the regulation of ETSIDNA interaction 
(figure I; lower panel), This mechanism may be common to a subgroup of ETS factors in 
which the ETS domain is located in the C-terminus of the protein. An interesting aspect is its 
relation with MNI-TEL. Additional studies may reveal whether in MNI-TEL the DNA 
binding inhibition is still present or not. 
anti -ETS-1 '",U-~EL  __ 
Figure L Model of repressioll of DNA binding by ITS factors. Sequences in the C-terminus of ETS factor 
interact with thc inhibitory domain, prcventing DNA binding via the ETS domain. DNA interaction is 
accompanied with uncoupling of the inhibitory domains, which allosterically alters the conformation of the ETS 
domain (upper panel). Interaction with heterologous factors or antibodies (middle panel), or deletion of one of the 
domains (lower panel) interferes with this intramolecular DNA binding regulatory mechanism 
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Clillical sigllificance ofl(12;21) 
Molecular characterization of t(l2;21)(p13;q22) made it possible to increase the level of 
detection of the translocation in childhood ALL from 0.05%, using standard cytogenetic 
techniques, to 25% (500x) by using molecular genetic and molecular cytogenetic techniques 
(chapter 3.1), This increase in sensitivity of diagnosis has important clinical implications. 
Retrospective analysis of children with ALL treated with high~risk treatment protocols, 
revealed that cases with TEL-AMLl t(12;21) do significantly better than those with genniine 
TEL, making this translocation the first example of a specific genetic abnonnality associated 
with a favorable prognosis in childhood ALL. Preliminary data of a study with patients treated 
with antimetabolite-based therapy reyealed that patients with TEL rearrangements also do 
significantly better than those with genlliine TEL (Rubnitz el al., 1996). This indicates that 
t( 12;21) patients may be treated less aggressively without loss of therapeutic efficacy, reducing 
the toxicity, effects on growth and development, and treatment induced secondary acute 
myeloid leukemia. However, preliminary data of other retrospective studies indicate that less 
aggressive treatment results in less favorable outcome (Chambost e/ at., 1996). Therefore, it 
will be necessary to perform protocol driven prospective studies to resolve this discrepancy. 
How may TEL-AMLI contribute to leukemogenesis? 
The AMLl/CBFll transcription complex is targeted by t(8;21) and t(3;2I), and inv(l6), 
associated with 30% of myeloid leukemias (figure 2). The rearrangements result in AML-
ETO, AMLI-EVII and CBFll-MYHII fusion genes, respectively (Erickson et al., 1992; Lin 
el al., 1993; Mitani et al., 1994; Miyoshi et al., 1993; Nisson et al., 1992; Sacchi et al., 1994). 
AMLI-ETO retains the ability to interact with the enhancer core DNA sequence and has been 
shown to negatively interfere with AMLI-dependent and AML2-dependent trans activation 
(Meyers et al., 1993; 1995; 1996). 
t(12;21) 
t(8;21) t(3'21) TEL-AML 1 
AML 1-ETO' 28°' 1 B '1 15% of AML AML 1-EV11 I~ o. -progent or 
~are cases 01 pedtatrtc ALL CML an\d MOl inv(16) CBFWSMMHC ,/'15%0IAML ~ I I Tarae! genes 
Figure 2. Schematic representatioll of chromosomal aberrations affecting the AMLlICBFf3 transcription complex 
(courtesy (0 Dr. l.R. Downing) 
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The crucial role of the AMLlICBFP transcription complex during hematopoiesis was 
further shown by gene knockout experiments in mice. The complex appeared to be essential 
for establishment of fetal liver hematopoiesis during embryonic development as demonstrated 
in mice nullizygous for AMLl or the gene encoding the CBFP subunit (Okuda ef al., 1996a; 
Wang ef al., 1996). Interestingly, mice carrying AMLI-ETO or CBFp-MYHII, generated by 
homologous recombination using the knock-in strategy, displayed a phenotype similar to the 
knockout mice (Castilla ef al., 1996; Okuda ef al., 1996b; Yergeau ef al., 1996). These data 
are consistent with the dominant negative inhibitory function of both fusion proteins over the 
AMLlICBFP transcription factor complex. 
Hiebert and collaborators discovered that TEL-AMLI negatively interfered with 
AMLI dependent transcription of the TCRP enhancer in transient transcription assays (Hiebert 
ef al., 1996), suggesting that TEJ.....AMLI may have a dominant negative inhibitOlY function in 
the nucleus as well. However, immunofluorescence analysis revealed that TEL-AMLI is 
located in the cytoplasm of viraUy transduced murine fibroblasts, despite the fact that the 
nuclear localization signal (NLS) in the RUNT domain of AMLI is present in the chimeric 
protein (chapter 3.2). A mutant version of this protein lacking the HLH domain localized to 
the nucleus. A similar subcellular localization was observed for a synthetic fusion protein in 
which the ETS domain of TEL had been replaced by the POU domain of OCT6. Several 
explanations are plausible for this phenomenon. TEL-AMLI or TEL-OCT6 may form 
homotypic complexes or heterotypic complexes with TEL via the HLH domain, preventing 
nuclear transfer. The HLH domain in TEL-AMLI and TEJ.....OCT6 may mask the NLS in the 
RUNT domain or POD homeodomain, respectively. The observation that highly expressed 
TEJ.....AMLI is a cytoplasmic protein opens the possibility that it, unlike AMLI-ETO, may not 
act as a dominant negative repressor of AMLl dependent transcription in the nucleus. In this 
respec, it is interesting to note that Tanaka et al. reported that AMLI-ETO and AMLl-EVIl 
accumulate CBFP more efficient in the nucleus than AMLI (Tanaka ef al., 1996). Our 
observation suggest that TEL-AMLI may sequestrate factors, such as CBFp, in the cytoplasm. 
This would provide a distinct mechanism for dominant interference. However, in human pre-
B cell lines carrying t(12;21), TEJ.....AMLI was found to be localized to the nucleus, suggesting 
the cytolasmic localization of TEL-AMLI in transient transfection experiments is due to 
overexpression of the chimeric protein. This observation argues for the hypothesis that TEL-
AMLI is a dominant negative repressor of AMLl dependent transcription. Nevel1heless, our 
observations of overexpressed protein may reflect the biology of the chimeric protein ill vivo. 
TEL-AMLI could associated with TEL in the nucleus and thereby hamper nuclear TEL 
activity. Thus, TEL-AMLI may have a dual effect; it could diminish the effective 
concentration of both AMLlICBFP and TEL in the nucleus. This biochemical mechanism 
would SUppOlt the hypothesis, until now based on genetic data, that progression of the 
leukemia is dependent on the dosage of TEL (Kim ef al., 1996; Raynaud ef al., 1996; 
Wlodarska ef al., 1996). Expression of TEL-AMLI would already diminish TELs nuclear 
function, which is completely ablated by inactivation/deletion of the second TEL allele, 
selected for during progression of the disease. 
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At present the physiological function of TEL in hematopoiesis is not known. One 
possibility is that TEL may be involved in regulation of differentiation or growth of precursor 
cells. Altematively, TEL may be involved in the regulation of cell death of pre-B cells, since 
overexpression of TEL in fibroblasts induced cell death (chapter 3.2). Ablation of TEL 
function may therefore have a reverse effect which would lead to an excess of pre-B cells. 
Fusion proteins, such as BCR-ABL, E2A-PBX I and E2A-Ill.F, associated with 10% of pre-B 
ALL (figure 2), were found to affect cell survival, making cells resistant to apoptosis induced 
by a variety of agents (Cortez ef al., 1996; Dedera ef al., 1993; Inaba ef al., 1996; Roger ef al., 
1996). They account for a considerable percentage of aberrations in pre-B ALL, indicating that 
interference with apoptotic pathways, necessary for maintenance of a balanced B-cell 
population, is a common step in development of B-ceUleukemia. 
HLH domaill o/TEL defines a specific oligomerization domaill 
The HLH domain is present in a subset of ETS factors (see chapter I; figure I). It has been 
termed the pointed domain (KHimbt, 1993), or the HLH domain, based on its weak sequence 
homology with HLH dimerization domain present in transcription factors such as c-Myc and 
MyoD (Seth & Papas, 1990). The HLH domain of TEL has been demonstrated to be a 
homotypic oligomerization domain (Jousset et al., 1997), essential for the oncogenic 
properties of TEL-PDGFpR, TEL-ABL (Carroll ef al., 1996; Golub ef al., 1996), and probably 
for TEL-AML (chapter 3.2). However, the domain is non-functional in MNI-TEL (chapter 
2.2). The physiological function of oligomerization of TEL is still elusive. Interestingly, 
Drosophila POINTED PI, which lacks the HLH domain, is a constitutive transcription 
activator. Transcriptional activation of its splice variant P2, which includes this domain, is 
regulated by RAS mediated phosphorylation (O'Neill ef al., 1994). It remains to be detenllined 
whether this difference in transcription activation is mediated through phosphorylation-
controUed oligomerization with a regulatory factor, and whether it reflects a mechanism for 
regulation of transcription control by ETS factors in general. MN 1 may contribute to the 
activation of TEL by substituting for an activating partner, or by preventing interaction with a 
negative regulatory factor. 
Fuhlre directions 
MNl·TEL 
Transcription regulation of the MSV LTR in NIH3T3 cells by MNI, TEL and MNI-TEL will 
be characterized in more detail. Deletion analysis of the MSV LTR will determine which 
enhancer/promoter sequences and putative cooperating factors are essential for the 
transcription activation by MNI and MN1-TEL in this cell type. 
To extend the evidence for MN 1-TELs involvement in leukemogenesis, cell line 
U937T (Boer and Grosveld, manuscript in preparation), a derivative of the human monoblast 
cell line U937 (Sundstrom & Nilsson, 1976) that expresses the tetracycline responsive 
chimeric transactivator TET-VPI6 (Gossen & Bujard, 1992) will be used. Combined 
treatment with transfomllng growth factor (TGF)p and 1,25 dihydroxyvitamin D3 was 
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demonstrated to induce monocytic maturation of U937 cells (Testa ef al., 1993). With this 
system the influence of tetracycline dependent expression of the TEL, MNl and MNl-TEL 
cDNAs on the proliferation or maturation potential of these cells will be analyzed. 
Potential target genes of TEL will be characterized by representational difference 
analysis of mRNAs in MNl-TEL transformed fibroblasts and U937T cells expressing MNl-
TEL, with the aim to unravel the transcription cascade controlled by TEL. This system has 
been used successfully to identify genes transcribed in response to the EWS-FLI-J chimeric 
protein, associated with Ewing's sarcoma (Braun et al., 1995). 
The human monocytic cell lines, UCSD/AMLl and MUTZ-3, catTying a 
to 2;22)(p 13;q 1 I) (lIu ef al., 1996; Oval ef al., 1990), represent very useful model systems for 
MN I-TEL leukemogenesis. They can be used to characterize additional genetic mutations, as 
well as to elucidate the pathophysiology of MNI-TEL. Furthennore, they can be used for 
studies on monocytic activation as well as ill vitro analyses of therapeutic agents. 
III vivo leukemogenesis of MNI-TEL will be investigated by generating MNI-TEL 
transgenic mice which express the fusion protein from the human cathepsin G gene promoter. 
This promoter was successfully used to direct expression of a PML-RARa cDNA to early 
myeloid precursor cells in transgenic mice (Grisolano ef al., 1995). Alternatively, MNI-TEL 
chimeric mice will be generated using a "knock-in" strategy, using homologous recombination 
of the human TEL eDNA into the mouse MN I gene. This approach has the advantage that 
expression of the fusion gene is driven from the MNl promoter. It has successfully been used 
to induce myeloid leukemia by MLL-AF9, associated with t(9;11)(p22;q23) in AML (Corral 
ef al., 1996 ), and has been applied to generate t(6;9) DEK-CAN chimeric mice (van Deursen 
and Grosveld, personal communication). Demonstration of the ill vivo oncogenicity of the 
MNl-TEL chimera would establish its role as an oncogene. If expression of MNI-TEL 
predisposes mice to develop myeloid leukemia, this would strongly indicate an intrinsic role of 
the protein in dismption of normal growth regulation of myeloid cel1s and would provide a 
rationale for its myeloid specific role in human malignancy. Dependent of the phenotype of 
the mice, induction of leukemogenesis may be accelerated by infection of the mice with 
murine leukemia vims (Haupt ef al., 1991; van Lohuizen ef al., 1991). This method has the 
advantage that cooperating oncogenes can be detected. 
TEL-AMLl 
Clinical trials will start to determine treatment protocols aimed at maintaining therapeutic 
efficacy but to reduce toxicity and the risk of secondary myeloid leukemia. Furthermore, pre-B 
cell lines generated from blasts of patients with ALL that express TEL-AMLl will be used to 
detennine the role of TEL-AML! in leukemogenesis (Kim ef al., 1996). The effects of 
chemotherapeutic agents used for treatment in t(12;21) ALL can be studied with these cell 
lines. 
To analyze whether TEL-AML.I interferes with apoptosis of the B-cell population ill 
vifro, growth factor dependent B-cell lines will be generated that express TEL-AMLI. 
Inhibition of apoptosis and growth characteristics of cell lines will be analyzed upon 
withdrawal of the growth factor. 
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To detennine the oncogenic potential ofTEL-AMLI ill vivo, B-ceH specific transgenic 
TEL-AML1 mice will be generated by expression of the chimeric protein from a Iymphoid-
specific Ell based expression vector (van Lohuizen ef al., 1991). These mice will be used to 
determine whether TEL-AMLI is involved in deregulation of apoptosis in the B cell 
population. The same vector will be used to generate B-ceU specific transgenic TEL mice. It 
will be very interesting to analyze the role of TEL in FAS and CD40 dependent regulation of 
B-cell proliferation and apoptosis (Rathmell ef al., 1996). 
We generated transgenic mice that express the cytoplasmic TEL DNA binding mutant 
from the lymphoid-specific Ell based expression vector (Buijs and Grosveld, unpublished 
results). These mice will allow us to study the phenotypic consequences of TEL inactivation 
by its sequestration in the cytoplasm. We will study the proliferation and maturation of 
lymphoid cells and assess whether these mice are predisposed to lymphoid malignancies and 
thus canfion TELs possible role as a tumor suppressor. 
TEL involvement ill other 12p13 aberrations ill leukemia alld other maligllallcies 
As discussed in chapter 1.5, TEL is a frequent target of chromosomal aberrations in human 
leukemia. Additional chromosome 12p 13 aberrations associated with human leukemia should 
be analyzed for TEL involvement. TEL may also be involved in other malignancies, since 
deletions of the short arm of chromosome 12 are observed in 10-20% of patients with non-
small cell lung carcinoma (Sato ef al., 1994; Tsuchiya ef al., 1992) and frequent LOH of 
region 12pl3 was observed in both non-small cell lung carcinoma and breast carcinoma 
(Spirin ef al., 1996; Takeuchi ef al., 1996).These data at least provide additional evidence for 
the presence of one or more tumor suppressor genes at this locus. Further analysis will show if 
TEL is one of these. 
Clinical significance of molecular diagnosis of chromosomal trmrsloclltiolls ill childhood 
ALL 
To date, more that 70% of children with ALL treated with current chemotherapeutical 
regiments will become long-term survivors (Rivera ef al., 1993). Cun-ent risk-based protocols 
emphasize intensified treatment for patients predicted to be at high risk of relapse, whereas 
less toxic therapy is reserved for lower-risk patients. 
Clinical features with recognized prognostic value include the initial leukocyte count, 
age at diagnosis, sex, presence of a mediastinal mass, degree of organomegaly, and early 
response to treatment (Rubnitz ef al., 1997). Patient age and leukocyte count at diagnosis 
provide the most imp0l1ant prognostic infoonation. Age 1 to to years and a leukocyte count of 
less than 50,OOO/l11m3 are recommended as standard-risk criteria, whereas other combinations 
of these features are considered to be high-risk. 
Genetic abnormalities have also been useful in defining prognostically important 
patient subgroups. Hyperdiploidy (i.e. >50 chromosomes per cell or DNA index of 1.16) is 
associated with favorable outcome. By contrast, specific chromosomal translocations, such as 
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t(9;22), t(1;19) and t(4;11) (figure 3), confer a poor prognosis. Taken together, these 
genetically defined risk-groups account for only 35% of childhood ALL patients (20% with 
hyperdiploidy and 15% with adverse translocations) (Pui, 1995; Raimondi, 1993). 
t(l ;19) 
E2A-PBXl 
t(9;22) 
BCR-ABL 
Pro-B cell 
t(12;21) 28.0% 
TEL-AMLl 
pre-B cell 
t(17;19) 
E2A-HLF 
Pro-B cell 
llq23 
MLL fusions 
Pro-B cell 
6.0% 
Random 
5.0% 
14qll{TCR 
Tcell 
3.0% 
7q35{TCR 
Tcell 
None 
1(8;14), t(2;8), t(8;22) 
Ig gene/MYC 
Bcell 
Figure 3. Distribution of translocation-generated fllSioll genes amollg commonly recognized immlillologic 
sflbtypes of ALL ill childrell alld )'Ollllg adults (courtesy to Dr. A.T. Look). 
The discovery that the cryptic t(12;21) has a favorable prognostic outcome and occurs 
in >25% of patients with pediatric ALL, is extremely important for risk-directed 
chemotherapy. For instance, a patient with a white blood count of >50,000 fmm3 with a 
cryptic t(l2;21), who would have been considered to be of high-risk one year ago, will now be 
regarded to be of moderate to low risk. T(l2;21) is the first example of a specific genetic 
abnonnality to be associated with a favorable prognosis in childhood ALL. However, 
approximately 40% of the cases with ALL still lack risk-identifying genetic features. Most of 
these cases have non-recurring chromosomal abnonnalities or rare recurring translocations. 
Molecular characterization of these alterations may lead to the identification of additional 
clinically important genetic risk groups. 
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Summary 
Leukemias and lymphomas, malignancies derived from the hematopoietic system, are 
frequently associated with specific chromosomal aben"ations, such as translocations and 
deletions. Characterization of these aberrations resulted in the isolation of affected genes. 
Investigations with these genes contributed to the understanding of the function of their 
protein products in physiology and pathology. 
Aberrations on the short (p) arm of chromosome 12 can be detected in 2 % of myeloid 
leukemia and 10 % of acute lymphoblastic leukemia (ALL) in children. These abeITations 
consist of both chromosomal translocations as well as deletions, involving band p, suggesting 
that this region may contain one or more (tumor suppressor) genes. 
The aim of the investigations described in this thesis was to characterize translocation 
(l2;22)(pI3;qll), associated with myeloid leukemia. The following questions needed to be 
answered: I) Is t(l2;22)(pI3;qll) a variant Philadelphia translocation, resulting in fusion of 
the BCR gene on chromosome 22q with a gene on chromosome 12p? 2) Is this gene on 
chromosome 12p also the target of other translocations in this chromosomal region? 3) Is the 
gene on chromosome 12p13 a tumor suppressor gene, because of the fact that this region is 
frequently deleted in childhood ALL? 4) Via which biochemical mechanism contributes 
t(12;22)(p 13;q II) to leukemogenesis? 
Because the gene on chromosome 12pl3 appeared to be a new member of the family 
of ETS transcription factors, an introduction about the fUllctions of ETS factors in the 
development of organs and organisms, hematopoiesis and malignancies is preceding the 
description of the experimental work (chapter 1). 
In chapter 2.1 we describe that t(l2;22)(pI3;qll) results in fusion of the MNI gene, 
not the BCR gene, on chromosome 22qll with the TEL (E1V6) gene on chromosome 12p13. 
MNl was recently isolated because of its involvement in t(4;22) in a cell line derived from a 
multiple meningioma. The MNl protein contains two homopolymeric glutamine chains and 
many proline residues. These are two properties that suggest that MN 1 may be involved with 
transcription regulation. TEL was independently isolated by three other groups by 
characterization of chromosomal trans locations t(5;12)(q33;pI3), t(9;12)(q34;pI3), 
t(l2;21)(q22;p13). TEL contains a protein-protein interaction domain and an ETS DNA 
binding domain. T(l2;22) results in two reciprocal fusion transcripts, because of difference in 
the localization of the breakpoints in TEL in different patients. We postulated that the MNI-
TEL may be involved in the ontogeny or progression of the leukemia by aben"ant transcription 
regulation of genes that are nonnally controlled by TEL, because 1VINI-TEL contains the 
major part ofMNI and the DNA bindingETS domain of TEL. 
Experiments described in chapter 2.2 suggests that this hypothesis seems to be valid. 
We demonstrated that TEL binds to a canonical GGAA sequence. We determined the TEL 
consensus recognition sequences as CCGGAAGT. Binding of TEL to the consensus 
sequences was confitmed by bandshift analysis. These studies suggested that the DNA binding 
of TEL is negatively regulated by intramolecular interactions in the polypeptide. In transient 
transcription a'isays we demonstrated that MNl-TEL is a transcription regulator of the 
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Moloney sarcoma vil1ls LTR, dependent on the ETS domain in the fusion protein. 
Furthennore, MNI-TEL, but not MNI or TEL, transfonned murine fibroblasts. Sequences 
within the first 228 aminoacids of :MN1 are cl1lcial for transfommtion by MNt-TEL. 
Furthermore, the ETS domain of TEL mediates transfomlation by MNI-TEL. Indirect 
illIDmllofluorescence revealed that :MN I TEL locates to nuclear speckles characteristic for the 
fusion protein. Our data suggest that :MN I-TEL is involved in leukemogenesis. 
In the meantime it was clear that TEL was involved in many translocations 
(summarized in chapter 1.S). One of them is t(12;21)(pI3;q22), that results in expression of a 
TEL-AMLI chimeric product. T(12;21) is a cryptic translocation that can be detected in 
0.05% of childhood ALL by cytogenetic analysis. Preliminary data suggested that t(12;21) 
could be more frequent. In chapter 3.1 we describe that TEL-AMLI occurs in 25% of 
childhood ALL, when analyzed by Southern analysis and reverse transcriptase-polymerase 
chain reaction (RT-peR), which is an increase of 500x in sensitivity of diagnosis. 
Retrospective analysis revealed that TEL-AMLI defines a subgroup in childhood ALL that is 
characterized by an age of onset of 1 to 10 years, a non-hyperdiploid DNA index, a B-cell 
immunephenotype and a good prognosis. It may be possible to use t(12;21) as a genetic 
marker and a positive prognostic indicator for outcome of the disease. We observed that 
exogenous TEL-AMLl, in contrast what had been suggested, localized to the cytoplasm of 
transfected cells, and not to the nucleus (chapter 3.2). Cytoplasm localization was dependent 
on the helix-loop-helix oligomerization domain in the TEL moiety. Endogenous TEL 
colocalized with transfected TEL-AMLI in the cytoplasm. However, in human pre B-cells 
carrying t( 12;21) TEL-AMLI localized to the nucleus, suggesting the cytoplasmic localization 
of TEL-AMLI in transfected cells is due to overexpression of the chimeric protein. Therefore, 
our observations are important for the correct interpretation of the role of TEL-AMLI in 
transient transactivation experiments. Futthermore, TEL-M1Ll may still interfere with TEL 
dependent transcription regulation via association of the two molecules. This may suggest a 
biochemical mechanism, arguing for the hypothesis that loss of nuclear TEL function results 
in progression of the leukemia. We hypothesize that TEL is involved in the regulation of 
growth or differentiation of pre B-ceHs. Our observation that overexpression of TEL in 
fibroblast results in cell death, suggest that TEL-A.tV!LJ in t(12;21) may contribute to B-cell 
leukemogenesis by negative1y influencing TELs alleged function in inducing apoptosis. 
t t8 
Samenvatting 
Leukemien en lymfomen. maligniteiten die uitgaan van het bloedvorrnende systeem, zijn vaak 
gea.o;;socieerd met specifickc chromosoom afwijkingcn, zoals translocaties en deleties. Het 
karakterizeren van deze afwijkingen heeft geleid tot de isolatie van genen betrokken bij deze 
afwijkingcn. Onderzoek aan deze genen heeft bijgedragcn aan de kennis van hun 
eiwitprodukten in fysiologic en pathologic. 
Afwijkingcn van de kortc (p) ann van chromosoom 12 zijn detekteerbaar in 2% van de 
mycloide leukemien en in 10% van acute lymfoblastische leukemic bij kinderen. Deze 
afwijkingcn bestaan zowel uit chromosoom translocaties als deleties, waarbij band p13 
betrokken is. Deze observaties deden vermoeden dat in dit gebied een of wellicht meerdere 
genen liggen, die het doelwit zouden kUlmen zijn van verschillende translocaties. De deleties 
suggereerden dat dit gebicd oak een of meerdere tumor suppressor gellen zou kunnen 
bevatten. 
Het onderzoek beschreven in dit proefschrift had tot doel de chromosomale 
translocatie (12;22)(p 13;q II) te karakteriseren, die geassocieerd is met myeloide leukemie. De 
volgeude vragen moesten beantwoord worden: I) Is t(12;22)(pI3;qll) een variante 
Philadelphia translocatie die leidt tot de fusie van het BCR gen op chromosoom 22q met een 
gen op chromosoom 12p? 2) Is dit gen op chromosoom 12p ook het doelwit van andere 
translocaties in deze chromosomale regio? 3) Is het gen op chromosoom 12p13 wellicht een 
tumorsuppressor gen, omdat deze regio frequent gedeleteerd is in ALL bij kinderen? 4) Wat is 
het moleculaire mechanisme waannee t(l2;22)(pJ3;qIJ) bijdraagt aan het ontstaan van de 
leukemie? 
Aangezien het gen op chromosoom 12p 13 een nieuw familielid van de ETS 
transcriptie factoren bleek te zijn. wordt de beschrijving van de bevindingen van het 
experimenteie werk voorafgegaan door een inleiding over de rol van ETS factoren bij de 
ontwikkel1ng van organen en organismen, de bloedvonning en maligniteiten (hoofdstuk 1). 
In hoofdstuk 2.1 wordt beschreven dat t(12;22)(pJ3;qll) resulteer! in de fusie van het 
MN J gen en niet het BCR gen, op chromosoom 22q II met het TEL gen op chromosoom 
12pJ3. MNI was juist daarvoor geisoleerd omdat het betrokken bleek te zijn bij een t(4;22) in 
een cellijn geYsoleerd uit meningioom weefsel. Het MNt eiwit bevat twee homopolymere 
glutamine ketens en is rijk aan prolines. Dit wijst erop dat het eiwit betrokken zou kunnen zijn 
bij regulatie van transcriptie van genen. Het TEL gen werd onafbankeJijk door drie andere 
groepen ontdekt bij de karakterizeriug van chromosoom translocaties t(5;12)(q33;pJ3), 
t(9; 12)(q34;pJ3), t(l2;21)(q22;pI3). Het TEL eiwit bevat een domein, dat mogeJijk betrokken 
is bij interactie met andere eiwitten, en een ETS DNA bindend domein. T(l2;22) reslliteert in 
twee typen reciproke fusie transcripten als gevolg van het verschil in de lokatie van de 
breukpunten in TEL bij verschillende patienten. Op grond van de struktllllr van de MN I-TEL 
fusie-eiwitten, die een groot gedeelte van MNI en het DNA bindende ETS domein Van TEL 
bevatten, postuleerden we dat dit eiwit betrokken zou zijn bij het ontstaan of de progressie van 
de leukemie door afwijkende regulatie van gcnen. die normaal onder controle staan van TEL 
of verwante ETS factoren. 
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Experimenten, beschreven in hoofdstuk 2.2 toonden aan dat deze hypothesis 
waarschijnlijk juist is. Door middel van amplificatie van DNA oligonucieotiden, die bonden 
aan het ETS domein van TEL, uit een verzameling van willekeurige oligomeren werd 
aangetoond dat TEL bindt aan een GGAA nucleotide sequentie. Op grond van vergelijking 
van omliggende sequenties werd de consensus herkenningssequentie van TEL gedefinieerd als 
CCGGAAGT. Binding van TEL aan deze sequentie werd bevestigd door bandshift assays. 
Daarnaast gaven deze studies aanleiding te veronderstellen, dat DNA binding van TEL 
negatief beYnvloed wordt door cell intramoleeulaire interactie in het TEL eiwit. In transcriptie 
studies werd aangetoond dat :MN 1 domeinen toevoegt aan TEL, waardoor MN I-TEL een 
sterke activator wordt van de Moloney sarcoma vims LTR. Activatie van de LTR bleek 
afhankelijk te zijn van het DNA bindend domein van TEL. Daarnaast bleek MNI-TEL, in 
tegenstelling tot TEL en MNl, in staat te zijn om muize fibroblasten te transformeren. Voor 
transfonnatie is een domein in de eerste 228 aminozuren van MN 1 van cmciaal belang. 
Daamaast draagt het ETS domein van TEL bij aan transformatie. Deze observaties maken het 
waarschijnlijk dat MNI-TEL betrokken is bij leukemogenese. MNI-TEL bleek gelokaliseerd 
te zijn in korrelige stmcturen in de kern. Op dit moment is de relevantie van de expressie van 
MNl-TEL in deze nucleaire stmcturen voor eell mogelijke rol bij leukemogenese onbekend. 
Inmiddels was duidelijk dat TEL betrokken was bij meerdere translocaties 
(samengevat in hoofdsluk 1.5), waaronder t(12;21)(pI3;q22), die leidt tot expressie van een 
TEL-AMLI fusie produkt. T(l2;21) is een cryptische translocatie die slechts in 0.05% van de 
gevallen van ALL bij kinderen met behulp van cytogenetica gediagnostiseerd kon worden. Er 
waren sterke aanwijzingen dat t(12;21) veel frequenter voor zou kunnen komen dan 
aanvankelijk werd gedacht. In hoofdstuk 3.1 wordt beschreven dat de TEL-AMLI fusie 
voorkomt bij 25% van de ALL bij kinderen, hetgeen een 500-voudige toename in detectie 
gevoeligheid van deze ehromosoom transIocatie betekent. Daarnaast werd duidelijk dat TEL-
AMLI specifiek is voor een groep van klnderen in een leeftijds eatagoric van 1 to 10 jaar, 
waarvan de ALL gekenmerkt wordt door een B eel immunofenotype, eell niet-hyperdiploide 
DNA index, en cen uitermate gunstige prognose. Uitbrciding van het aantal onderzoehte 
patienten stelde vast dat de transloeatie mogeJijkerwijs als een genetiseh merker en aIs 
positieve prognostische indicator voor de uitkomst van de ziekte gebnlikt kan worden. 
Onderzoek aan het moleeulaire meehanisme waarmee TEL-AMLI aan leukemogenese 
bijdraagt, leidde tot de observatie dat getransfecteerd TEL-AMLl, in tegenstelling tot lVat 
veronderste1d werd, in het cytopJasrna van de eellen, en niet in de kern, to expressic komt 
(hoofdsluk 3.2). De localisatie van TEL-AMLI bleck af te hangen van het HLH domein in 
het fusie-eiwit. Evenals getransfcctcerd TEL-AMLl, bevond endogeen TEL zich in het 
eytopIasma van de eel. Deze observatie suggereerde dat eell eonsequenties van t(12;21) zou 
kunnen zijn dat TEL uit de kem in het cytoplasma gchonden wordt. Dit zon de hypothese, dat 
verlies aan functioneel TEL bijdraagt aan progressie van de leukemic, gepostuleerd op grand 
van genetisehe studies, steunen. Eehter in humane pre-B eellijnen die t(l2;21) bevatten, bleek 
TEL-AMLI in de kern gelocaliseerd te zijn, hetgeen suggereert dat de cytoplasmatische 
localisatie van getransfeeteerd TEL-AMLI bemst op overexpressie van het fusie-eiwit. Dit 
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neernt echter niet weg dat TEL-AMLI door associatie met TEL bij kan dragen aan 
leukemogenese door functionele TEL activiteit in de kern negatief te be"invloeden. Onze 
observaties zijn van belang voor de interpretatie van transaetivatie experimenten met TEL-
AMLI eDNA constmcten. Daarnaast duiden ze op een mogelijk biochemisch meehanisme, 
wat de hypothese steunt dat verlies aan TEL functie leidt tot progressie van de leukemie. 
Enerzijds kunnen we veronderstellen dat TEL betrokken is bij de regulatie van groei en/of 
differentiatie van pre-B cellen. Anderzijds, gesteund door de observatie dat overexpressie van 
TEL in fibroblasten leidt tot celdood, kunnen we postuleren dat t(l2;21) TEL-AMLI bijdraagt 
tot pre-B celleukemie door remming van TELs apoptose indueerende functie te bei'nvlaeden. 
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Abbreviations 
ALL 
AML 
ANNL 
APL 
bp 
cALL 
eDNA 
C-terminus 
CML 
CMML 
DNA 
EGF 
ETS 
FAB 
FISH 
GM-CSF 
HLH 
HTH 
n 
kb 
kDa 
LOH 
LTR 
MAPK 
M-CSF 
MDS 
MPD 
mRNA 
MSV 
NLS 
N-tenninus 
PCR 
PDGFpR 
RAR 
RNA 
RTK 
SRE 
SRF 
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acute lymphoblastic leukemia 
acute myeloblastic leukemia 
acute non-lymphoblastic leukemia 
acute promyelocytic leukemia 
base pair 
common ALL 
complementary deoxyribonucleic acid 
carboxyl terminus 
chronic myelogenous leukemia 
chronic myelomonocytic leukemia 
deoxyribonucleic acid 
epidermal growth factor 
E26 transformation-specific 
French-American-British Cooperative Group 
Fluorescence ill situ hybridisation 
granulocyte macrophage colony stimulating factor 
helix-loop-helix 
helix-tum-helix 
interleukin 
kilo bases 
kilo Dalton 
loss of heterozygosity 
long terminal repeat 
mitogen activated protein kinase 
macrophage colony stimulating factor 
myelodyspJastic syndrome 
myeloproliferative disorder 
messenger ribonucleic acid 
Moloney sarcoma vil1ls 
nuclear localization signal 
amino termimus 
polymerase chain reaction 
p chain platcled derived growth factor receptor 
retinoic acid receptor 
ribonucleic acid 
receptor tyrosine kinase 
sel1lm response element 
sel1lm response factor 
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